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o Insulin analogues are widely used by diabetic patients to control blood glucose levels 
o The use of some of these compounds is correlated with an increased cancer risk 
o The medicine administration agencies propose new carcinogenic risk assessment strategies for 
insulin analogues  
     IN THE PICTURE 
 Insulin analogue pens and refills. Diabetic 
patients will certainly recognise these user 
friendly injection pens. Using the rotating cap 
the patient can adjust the required dose. The 
needle can be mounted on top of the pen.  
Typically, the thigh or belly is used as suitable 
injection site. All analogue flasks (as well as 
those of regular insulin, IGF1 and glargine 
metabolites) in the picture have been used in 
this research. Recently it appeared that IGF1 
was misused to enhance sport performances 
by bodybuilders and cyclist.  
    IN BEELD
Insuline analogen pennen met navulsysteem. 
Diabetes patiënten zullen deze 
gebruiksvriendelijke pennen zeker herkennen. Met 
de roterende dop kan de dosis ingesteld worden. 
De naald wordt op de voorkant geschroefd. 
Normaal gesproken wordt de dij of buik gebruikt 
als injectieplaats. Alle analogen flesjes (evenals die 
van normaal insuline, IGF1 en de metabolieten van 
glargine) op de foto zijn gebruikt in dit onderzoek. 
Recent is gebleken dat IGF1 is misbruikt door 
bodybuilders en wielrenners om hun 
sportprestaties te verbeteren. 
 




Every year hundreds of new chemical entities are produced intended for the human 
pharmaceutical market. Many of these compounds will never reach the market or will eventually 
be redrawn from it because of serious side effects. The process to get safe medicines on the 
market is regulated by national authorities of each individual member state in Europe, and a 
centralized organization called the European Medicines Agency (EMA).  
The demands for the development of a medicinal product are laid out in numerous guidelines, 
drawn up by the regulatory authorities. A number of these guidelines is aimed at providing 
guidance on the non-clinical development and risk assessment of new products, mainly of the 
small chemical type.  However, because of their unique biological and physiochemical 
characteristics, a specific guideline was written for biotechnology-derived compounds which is 
based on a scientific case-by-case approach [1] [2].  
Although biopharmaceuticals are not genotoxic and therefore are not expected to be ‘complete 
carcinogens’, chronic administration could potentially lead to tumor promotion or progression of 
specific neoplasm(s) based on their expected pharmacologic activity [3]. In several scenarios 
evaluation of the carcinogenic potential should be considered for non-genotoxic 
biopharmaceuticals:  
1. In case different biological effects are observed between the recombinant product and 
the endogenous protein. 
2. When there are structural differences between the recombinant product and natural 
product. 
3. If the recombinant products are administered at pharmacologic doses greater than 
expected endogenous levels.  
But emphasizing a 2-year rodent study (rat or mouse), and thus referring to rodents as a golden 
standard is neglecting the high number of false positives in these species as compared to humans. 
Half of all long- term used pharmacotherapies induces rodent cancer, due to the high sensitivity 
of rodents versus humans, human irrelevant age-related tumors arise in these animals [4]  [5]. 
The purpose of the S6 guideline with the recent addendum was to offer alternative strategies 
rather than to default to the rodent bioassay to provide an appropriate carcinogenic risk 
assessment [2]. Alternative strategies include in vitro approaches and if necessary a more 
relevant rodent in vivo model, besides a review of available literature data, information from 
similar targets or class effects, and clinical data. 
The molecules discussed in this thesis are the insulin analogues, these molecules are very similar 
to regular insulin but have improved pharmaco-kinetic and -dynamic parameters. Insulin 
analogues are used by diabetic patients to regulate their blood glucose levels. Long- and short- 
acting insulin analogues have been developed so that plasma levels can be tuned accurately 
during the day reflecting the physiological activity of endogenous insulin without much 
fluctuation after physical activity or food intake.  
 




Insulin analogues (as well as regular insulin) are growth factors and have besides the intended 
metabolic effects also an intrinsic mitogenic behavior. While the pharmacological action of 
insulin is mediated through the insulin receptor, the mitogenic potential of insulin and insulin 
analogues are mainly related to their affinity for and downstream effect via the insulin like 
growth factor-1 receptor (IGF1R) (Figure 1). The natural ligand of the IGF1R, IGF1, is structurally 
very similar to insulin which results in cross-reactivity of the different ligands for the above 
mentioned receptors. An increased binding affinity towards the IGF1R compared to regular 
insulin could be the result, which is indeed the case for some insulin analogues. Therefore a major 
concern with respect to safety aspects for insulin analogues is a disproportional increased 
mitogenic activity. 
 
Figure 1. The insulin receptor (IR) and insulin like growth factor-1 receptor (IGF1R) signalling pathway. Activation 
of these receptors by a growth factor (e.g. insulin or insulin analogues) triggers its auto-phosphorylation. Several 
substrates (e.g. shc and gab1) can bind the membrane bound receptor and get phosphorylated, which in turn will 
activate two distinct signalling cascades, the PI3K/AKT and MAPK/ERK. The PI3K is thought to play a major role in 
metabolism (e.g. glucose uptake, glucogen synthesis), whereas the MAPK leads to the more mitogenic effects (e.g. 
cell proliferation and survival). But as is clear from the pathway many cross links can be made between these 
different cascades, making the IR/IGF1R signalling pathway highly complex. 
  
In 2002, the EMA proposed testing strategies for insulin analogues specifically in a guidance 
document [6], in which it was stated that the preclinical safety evaluation of these compounds 
should focus on the mechanisms of action of the expected carcinogenic effect. Besides receptor 
kinetics and binding affinity, characterization of the different intracellular pathways is needed, 
not only for the IGF1R both also for the different isoforms of the insulin receptor. There is 
 




evidence that these receptors might react differently in neoplastic tissue compared to normal 
tissue, therefore in vitro studies should be performed in both cancer cell lines and primary cells 
to make a comparison of insulin analogue induced pathway activation. The use of adapted animal 
models is encouraged to increase the human clinical relevance of these chronic rodent 
experiments. Furthermore, the importance of including the right reference compounds was 
highlighted.  Native insulin, IGF1 and AspB10 (an insulin analogue with a known increased 
mitogenic activity) should be included in the mitogenic assays to put the obtained results in 
perspective. 
In this thesis we have used the recommendations from the EMA as a guideline for the 
carcinogenic risk assessment of all commercial available insulin analogues. 
In chapter 2, an introduction is presented that included a literature search of all available 
experimental data on this topic. For this systematic review we have focused on the link between 
insulin analogue exposure and breast cancer development by including only in vitro studies that 
have used breast cancer cell lines or animal and patient derived studies that have focused on 
mammary gland tumor development specifically.   
An in vitro study is described in chapter 3, in which a new cell model was used to determine the 
mitogenic activities of insulin analogues. A stable knockdown was combined with a retroviral 
overexpression system by which the MCF7 human breast cancer derived cell model only 
expressed one of the involved receptors (IRA, IRB or IGF1R). Exposure experiments have been 
performed including all commercial insulin analogues as well as regular human insulin, AspB10 
and IGF1 as reference compounds. Several exposure times as well as concentrations have been 
included. Both a mechanistic information was gathered using the protein quantification methods 
as a read out as well as functional assays determining the direct proliferative effects of these 
compounds.  
In chapter 4, the same cell model was used as in chapter 3. This time a full transcriptomic analysis 
was performed using micro-arrays. The genes involved in insulin analogue mitogenic signaling 
were identified. The predictive potential of these mitogenic gene classifiers were tested using all 
commercially available analogues. Furthermore validation and possible clinical relevance was 
assessed by testing the gene expression levels of these classifiers in different models, including 
primary human mammary cells and mouse mammary glands. 
An in vivo experiment was carried out using the p53R270H/+WAPCre mouse model. This model has 
a human relevant mutation in the tumor suppressor p53 gene by which it will develop 
spontaneous mammary gland tumors. In chapter 5, we determined if chronic insulin analogue 
treatment would affect the tumor latency time. Furthermore a phospo-proteomic analysis on the 
tumors was performed to detect treatment specific differences between the insulin analogue 
induced tumors.  
 




These tumors were further characterized in chapter 6 using next generation sequencing. We 
anticipated that the full transcriptomic analysis would shed light on how these tumors have 
developed and to pick up treatment specific tumor-related effects. Furthermore a mutational 
analysis was performed on these tumors. 
Finally, chapter 7 provides a general discussion on the results obtained in our studies and on the 
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o The number of animal studies on the carcinogenic potential of insulin analogues is low 
o Epidemiological studies on this topic were underpowered 
o Both epidemiological and in vitro studies on this topic suffered from methodological limitations 
o There is no compelling evidence that any clinically available insulin analogue increases breast 
cancer 
     IN THE PICTURE 
Western blot analysis. This technique is widely 
used to quantify specific protein levels in a 
sample (a dark band indicates more protein). It 
became one of my favourite read-outs and 
plenty of WB overviews are presented in this 
thesis (during my PhD over 750 individual blots 
have been performed). In my opinion this 
technique is undervalued. In comparison to 
“State of the art” techniques like 
immunofluorescence, the protein levels are 
better quantifiable, results better reproducible, 
and easier to interpret. 
    IN BEELD
Western blot analyse. Deze techniek wordt 
wereldwijd gebruikt om eiwit niveaus te bepalen 
in een monster (een donkere band betekent 
meer eiwit). Het is een van mijn favoriete 
technieken en er staan veel WB overzichten in 
deze thesis (meer dan 750 individuele blots zijn 
uitgevoerd gedurende mijn PhD). Ik vind dat dat 
deze techniek door onderzoekers wordt 
ondergewaardeerd. In vergelijking met de 
“hippe” technieken, zoals immunofluorescentie, 
zijn de eiwitniveaus beter kwantificeerbaar en de 
resultaten gemakkelijker te duiden. 
 





The association between insulin and insulin analogue treatment and breast cancer 
development, and plausible mechanisms, was investigated. A systematic literature search was 
performed on breast cell-line, animal and human studies using the key words ‘insulin analogue’ 
and ‘breast neoplasia’ in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A 
quantitative and qualitative review was performed on the epidemiological data and a 
complete overview was composed for in vitro and animal studies. Protein and gene expression 
was analysed for the cell lines most frequently used in the included in vitro studies. In total 16 
in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included in this review. 
Insulin AspB10 showed mitogenic properties in in vitro and animal studies. Glargine was the 
only clinically available insulin analogue for which an increased proliferative potential was 
found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies 
did not show evidence for an association between insulin glargine treatment and increased 
breast cancer risk (HR 1.04; 95% CI 0.91, 1.17; p=0.49). It has to be taken into account that the 
number of animal studies was limited, and epidemiological studies were underpowered and 
suffered from methodological limitations. There is no compelling evidence that any clinically 
available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro) increases breast 
cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour 
initiation, but might induce breast tumour progression by up regulating mitogenic signalling 
pathways. 
 
Keywords: Breast cancer, insulin analogues, diabetes mellitus, systematic review, meta-analyses, 
epidemiology, animal studies, in vitro, glargine 
 
Introduction 
Breast cancer is the most prevalent cancer in women with 1.67 million new cancer cases 
diagnosed in 2012 worldwide [7]. There is evidence that diabetes mellitus (DM) is associated with 
breast cancer [8-13]. However, it is unknown if this association is due to the high blood glucose 
levels of DM, hyperinsulinaemia, shared risks factors such as obesity, or side-effects of diabetic 
treatment such as insulin. Insulin can act as a growth factor, and it is biologically plausible that 
high levels of endogenous insulin or exposure to exogenous insulin could stimulate neoplastic 
growth [14, 15].  
In 2009, the results of four large-scale epidemiological studies were published, raising the 
concern that insulin analogues, especially insulin glargine, might increase risk of cancer overall 
[16-20]. Although the results were inconsistent and the authors stressed the limitations of their 
studies, this led to an urgent call for more research by the European Association for the Study of 
Diabetes [21].  
 




Previous reviews that focussed on in vitro studies were consistent on the note that glargine has, 
in contrast to other commercially available analogues, an increased binding affinity towards the 
Insulin-like growth factor 1 receptor (IGF1R). Most studies concluded that glargine may have an 
increased mitogenic potential in particular cell lines at supra-physiological concentrations [22, 
23]. Extrapolation of these results to the human in vivo situation is difficult due to obvious 
limitations of in vitro studies, but also due to tissue-specific biological responses. A focus on a 
specific cancer type could clarify this issue.  
Moreover, no studies have reviewed the limited number of animal studies on insulin analogues 
and cancer, so far. In addition, meta-analyses of epidemiological studies have been inconsistent. 
One meta-analysis reported an increased relative risk of any cancer among insulin users 
compared to non-insulin treated diabetics of 1.39 (95% Confidence Interval (CI) 1.14, 1.70)  [24], 
while another reported a pooled estimate of 1.04 (95% CI 0.75, 1.45) [25]. Insulin use was not 
associated with an increased risk of breast cancer [24-26]. However, two [25, 26] out of four 
meta-analyses [25-28] concluded that risk of breast cancer was increased among glargine users 
compared to non-glargine users. 
Considering that cancer is a heterogeneous disease with different aetiologies involved, and 
breast cancer being the most common female cancer, we focussed this review on the association 
of exogenous insulin (analogue) exposure and the risk of breast cancer. Furthermore, we 
deducted from the literature review what is currently known on signalling pathways involved in 
insulin induced tumorigenesis. We included all widely prescribed insulin analogues and insulin 
AspB10 and included in vitro, animal, in vivo human and epidemiological studies. 
 
Methods 
This systematic review is registered at PROSPERO [29] with the registration number: 
CRD42012002477 and was developed according to the PRISMA guidelines [30], and 
supplemented by guidance from the Cochrane Collaboration handbook [31].  
 
Data sources and searches 
A search of three online databases, MEDLINE at PubMed, EMBASE, and ISI Web of Science, was 
performed using key words insulin analogue and breast cancer (or similar terms) through July 
2014. The full search strategy is displayed in the electronic supplementary material (ESM) 1. 
 
Study selection 
Eligible studies had to describe effect measures of exogenous insulin use on breast cancer 
development. We included studies with direct (tumour incidence, size, volume, and metastases) 
or indirect outcomes (cell proliferation, count, and apoptosis, as well as genes and/or proteins 
explaining mechanisms of breast cancer tumour development e.g. MAPK, PI3K, PTEN, mTOR, 
 




p53) associated with breast cancer. Studies were divided in 3 categories with the following 
selection criteria; 1) in vitro studies on mammary gland cell lines exposed to insulin analogues, in 
which direct proliferative effect was measured or pathway activation was monitored; 2) animal 
studies on models treated with insulin analogue, in which the mammary gland tumour 
progression/initiation was measured, or different insulin analogues were compared for their 
activation of mitogenic signalling pathways in mammary gland tissue, and 3) epidemiological and 
in vivo studies in humans, including patients with type 1 or type 2 DM treated with insulin 
analogues before breast cancer diagnosis; cohort and case-control studies as well as randomized 
controlled trials were included. Only epidemiological studies that presented relative or absolute 
risk estimates for breast cancer among insulin users were included. Studies that used a non-DM 
reference population were excluded. In case of multiple publications on the same dataset, we 
included the study with most complete data. An overview of the study selection is provided in 
Fig. 1.  
 
 
Fig. 1 Flow chart of study identification and study selection process.  
 





Data extraction  
For the in vitro and animal studies information was extracted on the cell (with INSR:IGF1R status) 
or animal model (species, tumour subtype), study design (in vitro: assay, starvation method, 
exposure time, type and refreshment of medium, and presence of phenol red; animal: tissue and 
proteins analysed, and time of sampling), the intervention (compounds and concentration/dose 
tested) and the study outcome (mammary tumour formation, mitogenic response, and pathway 
activation) (Tables 1 and 2).  
For each epidemiological study, information was extracted on study design and characteristics, 
i.e. country, source population, data sources, study period, age group, matching variables for 
case-control studies, DM type and definition, prevalent/incident insulin users, exposure 
definition, time of exposure definition, mean duration of exposure, latency period, and 
covariates (ESM Table 2-3c); and risk estimates for each exposure comparison (Table 3).  
 
Data synthesis and analyses  
In vitro and animal studies were grouped by type of insulin analogue, and common 
pathways/mechanisms of action were extracted and summarized. Plausible pathways were 
suggested based on the strength of the evidence. To substantiate the results of the in vitro 
studies included in this systematic review, we created an overview of the protein and gene 
expression in 8 commonly used mammary (tumour) cell lines of hormone receptor levels (INSR, 
IGF1R, ER, PR, HER2, EGFR) and some proteins essential for insulin-induced downstream 
signalling cascades. The methods of these experiments can be found in ESM 2.  
The exposure comparisons that were examined in the epidemiological studies were categorized 
as: 1) insulin use versus no insulin use (drug exposure undefined); 2) insulin use versus use of 
non-insulin anti-diabetic drug (NIAD) (type of NIAD defined); 3) use of insulin X versus no use of 
insulin X. Results were categorized on the exposure of interest. Data was ordered per risk 
estimate (Hazard Ratio (HR), Odds Ratio (OR), Incidence Rate Ratio (IRR)). If a study presented 
results within the same exposure comparison, but with different definitions of the exposure of 
interest (e.g. glargine users or glargine only users), the group that had most power was included 
to calculate the pooled estimate. We set a subjective cut-off of 10 studies needed for a pooled 
analysis; hence this was only performed for glargine. The pooled estimate was derived using the 
random effect model. Pooled analysis by dose or duration was not feasible, as risk estimates were 
reported for different exposure comparisons, exposure definitions (e.g. mean or cumulative 
dose, duration since start exposure, or cumulative duration) and stratification categories. The 
quality evaluation of the epidemiological studies focussed on potential selection bias, 
information bias, and confounding. In the ESM 3 the evaluation process of the bias and power of 
 




studies is displayed. Data were prepared in Microsoft Access 2010 and analysed in Stata version 
11.0. 
Table 1. (part 1) Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues. 
 
<To be continued on next page> 
  
 




Table 1. (part 2) Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues.  
A/B Often studies used multiple cell lines. In case of cell line specific conclusions the superscript A/B/C/D are used to refer to this specific cell line.  
* Some studies used a specific experimental setup that allowed a discrimination between the involvement of different pathways. For all these 
studies the p-ERK and p-AKT served as biomarker for activation of MAPK or PI3K, respectively.  
 
 









Table 3. Relative risk estimations for breast cancer among different insulin treatment groups and the evaluation of 








Studies are first ordered by type of exposure and then by type of risk estimate. Note: Hiesh 2012 is a cohort study but provided OR estimates in 
the paper. Names of exposure groups are defined by the authors of the study. Several papers showed multiple risk estimates for the same 
exposure with different analytical approaches. For each study and exposure, the results from the least biased or best performed analyses are 
shown; showing HRs, IRRs or ORs as applicable. Different exposure comparisons within one study are indicated by a,b,c etc. We choose to include 
the risk estimate that gave (in order of importance): 1) estimates for incident users was preferred over estimates for prevalent users; 2) as-treated 
analysis (during study period/follow up) was preferred over intention-to-treat analysis (during fixed period/at baseline); 3) estimates with, the 
longest, latency period were preferred. Estimates from statistical models adjusted for covariates were preferred over crude estimate. 
 
Results 
A search in MEDLINE at PubMed, EMBASE, and ISI Web of Science identified 1723 unique records 
(Fig. 1). After the eligibility assessment, 52 studies on exogenous insulin exposure and breast 
cancer were included, of which 16 in vitro, 5 animal, 2 human in vivo and 29 epidemiological 
studies (see ESM 4 for study descriptions). 
 
Evidence of mitogenic/carcinogenic potential 
Current evidence of the mitogenic/carcinogenic potential per insulin analogue is described 
below, highlighting the most important findings displayed in the tables and figures. In Table 1 an 
overview is presented of all in vitro studies in which the mitogenic potency and/or stimulation of 
signalling pathways MAPK and PI3K upon insulin analogue(s) exposure was determined in a 
mammary gland (tumour) cell line [32-47]. Protein expression of hormone receptors and some 
downstream signalling proteins for each cell line are provided in ESM Table 1 and Fig. 2. In Table 
2 an overview is presented of all relevant animal studies  [48-52]. Descriptions and characteristics 
of the epidemiological studies are presented in ESM Table 2-3c [18, 19, 53-79]. Table 3 lists the 
overall risk estimates for breast cancer per insulin analogue in the epidemiological studies; the 
corresponding forest plots are presented in ESM Fig. 1. Results of the meta-analysis on glargine 
can be found in Fig. 3. Some studies provided risk estimates by strata of duration or dose of 
exposure (ESM Table 4). The quality assessment of the epidemiological studies is shown in ESM 
Table 5.  
 
 
Bold = significantly different; *Calculated using data provided (if not indicated directly taken from table in paper); **Risk estimate are adjusted 
for covariates as stated in supplementary table 3. Covariates used in the various analyses are the same within one study. *** Case control studies; 
**** Cohort studies or randomized clinical trials; ***** Included in meta-analysis; ****** The exposure of interest is the exposure comparison 
group in this analysis. Abbreviations: NR= not reported, NE= not estimated, HI= human insulin, TZD= Thiazolidinedione, NIAD=non-insulin anti-
diabetic drug.  
 




Fig. 2 Protein expression profiling of eight commonly used human 
breast cell lines. Receptor levels and signalling molecules downstream 
of the INSR/IGF1R signalling pathway have been quantified. 
Furthermore some breast cancer subtype markers have been used to 
further characterize these cell lines that are commonly used in the 















Fig. 3 Forest plot reported hazard ratios for risk of breast cancer among insulin glargine users.  
 
 





The increased carcinogenic effect of insulin AspB10 was already discovered in 1992 [80]. Since 
then this insulin analogue has been used in many in vitro studies as a reference compound with 
a strong carcinogenic potential. In proliferation studies AspB10 was highly mitogenic compared 
to human insulin irrespective of the cell line used [33, 34, 38, 39, 41, 46] (Table 1). Most studies 
indicated that AspB10 induces proliferation by increased IGF1R signalling, but there are 
indications that the INSR is also involved since increased proliferation was not fully blocked when 
using a specific IGF1R inhibitor [38]. One study used two murine mammary tumour cell lines, 
both expressing INSR and IGF1R. These cell lines were stimulated with AspB10 and only activation 
of IR and not IGF1R was observed [32]. In a different study it was indicated that a prolonged 
occupancy time of this analogue towards the INSR results in sustained activation of this receptor 
and subsequently increased mitogenic potency [34]. With a collagen invasion assay it was 
determined in several breast cancer cell lines that AspB10 has an increased invasive capacity 
compared to human insulin [41]. In a very elaborate kinase/inhibitor study it was found that 
multiple core kinases are involved in the mitogenic behaviour of AspB10 since phosphorylation 
of AKT, p70S6K, S6, and 4E-BP1 was found to be increased compared to human insulin exposure 
[39].  
In animal studies, AspB10 was found to have a dose-dependent increased carcinogenic 
potential[80] (Table 2). Xenograft rodent models with injected mammary gland tumour cell lines 
were treated with either human insulin or AspB10. Tumours were significantly bigger after the 
AspB10 injections and, although not significant, more lung metastases were found in this 
treatment group. From a kinase activation analysis on these tumours a strong up regulation of p-
AKT was found indicating that the carcinogenic effects of AspB10 might be a direct effect from a 
PI3K response [32]. A very recent study used a p53R270H/+WAPCre mouse model, which develops 
spontaneous human relevant mammary gland tumours within 70 weeks, to show that chronic 
exposure to AspB10 significantly decreased the tumour latency time. A detailed protein 
expression analysis showed that tumours induced by AspB10 or IGF1 have a distinct expression 
pattern compared to tumours from insulin or vehicle treated mice; both the PI3K and the MAPK 
were found to be significantly up regulated after AspB10 and IGF1 treatment [52]. A different 
study focussed on the short term mitogenic effects of AspB10 and found a significant stronger 
receptor activation in the mammary glands of Sprague-Dawley rats one hour after AspB10 
injections compared to human insulin treatment [51].  
As Insulin AspB10 has been shown to have mitogenic properties in in vitro and animal studies, 








Insulin glargine (M1/M2) 
Seven of ten in vitro studies found an increased proliferative potential of glargine in comparison 
with human insulin [34, 37, 40, 41, 43, 46, 47] (Table 1). Two studies found proliferative behaviour 
of glargine as well, but human insulin was not included as a reference compound, therefore they 
could not confirm an increased proliferative response [44, 45]. One study is difficult to interpret, 
since IGF1 did not show an increased mitogenic potential either [36]. Glargine has, similar to 
insulin AspB10, an increased binding affinity towards IGF1R [81]. This receptor is assumed to be 
responsible for the increased mitogenic action. Studies including kinase activation assays 
indicated that the PI3K signalling cascade is significantly up regulated after glargine stimulation 
compared to human insulin stimulation [40, 43, 45, 46]. Two studies also found the MAPK 
signalling cascade to be up regulated [40, 43]. The clinical relevance of this increased mitogenic 
potential is yet unknown since glargine is rapidly metabolised in vivo into two metabolically 
active compounds, M1 and M2 [82, 83]. These metabolites possess low mitogenic signalling [40, 
46].  
In a 2-year follow up study, wild type Sprague-Dawley rats, Wistar rats, and NMRI mice have been 
used to test the effect of chronic glargine injections compared to the insulin NPH injections; no 
difference in tumour free survival was observed [49, 50] (Table 2). In contrast, a recent study 
revealed a (non-significant) decrease in tumour latency time after a similar chronic exposure to 
glargine; tumour multiplicity or metastases were not affected [52]. Glargine injections induced 
no increased receptor activation response in the mammary glands of Sprague-Dawley rats [51]. 
Three Randomized Clinical Trials (RCT) that investigated breast cancer risk among glargine users 
compared to non-glargine users [54, 64, 75] did not show significant differences (Table 3). Most 
case-control and cohort studies showed a non-significant increased risk. Only two observational 
studies [69, 76] showed a statistically significant increased risk of breast cancer of respectively 
IRR 1.58 (95% CI 1.09, 2.29) and HR 1.65 (95% CI 1.10, 2.47). Both studies included glargine only 
users and compared them to non-glargine insulin users [69] and human insulin only users [76]. 
As the glargine studies did not show statistically significant heterogeneity (I2=0.0%; p>0.05) a 
meta-analysis could be performed. The pooled HR for glargine vs. no use of glargine of 13 studies 
was (HR 1.04; 95% CI 0.91, 1.17; p=0.49) (Fig. 3 and Table 3), showing no evidence for an 
association between insulin glargine treatment and an increased incidence of breast cancer.  
 
Insulin detemir 
Detemir is like glargine a long acting insulin analogue. In general, it is assumed that detemir has 
a lower mitogenic potential compared to human insulin [34, 40, 43, 46], but in a number of in 
vitro studies a similar or even an increased proliferative behaviour was observed [37, 41, 47] 
(Table 1). The binding characteristics for detemir towards albumin are different among species. 
In almost all in vitro studies BSA (bovine serum albumin) or FBS (fetal bovine serum) is added to 
 




the stimulation medium. Interpretation of these mitogenicity studies is difficult since it is not yet 
known how the bovine albumin interacts with detemir compared to human albumin [84]. For the 
same reason it is not surprising that no chronic animal studies have been conducted with insulin 
detemir. Only 3 epidemiological studies have been performed, one RCT [58] and two cohort 
studies [59, 67]; none found an association with breast cancer development (Table 3).  
 
Insulin aspart, glulisine and lispro 
Compared to glargine and detemir, the insulin analogues aspart, glulisine and lispro are less well 
evaluated for mitogenic potential; no increased mitogenic behaviour was found in four in vitro 
studies [37, 40, 42, 46] (Table 1). Only one in vitro study suggested a small non-significant 
proliferative increase of aspart compared to human insulin [43]. Another in vitro study found the 
mitogenic potential of glulisine to be significantly lower than human insulin [42]. Evidence that 
lispro and glulisine had an increased proliferative potential was found in just one in vitro study 
and for just two of the tested cell lines (MDA-MB-157 and MDA-MB-468) [41]. We previously 
found that the PI3K signalling cascade is significantly more up regulated after lispro treatment 
than human insulin stimulation only in the IGF1R over expressing MCF7 cell line [46]. Similar as 
for the in vitro, epidemiological data on these short acting insulin analogues is scarce. Just one 
study reported ORs for aspart and lispro of 0.95 (95% CI 0.64, 1.40) and 1.23 (95% CI 0.79, 1.92), 
respectively [61] (Table 3). 
 
Insulin users versus non-insulin users 
In the epidemiological studies, risk of breast cancer mostly showed non-significant decreased 
associations with insulin use versus non-insulin use (drug exposure undefined) (Table 3). In 
contrast, most studies that compared insulin users with NIAD users, irrespective of the type of 
NIAD used, showed non-significant increased associations. Only one study comparing insulin 
users versus non-insulin users showed an statistically significant decreased breast cancer risk of 
HR 0.86 (95% CI 0.81, 0.91) in type 2 diabetic patients [72]. However, we judge this study is likely 
to be biased.  
 
Dose and duration effects in epidemiological studies 
No significant differences were found between strata of duration and risk of breast cancer among 
users of any insulin [53, 55, 74] and insulin glargine [61, 63, 68, 77, 78] (ESM Table 4). However, 
a non-significant increased risk was found after more than 5 years of any insulin treatment (HR 
2.25; 95% CI 0.72, 6.99) [74]. Among the glargine users, the study with the longest follow-up 
comparing exposure of 4-7 years versus <4 years did not observe an increased breast cancer risk 
[61]. Another study revealed that the risk of breast cancer increased in the first 3 years after start 
of insulin glargine use. After 3 years risk of breast cancer remained at the same level [68]. Results 
 




of glargine dose on the occurrence of breast cancer [59, 61, 68, 70, 71, 76] showed inconsistent 
results (ESM Table 4). Some studies found significant increased relative risks with increasing dose 
[68, 71, 76], while others did not [59, 61, 70, 71]; this seems partly dependent on the exposure 
definition. Only one of the studies investigating glargine dose used cumulative dose [59]. The 
results of one in vivo study in humans indicated that there is almost no glargine circulating in 
plasma regardless of the dose given. Plasma M1 concentration increased with increasing dose of 
glargine, but as was mentioned previously, M1 possesses low mitogenic signalling [83]. 
 
Discussion 
Based on the current epidemiological and animal data there is no compelling evidence that any 
clinically available insulin analogue increases breast cancer risk. However, animal data was 
limited while the epidemiological studies were underpowered and suffered from methodological 
limitations. In vitro studies have shown that only insulin AspB10 and glargine have an increased 
mitogenic potential compared to regular human insulin in breast cancer cell lines. The relevance 
of this finding for the clinical situation is unknown since AspB10 is not used in humans and it has 
been shown that glargine is rapidly metabolized in vivo into M1 and M2, metabolites with a low 
mitogenic potential. Evidence on the potential pathways involved in insulin analogue-induced 
breast cancer mitogenesis is limited.  
 
Limitations of the studies and interpretation of the findings  
 
In vitro studies 
The main reason for contradictory in vitro findings can be explained by differences in study 
design. The responsiveness to growth factors, like insulin and insulin analogues, is to a large 
extent dependent on the cell line that is used in the assay. Based on the cell characterization 
(ESM Table 1), there is a striking variation in receptor expression of the human cell lines used. 
The MDA-MB cell lines are characterized by high levels of the INSR but low levels of the IGF1R 
compared to MCF7. Therefore, studies that used both cell lines could detect an increased 
mitogenic potential of IGF1 and glargine due to enhanced IGF1R signalling only in the MCF7 cell 
line, but not in the MDA-MB-231, as expected [40]. Other cell lines with low or moderate 
expression levels of IGF1R are less suitable for a mitogenic evaluation of insulin analogues. In line 
with this, a recent study including four different breast cancer cell lines (MCF7, MDA-MB-157, 
MDA-MB-468 and T47D) found that mitogenicity of growth factors strongly depends on the cell 
line that was used. However, the authors concluded that the INSR/IGF1R status was not the only 
explanatory factor [41]. Therefore, expression of downstream signalling molecules has also been 
determined (Fig 2). This gives insight into the lack of responsiveness of MCF10A when exposed 
 




to glargine [37, 43, 44], since this cell line has low expression of IRS1, the first downstream target 
of the INSR/IGF1R.  
 
The majority of the mitogenicity studies used the MCF7 cell line [35-40, 42-47]. It is desirable that 
future studies include different cell lines, so that cell line specific effects can be excluded. For 
translational reasons it is essential that protein expression (and especially receptor profiles) in 
benign human mammary gland tissues are quantified, only in that way we can determine which 
cell model has the highest clinical relevance.  
Another important quality factor is the starvation method. For a proper effect of a specific 
stimulation it is essential that the target cells are deprived from other growth factors. Some 
studies did not starve their cells prior to the start of the assay [33, 37, 40, 45], especially for short 
term assays this might have major consequences. At last, the use of proper positive and negative 
controls is most important for a good quality experiment. Some studies [44, 45] did not include 
a positive control while others lack a negative control [35], thereby making it impossible to put 
the results in perspective. Furthermore, one study did include a positive control (IGF1) [36], but 
this compound did not show a positive effect, questioning the sensitivity of their experiments.  
 
Animal studies  
The type of the animal model used plays a major role in the quality of animal studies. Generally, 
it is thought that rats are more sensitive in terms of carcinogenicity towards compounds and 
have a higher clinical relevance than mouse models [85]. But there are also major disadvantages, 
like higher costs and the lack of good humanized breast cancer rat models. Two studies that used 
rats have rather small group sizes, which obviously affected the power of their studies [49-51]. 
The doses that were used in the reviewed animal studies are quite comparable to each other and 
are all thought to be supra-physiological (i.e. over 50 times the human dose, based on nmol/kg). 
In one study a non-equimolar comparison was made between the different compounds, but 
doses had been chosen to induce an equi-pharmacological/metabolic response [52]. In another 
study a high mortality was observed, probably due to hypoglycaemia, therefore the dose was 
lowered in a later phase of this study [51]. Surprisingly, other studies that used similar doses did 
not observe hypoglycaemia [49, 50, 52]. To verify the sensitivity of the models and techniques it 
is essential that the appropriate controls are included. Half of the included animal studies lacked 
proper controls. In our opinion both insulin and IGF1 (and ideally also AspB10) should always 
serve as controls to be able to put the obtained results in to perspective. 
 
Epidemiological studies 
The epidemiological studies included in this review have many limitations and results are difficult 
to compare across studies because the exposure of interest and exposure comparison groups 
 




have been defined differently. For example, some studies compared glargine only users with 
human insulin only users [76], while others compared glargine users with non-glargine insulin 
users [78]. In this case, the comparator is a mix of several exposures. Some studies examined 
several definitions for the exposure of interest and this resulted in slightly different effect 
estimates [69, 71]. Besides that, these categories do not specify whether these insulin users were 
using different NIADS at the same time.  
 
Inclusion criteria differed largely among studies. For example, some studies included patients 
with only 1 insulin prescription while others included continuous users over a period of six 
months. More important, there was large variation in the time of exposure definition. Some 
studies determined the use of different insulin types at baseline or during a fixed period 
(intention to treat), while others determined insulin exposure during follow-up (time-
dependently).  This may lead to patients with only one specific insulin prescription during follow-
up being falsely classified as continuous users during the whole period. Cumulative exposure over 
time, censoring for discontinuation, or switching and latency period could affect the results. The 
uncertainty surrounding the extent to which a registered prescription dispensed for an insulin 
analogue reflects real life use of insulin analogues limits the ability to detect the true effect on 
the occurrence of breast cancer. Furthermore, studies variably included incident and prevalent 
users of insulin compromising estimates of association between the duration of use and breast 
cancer development. 
Other methodological aspects that are important when interpreting the results of these studies 
are: incorrect and too short exposure time (max 3.8 years mean exposure time), reverse 
causation, confounding by indication, and residual confounding (ESM 3). Most studies were 
based on type 2 DM, and/or did not specify type of DM. 
Risk of bias was classified as low (for definition see ESM 3) in only 5 studies [54, 58, 61, 74, 75], 
but in these studies power was not adequate (ESM Table 5). Of these studies, only two studies 
considered breast cancer as a main outcome [61, 74]. Most risk estimates have wide CIs, due to 
lack of power of the study. Two of the three studies that found significant different results were 
classified as having a high risk of bias [69, 72] or even so had lack of power [69, 76]. So far there 
is not a single properly designed study that investigated insulin treatment and breast cancer risk 
as main outcome, and had sufficient power. The included RCTs had limitations too, such as 
limited follow-up (except for one RCT with a follow-up of 6 years [54]), insufficient power, or 
cancer incidence as a secondary outcome [75, 86]. 
 
All layers of evidence in perspective  
Studies in humans are the gold standard for evaluating evidence of exposure and disease. The 
epidemiological studies reviewed varied in study design and exposure definition to a too large 
 




extent among different insulin analogues to evaluate their impact on breast cancer risk 
estimates. The risk estimates seemed not to be biased by important confounders as adjusted and 
unadjusted risk estimates only differed slightly. However, unmeasured confounding may still be 
present. In addition, the upper limit of the 95% CI of the pooled risk estimate of BC among 
glargine users was 1.17. This strengthens our idea that if any, the risk increase of breast cancer 
due to currently used insulin (analogues) is likely to be very small. 
A distinction should be made between studying tumour initiation or progression, though in the 
human setting it difficult to discern these because of potential lag time in detection of cancer. 
The epidemiological studies investigated incidence of primary breast tumours upon insulin 
treatment in DM patients. True tumour initiation in animal studies can only be investigated with 
long-term exposure in rodents, which are costly experiments. The animal xenograft models and 
in vitro studies mammary tumour cell line summarized here investigated tumour progression; 
e.g. by evaluation of cell proliferation or up regulation of mitogenic pathways. All together, the 
results of this systematic review suggest that insulin treatment might be involved in tumour 
promotion.  
 
Tumour promotion is related to tumour subtype and survival. Compared to patients without DM, 
breast cancer in patients with DM is often diagnosed at an advanced stage [87-92]. However, 
only two studies reported information on breast cancer subtypes after insulin treatment. One in 
vivo study reported more PR- (38% vs. 26%) and less HER2+ (0% vs. 6%) tumours among glargine 
users compared to patients using other types of insulins [93]. One epidemiological study provided 
the occurrence of breast cancer subtypes among glargine users (HER2+: 8.1%, triple negative: 
14.8%, luminal: 9.0%) [61]. It has been shown that overall mortality after breast cancer diagnosis 
is 30 to 40% higher in diabetic women compared to their non-diabetic counterparts [90, 94-101]. 
Whether this increased mortality is caused by death due to breast cancer or death by 
comorbidities related to DM is not clear. One study found that the increased risk of dying in DM 
with breast cancer is comparable to the general increased risk of dying as a diabetic patient [102]. 
Studies that investigated the association between breast cancer-specific mortality and diabetes 
show inconsistent results [87, 90, 91, 94, 103]. Among patients with type 2 DM, insulin treatment 
was associated with a worse cancer outcome and increased all-cause mortality compared to 
metformin treatment [90, 104]. Only one study investigated the effect of cumulative dose and 
duration of insulin treatment on breast cancer specific survival, and found a lower breast cancer 








Unanswered questions and future research  
Except for Insulin AspB10, which has never been available to humans, all insulin analogues are 
still marketed. Although, there is evidence from in vitro data that insulin glargine has an increased 
mitogenic potential, so far, epidemiological studies have not shown evidence for an association 
between insulin (analogue) treatment and breast cancer risk in female diabetic patients. 
However, due to relatively short follow-up time in the epidemiological studies, it cannot be 
excluded that diabetic patients with pre-neoplastic lesions might be at higher risk of developing 
an invasive tumour when given a specific insulin treatment. Research on this topic is important 
but is still largely lacking. Therefore, we are awaiting the results of on-going efforts to pool 
multiple large national databases from different countries to perform a retrospective 
observational study in humans with a proper design, enough patients and long follow up. 
Additionally, further research in the aetiology of insulin and breast cancer development is 
important [106].  
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ESM Fig. 1 Forest plot of breast cancer risk among insulin (analogues) users stratified by treatment group and type 
of effect estimate. Different exposure comparisons within one study are indicated by a, b, c. The exposure 
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o IGF1R is transmitting most of the insulin analogue induced proliferative signalling 
o Glargine strongly induces mitogenic signalling cascades in a similar extent as AspB10 
o All other commercial insulin analogues  as well as the two metabolites of glargine have a mitogenic 
potential similar to insulin 
     IN THE PICTURE 
SRB proliferation assay plates. The SRB 
technique is used to quantify proteins in a 
sample, which is used as a measure for the 
total amount of cells. A high intensity of pink 
colour indicates a high number of cells present 
in the sample. By doing dose response 
experiments or measure sequential days, the 
growth potential of cells under specific 
conditions can be determined. A SRB-based 
screen will generate many plates. An 
estimated three hundred 96-well plates were 
used in this research. 
    IN BEELD
SRB proliferatie analyse platen. De SRB techniek 
wordt gebruikt om het totaal aan eiwitten te 
kwantificeren, hetgeen een maat is voor het totaal 
aantal cellen in een monster. Hoe rozer het 
welletje hoe meer cellen aanwezig zijn. Door op 
verschillende dagen te meten kan de 
groeipotentiaal van cellen bepaald worden onder 
specifieke condities (bijv. aanwezigheid van een 
bepaalde stof). Een analyse gebaseerd op deze 
methode resulteert al snel in veel platen. 
Ongeveer driehonderd 96-welletjes platen zijn 
gebruikt in dit onderzoek. 
 





Insulin analogues are widely used in clinical practice. Modifications on the insulin molecular 
structure can affect the affinity and activation towards two closely related receptor tyrosine 
kinases: the insulin receptor (INSR) and the insulin-like growth factor 1 receptor (IGF1R). A 
switch towards higher IGF1R affinity is likely to emphasize mitogenesis rather than glucose 
metabolism. Relevant well-validated experimental tools to address the insulin analogue 
activation of either INSR or IGF1R are missing. We have established a panel of human MCF-7 
breast cancer cell lines either ectopically expressing the INSR (A or B isoform) in conjunction 
with a stable knockdown of the IGF1R or ectopically expressing the IGF1R in conjunction with 
a stable knockdown of the INSR. In these cell lines, we systematically evaluated the INSR and 
IGF1R receptor activation and downstream mitogenic signalling of all major clinical relevant 
insulin analogues in comparison with insulin and IGF1R. While most insulin analogues primarily 
activated the INSR, the mitogenic activation pattern of glargine was highly similar to IGF1 and 
insulin AspB10, known to bind IGF1R and induce carcinogenesis. Yet, in a long-term 
proliferation assay, the proliferative effect of glargine was not much different from regular 
insulin or other insulin analogues. This was caused by the rapid enzymatic conversion into its 
two metabolic active metabolites M1 and M2, with reduced mitogenic signalling through the 
IGF1R. In summary, based on our new cell models, we identified a similar mitogenic potency 
of insulin glargine and AspB10. However, rapid enzymatic conversion of glargine precludes a 
sustained activation of the IGF1R signalling pathway. 
 
Keywords: insulin glargine, mitogenic, human breast cancer, IGF1R 
Introduction 
Both type 1 and type 2 diabetic patients benefit from insulin injections. Modifications to the 
structure of insulin have changed its absorption, distribution, metabolism and excretion (ADME) 
characteristics. Fast acting analogues (e.g. aspart, lispro and glulisine) have been developed that 
are more readily absorbed from the injection site compared to regular insulin, intended to supply 
bolus level of insulin needed after a meal. Long acting analogues (e.g. glargine and detemir) are 
released slowly and steady from the injection site, intended to supply basal level of insulin activity 
during the nocturnal period.  
Two decades ago, the fast acting insulin AspB10 [107] was found to induce tumor formation in 
rats [108] and therefore never entered the market. Yet it raised speculations on the cancer risk 
of insulin analogues. Therefore, all new insulin analogues require testing for their mitogenic and 
carcinogenic potential in in vitro and in vivo assays, which have severe limitations. While insulin 
glargine (Lantus) was negative in the 2-year rodent carcinogenicity studies, epidemiological 
studies on cancer incidence based on diabetic patient data are conflicting. While one camp 
 




suggests no relation between the use of insulin glargine and the occurrence of any cancer [18, 
109] [19] [67] [86], others found an association with (breast) cancer development [16] [70] [17] 
[76]. The relevancy of life-long bioassays in animals for these type of products can be questioned.  
Similarly, in vitro studies have led to contradictory findings regarding the mitogenic potency of 
insulin analogues. Comparisons are difficult to make as sometimes no distinction was made 
between activation of the different isoforms of the insulin receptor, different cell lines, culture 
conditions and/or treatment regimens were used. Some studies indicate a clear increased 
mitogenic potency of insulin glargine in comparison with regular human insulin [37, 43, 45, 110-
117] whereas others found no difference in mitogenic potential [118-126]. In vitro studies have 
shown that insulin glargine has, like AspB10, an increased binding affinity for the IGF1R [114] 
[127]. A prolonged occupancy time for the insulin receptor A isoform (IRA, the insulin receptor 
isoform without exon 11) might also contribute to the increased mitogenic effect of some insulin 
analogues [113]. A major drawback of these studies is the presence of both INSR and IGF1R in 
the cells, precluding the relative contribution of these receptors to the downstream mitogenic 
signalling and ultimate increased cell proliferation. 
Here we applied a unique approach by integrating receptor overexpression studies with RNA 
interference techniques to selectively assess the contribution of the insulin and IGF1 receptors 
in insulin analogue-based signalling. Thus we established a complete novel panel of human MCF-
7 breast cancer cell lines that either ectopically expresses the IGF1R combined with stabile 
lentiviral shRNA-based knockdown of IR, and reversely cell lines ectopically expressing IRA or IRB 
with stabile shRNA-based knockdown of IGF1R. The different human cell lines were 
systematically treated with physiological relevant concentrations of insulin and various clinical 
relevant insulin analogues including insulin glargine, the metabolites of glargine (M1 and M2), 
AspB10, aspart, glulisine, lispro, detemir as well as IGF1. The pro-mitogenic signalling cascade 
activation and proliferation potential were systematically determined for the different insulin 
analogues. The effect in these breast cancer cell lines was compared with the in vivo activation 
of the pro-mitogenic signalling in the mouse mammary gland. 
Materials and Methods 
Antibodies and reagents 
Antibodies against rabbit anti-phospho-IGF1Rβ (tyr1135/1136)/phospho-IRβ (Tyr1150/1151), 
anti-Akt, anti-phospho-Akt (Ser473), anti-Erk, anti-phospho-Erk (Thr202,Tyr204) (Cell Signalling 
Technology, Danvers, MA, USA), mouse anti-IGF1Rβ and rabbit anti-IRβ (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and mouse anti-tubulin (Sigma-aldrich, St. Louis, MO, USA) 
were commercially purchased. Conjugated secondary antibodies included anti-mouse 
 




horseradish peroxidase (HRP) and anti-rabbit HRP (Jackson ImmunoResearch, West Grove, PA, 
USA). 
Human insulin (Humalin Lilly, Fegersheim, France), the insulin analogues (table 1) and IGF1 
(Increlex, Ipsen Pharma, Boulogne-Billancourt, France) were commercially purchased. The two 
main metabolites of insulin glargine (M1 and M2) were kindly provided by Dr. N. Tennagels 
(Sanofi-Aventis, Frankfurt, Germany). Insulin AspB10 was kindly provided by Dr. B. Falck Hansen 
(Novo Nordisk, Copenhagen, Denmark). To maintain the stability of these analogues 1000x 
concentrated stock solutions were prepared in their original vehicle solutions.  
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MCF-7 cells (ATTC, Manassas, VA, USA) were cultured in RPMI 1640 medium (Gibco, Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin-
streptomycin (Invitrogen), which is referred to as complete medium. Cells were grown in cell 
culture flasks (Corning) till 70-80% confluence was reached. For all the assays described in this 
manuscript, cells with a passage number between 2 and 6 after transduction were used. 
Phoenix retroviral overexpression 
pBABE-zeo (containing zeomycin resistance gene) and pBABE-IRB (containing both a zeomycin 
resistance gene and the cDNA of the human Irb gene) were  kindly provided by Prof. G. R. Guy 
 




(Signal Transduction Laboratory, Institute of Molecular and Cell Biology, Singapore). The pNTK2-
neo plasmid containing the neomycin resistance gene and pNTK2-HIR (a vector with a neomycin 
resistance gene and the cDNA of the human Ira gene) were kindly provided by Prof. A. Ullrich 
(Max Planck institute of Biochemistry, Germany). IRA and IRB encoding retroviruses were 
produced by transfection with the previously mentioned plasmids into the phoenix amphotropic 
packaging cells described by Swift et al. [128]. MCF-7 cells were infected with freshly harvested 
retroviral supernatant, cultured for two days on complete medium and selected with 400 µg/ml 
neomycin (for MCF-7 IRA) or 400 µg/ml zeomycin (for MCF-7 IRB) for one week. Multiple clones 
were generated and with western blotting the highest stable IR overexpressing MCF-7 lines were 
selected. Stable IGF1R over expressing MCF-7 cells (using the pMSCV-neo-IGF1R vector) were 
described previously by us [129]. 
Lentivirus shRNA knockdown 
For the preparation of stable shIR and shIGF1R cell lines, MCF-7 wt, MCF-7 IGF1R, MCF-7 IRA or 
MCF-7 IRB cells were transduced by using lenti-viral shRNA vectors (Sigma-Aldrich), kindly 
provided by Prof. R. Hoeben, Leiden University Medical Center (LUMC). Several shRNA constructs 
per receptor were tested. TRCN0000000424, target sequence: GCTGATGTGTACGTTCCTGAT 
(shIGF1R) and TRCN0000000380 target sequence: GTGCTGTATGAAGTGAGTTAT (shIR) showed 
the highest (>90%) knockdown efficiency (data not shown), these constructs were used to 
knockdown the receptors. Cells were selected using puromycin (4 µg/ml) for one week. 
Cell treatment 
Cells were seeded in 6-well plates at a confluence of 60-70% in complete medium. The next day, 
cells were starved overnight with 1% FBS containing RPMI medium, followed by 2 hours of serum 
deprivation with serum free medium (SFM). Cells were exposed to insulin and its analogues at a 
given dose in SFM for 30 minutes, directly followed by cell lysis.  
Western blot analysis 
For the general materials and methods of the cell lysis and Western blot analysis we refer to 
Zhang et al., 2011 [129]. Total protein was separated on a 7.5% (IR, IGF1R and p-IGF1R) or 10% 
(Erk1/2, p-Erk, Akt, p-Akt). Blocking was performed at room temperature for 1 h in either 5% 
(w/v) bovine serum albumin BSA (for Erk, Akt, p-Erk, p-Akt and tubulin) or 5% (w/v) not-fat dried 
milk (for IGF1Rβ, IRβ and p-IGF1R/p-IR) dissolved in washing buffer (100 mM Tris, pH 7.4, 500 
mM NaCl, 0.05% Tween 20). PVDF membranes were exposed to Pierce® ECL Western blotting 
substrate (Thermo Scientific, Rockford, IL, USA) and proteins were visualized by placing the 
membrane in contact with standard X-ray film (GE Healthcare, Little Chalfont, England). 
Thereafter the film was developed with a Kodak X-omat 1000 processor. A Cy-5 conjugated 
secondary antibody, diluted 2000 times in 1% BSA/washing buffer, was used for the tubulin 
 




stained membrane, which was scanned using a Typhoon 9400 imager. For the quantification of 
the western blot results, all bands were quantified using ImageJ software (ImageJ, 1.43u). The 
intensity of each band was divided by the tubulin intensity of that same sample and subsequently 
divided by the corrected intensity of the endogenous control of the same blot. Hierarchical 
clustering on these values was performed using Spotfire (Spotfire®DecisionSite®9.1.2, Version 
20.5.1039) with a Euclidean distance. 
Cell proliferation 
Cells were seeded with 10,000 cell/well in 96-well plates in complete medium and incubated 
overnight. Prior to the insulin (analogue) or IGF1 stimulation, cells were starved for two days in 
phenol red free RPMI 1640 medium (Gibco) supplemented with 5% charcoal/dextran-stripped 
FBS (CDFBS) (HyClone Laboratories, Thermo Scientific, Logan, USA), devoid of steroid hormones 
and very low (0.18 pM) insulin levels. Starved cells were stimulated with insulin, its analogues or 
IGF1 with a given concentration in triplicate and allowed to proliferate for four days. 
The sulforhodamine B (SRB) colorimetric assay [130] was used to determine the relative number 
of cells. This assay was described previous by our group [129]. 
IR PCR and AVRII restriction analysis 
Cells were harvested using a cell lifter, followed by RNA isolation using the RNeasy ® Plus mini kit 
(Qiagen GmbH, Germany). From the isolated RNA, cDNA was synthesized using a RevertAid H 
minus first strand cDNA synthesis kit (Fermentas international Inc.). Primers were designed 
around exon 11 of the IR (5’-TGGATTATTGCCTCAAAGGGC-3’ and 5’-GAGACGCAGAGATGCAGC-
3’). The Phire polymerase chain reaction (PCR) kit (Finnzymes) was used to generate a 691 bp 
(IRB) or a 655 bp (IRA) amplicon. Thereafter, the samples were cut using the AVRII restriction 
enzyme (Bioke, New England Labs). This restriction enzyme makes an asymmetrical cut within 
the exon 11 of IRB, cleaving the 691 bp amplicon in a 435 bp and 256 bp fragment. The 
PCR/restriction enzyme mix was loaded on a 2% agarose gel and imaged with a UV 
transilluminator. 
Insulin glargine metabolism in vitro 
In vivo, insulin glargine is rapidly processed into two metabolically active metabolites (A21-Gly-
insulin as M1 and A21-Gly-des-30G-Thr-insulin as M2) from the injection site [131]. The extent of 
glargine degradation in our SRB assay set-up was determined. MCF-7 cells were starved for two 
days with 5% CDFBS containing RPMI medium and stimulated for 0, 6, 24, 48, 72 or 96 hours with 
100 nM insulin glargine (diluted in 5% CDFBS). 50 µL of supernatant was taken at the given time 
points and directly added to 50 µL of HCl (100 mM). Samples were kept frozen (-20 ˚C) until the 
analysis. Using immunoaffinity columns glargine, M1 and M2 were extracted and quantified by a 
specific liquid chromatography mass-tandem spectrometry assay [132]   
 




Insulin glargine metabolism in vivo 
Ten female p53+/R270H mice (Jackson laboratories (Bar Harbor, ME)) got a single subcutaneous 
injection with 100 nmol/kg of glargine, 1 hour (n=5) and 2 h (n=5) after injection mice were 
sacrificed, at both time points also LANTUS-vehicle injected mice were sacrificed. Two mammary 
glands per mouse were snapfrozen in liquid nitrogen and used in a Western blot analysis to 
measure activation of mitogenic pathways upon glargine treatment. Blood was extracted in K2-
EDTA coated blood collection vials (Sarstedt) with 20 µl/ml protease inhibitor cocktail and put 
immediately on ice. Within 1.5 hours the tubes were centrifuged (1500g, 10˚C for 10 min) and 
transferred to regular eppendorf tubes. Samples were stored at -20C and within a month 
measured. Using the before mentioned liquid chromatography mass-tandem spectrometry assay 
the M1, M2 and glargine concentrations have been determined in the plasma.  
Statistical analysis 
Each SRB data point represents the average of corrected proliferation data from five independent 
experiments. Within such an experiment each average SRB absorbance value was derived from 
triplicate samples. For each experiment the average SRB was corrected against the unstimulated 
(0% SRB proliferation) and the maximal, 333 nM stimulated sample (100% SRB proliferation). A 
non linear sigmoidal dose response (with variable slope) curve was used to fit the data and 
retrieve the EC50 values. 
 
Results 
MCF-7 wt expresses biologically active IR and IGF1R and downstream pathways of these receptors 
are intact 
First we selected the most appropriate cell line for our model. As IGF1 and insulin AspB10 
signalling has been associated with breast cancer [133] [108], a human breast cancer cell line was 
a logical choice. To ensure the presence of both the IR and IGF1R signalling pathways we first 
evaluated the IR and IGF1R protein levels in 41 human breast cancer cell lines (data not shown). 
Five were selected that expressed both the IR and IGF1R at relatively high levels (HCC38, MCF-7, 
MDA-MB-231, SUM44PE and UACC812). SUM44PE and UACC812 are known to express high 
levels of ErbB2, a dominant oncogene for mitogenic signalling, and were therefore discarded. The 
MCF-7 cell line showed the highest overall IR and IGF1R levels as compared to other breast cancer 
cell lines and since this is a well defined cell model, it was selected to further study the 
responsiveness to insulin and IGF1 (fig 1). IGF1 caused strong phosphorylation of the IGF1R and 
subsequent activation of the canonical pathways downstream of these receptors (MAPK/Erk and 
PI3K/Akt); also insulin caused activation of these mitogenic programs, with mild phosphorylation 




Fig 1 Dose dependent activation of receptors and 
downstream signalling pathways in MCF7 cells. 
Treatment of MCF-7 cells with either insulin or IGF1 
caused a concentration dependent activation of the IR 
and IGF1R, respectively. MCF-7 was stimulated for 30 
minutes with human Insulin and IGF1 (at 1, 3, 10, 33 and 
100nM). IR, IGF1R, p-IR/IGF1R, Akt, p-Akt, Erk, p-Erk and 




IRA, IRB, IGF1R over-expressing MCF-7 cell lines with knockdowns of IR or IGF1R have varying 
IRA/IRB/IGF1R levels and the transfections did not affect the Erk or Akt levels. 
We wanted to selectively study the effect of insulin analogues on IR (IRA and IRB) and IGF1R. 
Therefore, we generated MCF-7 cell lines with increased IR or IGF1R receptor levels. Importantly, 
we subsequently created stable lentiviral-based knockdown of the IR, for the IGF1R over 
expressing cell line (MCF-7 IGF1R) and knockdown of the IGF1R in the IRA and IRB over expressing 
cells (resp. MCF-7 IRA and MCF-7 IRB). This resulted in a unique panel of cell lines to selectively 
study IRA, IRB and IGF1R signalling (fig 2a). 
The lentiviral shCtrl and the pBABE-empty did neither affect receptor levels nor the total levels 
of Akt or Erk. Overexpression IRA/IRB/IGF1R (all around 200% in comparison with MCF7 wt) and 
knockdown of IR did not have a clear effect on the activation of Akt and Erk (fig 2b-f). But shIGF1R 
led to a strong decrease in Erk activation, without affecting Akt. The IRA and IRB overexpressing 
cell lines did show activation of the receptor by insulin and subsequent subtle Erk and Akt 
phosporylation; this was not observed in the wildtype MCF-7 cell line. The IGF1R overexpressing 
MCF-7 cell line strongly responded to IGF1 stimulation in terms of IGF1R, Erk and Akt 
phosphorylation. Some residual IGF1R expression remained in the MCF-7 IRA shIGF1R and MCF-
7 IRB shIGF1R cell lines. The antibody that was used to detect the beta-subunit of the IR can not 
discriminate between the two isoforms IRA or IRB of the insulin receptor. To qualify the insulin 
receptor isoforms in the established cells a PCR was performed on cDNA with primers that 
amplify around exon 11 of the IR, resulting in an amplicon of 691 bp (in case of IRB cDNA) or 655 
bp (in case of IRA cDNA). To confirm the presence of exon 11 in the IRB amplicon an AVRII 
restriction was performed, cleaving the IRB amplicon in two asymmetric pieces of 435 bp and 
256 bp. The MCF-7 wt cells expressed both isoforms of the insulin receptor. Further, it was 
confirmed that the appropriate isoform is expressed in the different cell lines, with some residual 
expression of IRA in the MCF-7 IRB shIGF1R cell line (data not shown). 
 




Fig 2 Generation of a panel of MCF7 cell lines with different receptor levels with an active downstream signalling 
pathway. A) Western blot analysis on protein levels (IR, IGF1R, Erk and Akt) of the established cell lines (MCF-7 wt, 
MCF-7 shCtrl, MCF-7 pBABE-empty, MCF-7 IGF1R, MCF-7 IGF1R shIR, MCF-7 IRA,  MCF-7 IRA shIGF1R, MCF-7 IRB, 
MCF-7 IRB shIGF1R). B-F), 1 hr exposure of 10 different cell lines to insulin and IGF1 to measure activation of 
downstream signalling cascades. This graph indicates that the ectopic expression and knockdown of the IR and IGF1R 
cell lines have a clear effect on the IR and IGF1R levels and that this has a clear effect on the activation of mitogenic 
pathways. The cell lines transfected with the control (empty) vectors (shCtrl or overexp. Ctrl pBABE-empty) show 
protein levels comparable with MCF-7 wt. EC is endogenous control (MCF7 IGF1R stimulated with 10 nM of IGF1) 
loaded on every blot to be able to make a fair comparison between different blots.  
Insulin glargine activates Akt and Erk similar to AspB10 and IGF1  
Next, we systematically investigated the mitogenic signalling activity of the various insulin 
analogues in three of the established cell lines: MCF-7 IRA shIGF1R, MCF-7 IRB shIGF1R and MCF-
7 IGF1R shIR (from now on referred to as MCF-7 IRA, MCF-7 IRB and MCF-7 IGF1R respectively). 
Most insulin analogues showed a concentration dependent activation of the receptors and the 
downstream Akt and Erk pathways, except IGF1 and detemir (fig 3). IGF1 demonstrated maximal 
activation of the IGF1R already at the lowest (10 nM) concentration. Despite the fact that IGF1 
has a very low binding affinity towards the IRB [114] [127], in the MCF-7 IRB cell line and after 
IGF1 stimulation some activation of Erk and Akt was observed. This might be due to an 
incomplete knockdown of IGF1R in these cells. Insulin stimulation led to activation of the IRA and 
IRB, while IGF1R was only activated at the highest concentration (100 nM) of insulin. The Erk 
activation follows the activation of these receptors quite strictly, yet the phosphorylation of Akt 
was typically stronger via the IGF1R. Like IGF1, AspB10 was able to activate the IGF1R and the 
downstream signalling cascade at low concentrations. Low concentrations of glargine also led to 
a strong activation of the IGF1R, Erk and Akt, mimicking the AspB10 response. In contrast, aspart 
 




and glulisine have a similar receptor and downstream activation pattern that is most similar to 
that of regular insulin. Lispro seems to be able to activate the IGF1R slightly more, but the 
phosphorylation of Akt and Erk is not more induced compared to regular insulin stimulation. 
Detemir only mildly activated the receptors, and only a very slight Erk activation was observed 
via the IRB. Overall, the IGF1R seems to have the strongest effect on mitogenic (Erk/Akt) 
signalling, whereas the IRB is hardly involved. These findings are in agreement with literature 
[134] [135] [136]. To allow for a more unbiased comparison of the effects of insulin homologues 
we quantified all the different signalling responses followed by hierarchical clustering of the data 
(fig 4). The activation pattern of insulin glargine stimulation via the IGF1R and IRA clustered with 
the activation pattern of AspB10 and IGF1. In contrast, aspart, lispro and glulisine showed an 
activation pattern similar to that of regular insulin. Insulin detemir was the least potent compared 
to regular insulin in activating mitogenic pathways at the tested concentrations; which fits with 
its in vivo potency (1 unit of human NPH insulin is 6 nmol vs 1 detemir unit is 24 nmol). [137] In 
conclusion, insulin glargine appears to activate the Erk (MAPK) and Akt (PI3K) through IGF1R 
signalling in a similar extent as AspB10.  
The proliferative effect of insulin glargine is similar to that of human insulin 
Next we evaluated whether the similarity of the activation of the mitogenic signalling by insulin 
glargine, AspB10 and IGF1 correlated with cell proliferative effects of these insulin analogues. For 
this we determined the proliferative capacity in our three cell lines (MCF-7 IRA, MCF-7 IRB and 
MCF-7 IGF1R) using a broad concentration range (0.01 to 333 nM). All insulin analogues showed 
a clear concentration dependent proliferative effect that followed a sigmoidal dose response (fig 
5a-c). Also regular insulin had a clear intrinsic proliferative effect. MCF-7 IGF1R cells showed the 
highest response to insulin analogues; again, the MCF-7 IRB showed the lowest response. In all 
cell lines AspB10 and IGF1 had the lowest EC50 values (fig 5d). Aspart, lispro and glulisine had 
very similar proliferation effects to regular insulin. Insulin detemir showed the lowest effect on 
proliferation in all cell lines. Importantly and unexpectedly, insulin glargine had comparable EC50 
values to regular insulin, indicating that initial strong mitogenic signalling mediated by insulin 
glargine exposure did not lead to an increased mitogenic potential compared to regular insulin.  
Insulin glargine is rapidly metabolised 
To clarify the discrepancy between insulin glargine mitogenic signalling and proliferation we 
carefully studied the metabolism of glargine and the formation of M1 and M2 (the two main 
metabolites of insulin glargine). Glargine processing appeared to be very rapid: in our 5% CDFBS 
culture medium in the absence of cells it took less than 24 ours to process 70% of the glargine 
into M1 (40%) and M2 (60%), after 4 days less than 3% of the original glargine was detected (fig 
6a). The addition of MCF-7 cells did not affect glargine metabolism into M1 or M2, but did 
influence glargine, M1 and M2 degradation. Thus, in 24 hours 50% of the insulin analogues 
 




(glargine, M1 and M2) were degraded by the cells. The degradation speed appeared to be similar 
for glargine, M1 and M2.  
Fig 3. Stimulation of a panel of 
MCF7 cell lines with insulin 
analogues to measure 
downstream mitogenic 
signalling. Westernblot 
analysis of 3 different cell lines 
(MCF-7 IRA shIGF1R, MCF-7 IRB 
shIGF1R and MCF-7 IGF1R shIR) 
stimulated by 8 different 
insulin like molecules (human 
insulin, AspB10, IGF1, glargine, 
aspart, lispro, glulisine and 
detemir) at 4 different 
concentrations (0, 10, 33 and 
100 nM). On each blot also an 
endogenous control, EC (MCF-7 
IGF1R shIR stimulated with 100 
nM of IGF1), was loaded. This 
sample was used for the 
quantification of the individual 
protein bands, to correct for 
any blot differences, exposure 
time differences etc. This 
experiment is performed twice 
and highly similar results were 
obtained. Only blots of the first 














Fig 4. Hierarchical clustering 
(using Euclidean distance) of 
quantified westernblot exposure 
data. A White color indicates no 
difference in activation compared 
to the unstimulated sample, the 
increasing dark green color 
indicates an increasing 
phosphorylation of either the 
receptor, p-Erk or p-Akt.  (n=2) 
 
 
Fig 5 Dose dependent proliferative effect of all insulin analogues in panel of MCF7 cell lines a-c Effect of insulin 
analogues on MCF7 cell proliferation. 3 Cell lines (MCF-7 IGF1R, MCF-7 IRA and MCF-7 IRB) stimulated with 10 
different insulin like molecules. Proliferation measured after 4 days of stimulation. All values are normalized against 
the unstimulated sample, (n=5). d) EC50 values of SRB proliferation assay.  
Repeated glargine dosing lowers the EC50 reflecting IGF1 
Since glargine appears to be metabolised and degraded rapidly under culture conditions we 
questioned whether the proliferative potential of glargine could be fully ascertained to the 
unprocessed form of glargine. Therefore an additional experiment was performed in which the 
growth factor containing medium was refreshed twice a day and compared to single growth 
factor stimulation (fig 6b,c). Repeated refreshing of glargine medium significantly reduced the 
EC50 value by more than 7-fold from approximately 23nM to about 3nM. Repeated refreshing of 
 




IGF1 medium caused a much smaller shift from 1.8nM to 0.53nM, which is likely only due to 
degradation. This observation suggests that glargine has an intrinsic high mitogenic potency, 
while the mitogenic potential of the metabolites M1 and M2 is likely to be in the order of human 
insulin.  
Fig 6 Glargine metabolism in 
long term in vitro assay A) 
Concentrations of insulin 
glargine, M1 and M2 over time in 
5% CDFBS containing RPMI 
medium in the presence and 
absence of MCF-7 cells. B) 
Relative proliferation measured 
in MCF-7 IGF1R, stimulated once 
with IGF1 (light red) or glargine  
(light green) or the growth factor 
containing medium was 
refreshed twice a day with IGF1 
(dark red) and glargine (dark 
green). Proliferation measured 
after 4 days of stimulation. All 
values are normalized against 
the unstimulated sample. N=3. 
C) The EC50 values of the 
proliferation curves. (* p < 0.05) 
 
The insulin glargine metabolites M1 and M2 reflect insulin in their mitogenic potency 
We next determined the mitogenic potency of the two main metabolites of glargine, M1 and M2. 
The activation pattern via the IRA and IRB as well as downstream Erk and Akt activation were 
similar for M1 and M2 and were comparable to insulin (fig 7). Importantly, little signalling was 
observed through the IGF1R pathway. Hierarchical clustering of the quantified Western blot data 
showed that the activation patterns of M1 and M2 were highly comparable to regular insulin. 
Finally, the proliferation assays (fig 8) confirmed that M1 and M2 have a low mitogenic potency 
which is comparable to regular insulin. 
Glargine is rapidly metabolised into M1 in vivo but activates mitogenic signalling in the mammary 
gland. 
Finally,  we evaluated the mitogenic signalling under in vivo conditions. We selected glargine as 
the model compound since it has a major concern regarding specificity for INSR versus IGF1R. 
One and two hours after glargine injection, M1 and M2 levels were measured in the plasma of 
mice.  
 




Fig 7 Metabolites of glargine show 
mitogenic pathway activation pattern 
similar to regular insulin. Westernblot 
analysis of 3 different cell lines (MCF-7 IRA 
shIGF1R, MCF-7 IRB shIGF1R and MCF-7 
IGF1R shIR) stimulated by M1 and M2 at 4 
different concentrations. (n=2) Only blots 
of the first experiments are shown. 
Hierarchical clustering (Euclidean distance) 
of quantified WB exposure data (including 
insulin, glargine, M1, M2, aspB10 and IGF1). 
The white color indicates no difference in 
activation compared to the non-stimulated 
sample, the increasing dark green color 
indicates an increasing phosphorylation of 
either the receptor, p-Erk or p-Akt.  (n=2) 
 
 
Fig 8 Metabolites of glargine show similar proliferative potential compared to regular insulin. a-c Relative 
proliferation measured for 3 Cell lines (MCF-7 IGF1R, MCF-7 IRA and MCF-7 IRB) stimulated with 6 different insulin 
like molecules. Proliferation measured after 4 days of stimulation. All values are normalized against the unstimulated 
sample, (n=5). d) EC50 values of SRB proliferation assay.  
 
 




Fig. 9. Glargine metabolism and 
mitogenic signalling in vivo. 
Samples for glargine metabolism 
were taken at 1 or 2 hours after 
injection with glargine/vehicle. 
Activation of Akt and Erk in the 
mammary gland of mice was 
detected at 1 and 2 hours after 




One hour after the injection M1 could be detected in all mice at high concentrations (Fig. 9a); 
only low levels of glargine and M2 could be detected. Two hours after the injections no glargine 
could be detected at all, very low levels of M2 (in 2/5 mice) were observed and in four out of five 
plasma samples M1 could be detected.This assay was used to discriminate glargine, M1 and M2 
from each other and human insulin. Some cross-specificity with the mouse insulin exists for M1. 
This explains why small amounts of M1 were found in one vehicle control. We then evaluated 
the differential levels and activation of IR, IGF1R, Akt and Erk in the mammary glands of the same 
mice (fig 9b). While one hour after glargine injections a strong activation of both Erk and Akt was 
detected, after two hours hardly any activation of these mitogenic pathways was left. This 
indicates that glargine treatment does not provide sustained activation of the mitogenic 
signalling in the mouse mammary gland.  
 
Discussion 
To systematically evaluate the IR and IGF1R signalling potency of insulin analogues, in the current 
study a novel, simplified, well characterized cell system was established including three MCF-7 
cell lines that either ectopically express the IR (A or B isoform) in conjunction with a stable shRNA-
based knockdown of the IGF1R, or the ectopic expression of the IGF1R in conjunction with a 
stable knockdown of the IR. Through measurement of the activation of downstream signalling 
cascades as well as the proliferation capacity of different insulin analogues we obtained an 
improved definition of the mechanisms behind the cellular signalling of individual insulin 
analogues. Our comparative study showed that insulin glargine has a higher mitogenic potential 
than regular human insulin, and closely resembles that of the known mitogenic insulin AspB10, 
which act mainly through IGF1R. In contrast, the two main metabolites of glargine, M1 and M2, 
did not have such an increased mitogenic potential and have a profile closely resembling that of 
human insulin. Other marketed insulin analogues tested in our study, aspart, lispro, glulisine and 
detemir, have a mitogenic potential comparable to that of regular human insulin. 
 




As mentioned before, there are conflicting data in the literature regarding the mitogenic 
potential of glargine in vitro. We postulate that metabolism of glargine is a very important 
parameter that can explain the conflicting literature data. In two studies describing long term (>2 
days) proliferation assays in which the glargine containing medium was refreshed twice during 
the assay, a significant increased mitogenic potential of glargine was found [43] [116]. On the 
other hand, long term studies in which the glargine containing medium was not refreshed, and 
therefore significant metabolism and degradation of the compound had likely occurred, an 
increased mitogenic potential compared to regular human insulin was not seen [122] [124] [125, 
126]. Moreover, these latter studies all used serum containing medium for their assays, making 
it likely that metabolizing enzymes are indeed present in the medium. Consistently, a study 
describing a four day proliferation assay, in which the (serum free) medium was refreshed only 
once, showed a non-significant increased mitogenic effect of insulin glargine compared to regular 
human insulin [118]. This modest effect is likely due to degradation of glargine during the two 
consecutive days in which the medium was not refreshed. Taken together, the conflicting results 
found in the literature can be explained by metabolism and degradation, as shown in our 
experiments, and point to a higher mitogenic potential of insulin glargine as compared to human 
insulin. Although we focused on the ambiguous conflicting results of glargine, some degradation 
is likely also the case for the other insulin analogues tested [138] [139]. 
Agin et al. studied how glargine is processed in vivo and found that on average over 70% of the 
injected glargine is metabolised into M1 (M2 was not determined in this study) within half an 
hour; carboxypeptidates present in serum are likely to be involved in this process [131]. Bolli et 
al. and Lucidi et al. and Varewijck et al. concluded that in patients almost all glargine is converted 
into M1 with no significant conversion into M2 [83] [140] [141]. In our in vitro assay the majority 
of glargine appeared to be converted into M2 (60%) and a smaller part in M1 (40%). This 
difference in study outcome with regard to levels of metabolites could in part be explained by 
differences in enzyme levels in the serum. Regardless, it is clear that glargine metabolism plays 
an important role in vivo, and it is therefore essential to clarify which specific enzymes are 
involved in this process and to what extent this process differs from person to person.  
To further substantiate our in vitro findings, we studied glargine metabolism in vivo in the mouse. 
Similar to the human situation glargine was rapidly metabolised. M1 appeared to be the 
predominant form and could be detected at high concentrations after glargine injections.  
A subsequent Western blot analysis indicated that one hour after glargine injections activation 
of mitogenic pathways in the mammary glands is detectable, but there is no sustained activation 
of these pathways. These in vivo results underline that the in vitro results are also relevant for 
 




the in vivo situation. The consequences for carcinogenic outcome of these brief pulses of 
mitogenic signalling caused by glargine treatment needs further evaluation.  
In conclusion, we have developed a unique cell-based assay that can be used to systematically 
screen insulin analogues for their mitogenic potential in relation to activation of INSR or IGF1R. 
Using this assay it was shown that insulin glargine has an increased mitogenic activity comparable 
to that of AspB10, that acts mainly via the IGF1R. The physiological relevance of this in vitro 
finding to insulin glargine patients is yet unknown, since the injected glargine is rapidly 
metabolised in vivo into low mitogenic but metabolically active compounds.  
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Supplemental figure 1. Western blot analysis to determine the IR and IGF1R levels in 41 human breast cancer cell 
lines. a) and b) represent triple negative breast cancer cell lines. c) Luminal like cell lines and d) epithelial-like and 
“round” like cell lines. The MCF7 IGF1R shIR cell line was included as an endogenous control. 
 
 
Supplemental figure 2.  Restriction enzyme analysis with AVRII on Insulin receptor PCR fragment to check isoform 
type in MCF-7 wt, MCF-7 IRA and MCF-7 IRB. M=100bp marker. (-) represents a negative control (PCR mix) 1=MCF-
7 wt PCR fragment, 2= MCF-7 IRA, 3=MCF-7 IRB, 4=pNTK2-IRA and 5=pBABE-IRB PCR fragment (A=uncut, B=cut with 
AVRII restriction enzyme). The 691 bp band represents the IRB PCR fragment. The 655 band represents the IRA 
fragment. AVRII will cut the IRB band into two smaller fragments of 435 and 256 bp. 
 
 





Supplemental figure 3. Western blot analysis to determine knockdown efficiency of several shRNA constructs.  shIR 
#1; TRCN0000000380, #2; TRCN0000000381, #3; TRCN0000000382. shIGF1R #1; TRCN0000000424, #2; 
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     IN THE PICTURE 
Immunofluorescent microscopy set up. This 
type of microscopes is often used to detect 
fluorescent light emitted by your protein of 
interest. In this way a high resolution and 
magnified picture can be created so that 
specific cell features can be studied. By taking 
pictures over time, the migratory behaviour of 
certain cells under specific conditions can be 
studied. 
    IN BEELD
immunofluorescentie microscoop opstelling. Dit 
type microscoop wordt vaak gebruikt om 
fluorescerend licht, uitgestoten door een te 
onderzoeken eiwit, te detecteren. Op deze 
manier kunnen hoge resolutie en vergrote 
plaatjes worden gecreëerd. Door op 
verschillende tijdpunten foto’s te nemen, kan 
het migrerende gedrag van cellen onder 
bepaalde condities worden bestudeerd. 
o IGF1 and AspB10 induce a very strong transcriptomic response, especially 1hr after stimulation 
o A mitogenic gene expression signature could be defined that was validated with different 
models and showed a high predictive potential as compared to functional assays 
o AspB10 and glargine are the only insulin analogues with an increased mitogenic potential 
compared to regular insulin as determined with this transcriptomic analysis 





Insulin analogues are designed to have improved pharmacokinetic parameters compared to 
regular human insulin. This provides a sustained control of blood glucose levels in diabetic 
patients. All novel insulin analogues are tested for their mitogenic side effects, however these 
assays do not take into account the molecular mode-of-action of different insulin analogues. 
Insulin analogues can bind the insulin receptor and the insulin-like growth factor-1 receptor 
with different affinities and consequently will activate different downstream signaling 
pathways. Here we used a panel of MCF7 human breast cancer cell lines that selectively express 
either one of the isoforms of the INSR or the IGF1R. We applied a transcriptomics approach to 
assess the differential transcriptional programs activated in these cells by either insulin, IGF1 
or X10 treatment. Based on the differential expressed genes between insulin versus IGF1 and 
X10 treatment we retrieved a mitogenic classifier gene set. Validation by RT-Q-PCR confirmed 
the robustness of this gene set. The translational potential of these mitogenic classifier genes 
was examined in primary human mammary cells and in mammary gland tissue of mice in an in 
vivo model. The predictive power of the classifier genes was evaluated by testing all 
commercial insulin analogues in the in vitro model and defined X10 and glargine as the most 
potent mitogenic insulin analogues. We propose that these mitogenic classifier genes can be 
used to test the mitogenic potential of novel insulin analogues as well as other alternative 
molecules with an anticipated affinity for the IGF1R. 
Keywords: insulin analogues, transcriptomics, IGF1R and INSR pathway, mitogenic classifier, 
breast cancer  
Introduction 
Diabetes mellitus is the most common endocrine disease with over 380 million patients in 2013, 
worldwide [142]. A common treatment for both type-1 and type-2 diabetics is the use of insulin 
analogues, which are insulin-like molecules with altered pharmacokinetic parameters so that 
they are either absorbed more rapidly or slower compared to regular insulin after injection. A 
combinational treatment with these short and long-acting insulin analogues provides the patient 
with normal blood glucose levels. These insulin analogues have been used for several decades, 
but recently some epidemiological studies found a correlation between the use of some of these 
compounds and the cancer occurrence, especially breast cancer [16] [76, 143] [144]. On the 
contrary, other epidemiological studies could not confirm these results and suggested that 
confounding factors (e.g. hyperinsulinemia and age of patients) might have caused this effect 
[64] [18] [19, 145, 146] [77]. There are two main hypotheses by which insulin analogues might 
increase the risk of cancer [147]. Firstly, the changes to the molecular structure of insulin affect 
the binding properties towards different receptors (e.g. insulin receptor-A (IRA) [134] or insulin-
like growth factor-1 receptor (IGF1R) [148]). As a consequence these insulin analogues have an 




increased mitogenic potential. In this scenario the insulin analogues could act either as a tumor 
initiator by transforming benign  or (pre-) neoplastic cells which often express increased levels of 
IRA and IGF1R [136], or as a tumor promoter by stimulating the increased growth potential of 
these cells. Secondly, insulin analogues might induce mutagenic action either directly or 
indirectly as a statistical consequence of the increased mitogenic potential. However, evidence 
for an indirect enhanced mutagenic effect due to insulin analogue treatment has never been 
observed and therefore the first hypothesis is the most plausible scenario. As indicated before 
some insulin analogues have an increased binding potential towards the IGF1R [114] and/or a 
prolonged occupancy time for the IRA [149]. A simple evaluation of this effect has been the 
proliferative potential of insulin analogues, but the obtained results strongly depend on the used 
cell model and experimental procedures (reviewed in Bronsveld et al.) (Bronsveld, 2015 
manuscript submitted) and are excluding the systematic evaluation of the actual role of the 
different insulin receptor families. We have developed a panel of MCF7 cell lines that express 
selectively either the IRA, IRB or IGF1R [46], which now allows us to differentiate the effect of 
individual insulin analogues on cellular signaling more precisely. 
The downstream signaling of IRA and IGF1R is a complex diverse network leading to the activation 
of a diverse set of downstream cell signaling cascades and various transcription factors. The 
difference in activating either INSR or IGF1R signaling ultimately defines the cell biological 
outcome, roughly metabolic control versus pro-mitogenic signaling respectively. The diversity of 
signaling events can be mapped using proteome-wide phospho-proteomics analysis [46]. 
Alternatively genome-wide transcriptomics may more broadly define the different signaling 
networks that are activated by either INSR or IGF1R. For the safety evaluation of novel chemical 
entities transcriptomics-based profiling is often used to correctly classify the potential toxic 
properties [150] [151]. Given the differential activation of INSR and IGF1R by some insulin 
analogues, we anticipate that an IGF1R activation gene expression signature would be 
advantageous to define the mode-of-action of highly mitogenic insulin analogues. Therefore, in 
this study we used our MCF7 human breast cancer cell lines  that differentially express  the 
different insulin receptor family members [46]. We used transcriptomics to define gene sets 
involved in insulin analogue induced mitogenic signaling. These genes are candidate mitogenic 
classifiers to predict the mitogenic potential of newly developed insulin analogues or growth 
factors in general that act on the IGF1R. 
 
Methods 
Primary cell isolation, Cell line generation and cell culturing 
Cell lines based on the human breast cancer MCF7 cell lines, which predominantly express the 
IRA, IRB or IGF1R have been described previously [46]. All MCF7 derivatives were cultured in 




RPMI 1640 medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (FBS) and 100 U/mL penicillin-streptomycin (Invitrogen). 
Primary human mammary cells have been isolated from cryopreserved biopsies of two 
individuals as described previously [152]. The two biopsies were obtained from two female 
patients who had undergone breast cancer-related surgery at the Leiden University Medical 
Center (LUMC). Procedures were followed according to the Dutch Medical Treatment Act and 
the study protocol was compliant with “the Code of proper secondary use of human tissue in the 
Netherlands” issued by the Dutch Federation of Medical Scientific Societies and approved by the 
Medical Ethical committee of the LUMC (P10.226). Specimens were coded anonymously in a way 
that they were not traceable back to the patient by laboratory workers. As much as possible fat 
tissue was removed from the human mammary biopsies, thereafter they were cut into 8 
mm3 pieces, which were then dried and attached to the culture flask for 30 minutes. 20% FBS 
containing DMEM-F12 medium (GIBCO/Invitrogen, Breda, the Netherlands) was gently added 
and refreshed every 5 days. Around the edges of the tissue, cells (mainly fibroblasts) started 
growing and after 3 weeks the culture flask was confluent with cells. The fraction of epithelial 
cells was enriched by multiple short trypsinisation steps in which part of the fibroblasts were 
removed. For 2 more passages the cells were cultured in HuMEC Ready Medium 
(GIBCO/Invitrogen). After this step the primary mammary cells were cultured in DMEM-F12 
medium supplemented with 10% FBS and 100 U/mL penicillin-streptomycin (Invitrogen). 
 
Insulin, insulin analogues and IGF1 in vitro stimulation 
Prior to compound stimulation the cells were starved in 5% charcoal/dextran-stripped fetal 
bovine serum (CDFBS) containing medium. Stimulations included: insulin NPH (Insuman Basal, 
Sanofi Aventis), insulin glargine (Lantus, Sanofi Aventis), M1 (metabolite of glargine, Sanofi 
Aventis), M2 (metabolite of glargine, Sanofi Aventis), glulisine (Apidra, Sanofi Aventis), lispro 
(Humalog, Elly Lilly), insulin X10 (not marketed, Novo Nordisk), aspart (B28Asp, Novo Nordisk), 
detemir (Levemir, Novo Nordisk) and IGF1 (Increlex, Ipsen). All insulin analogues were dissolved 
in their original vehicle solutions [46]. For the in vitro experiments 1000x stock concentrations 
were prepared. Except for the first exposure experiment (Figure 1C) in which a dose response of 
10, 33 and 100 nM was used, all exposures were performed with a concentration of 10 nM. 
 
siRNA transfection 
A transient transfection method with siRNA Smartpool mix (Dharmacon Technologies, Thermo 
Scientific, Lafayette, CO, USA) was used to test the effect of individual gene on cell proliferation. 
For this 10,000 MCF7 cells per well were seeded in 96-well plates in complete growth medium. 
24 hours after seeding, 50 nM smartpool siRNA mix was delivered to the cells using a standard 
transfection method with DharmaFECT 4 transfection reagent (Dharmacon Technologies) 




according to the company’s instructions. 24 hours after transfection, the small interfering RNA 
(siRNA) transfection mixture was replaced with 5% CDFBS starvation medium for drug treatment 
and sulphorhodamine B (SRB) proliferation assay.  
 
Sulforhodamine B colorimetric assay determining cell proliferation 
A SRB assay was used to measure the total amount of protein as a measure for cell proliferation. 
Transfected and drug-treated cells in 96-wells plates were fixed with 30 μl 50% trichloroacetic 
acid directly added to 100 μl of assay medium per well for 1 hour at 4°C on a shaker, washed five 
times with distilled water and air-dried. Fixed cells were stained with 60 μl of 0.4% SRB (dissolved 
in 1% acetic acid) at room temperature on a shaker for 30 minutes. After the SRB protein binding, 
the plates were washed five times with 1% acetic acid to remove unbound dye and air-dried 
between the washing steps. Next, the protein-bound SRB in each well was solubilized in 200 μl 
10 mM unbuffered Tris solution (pH>10) for 10 minutes on a plate shaker. Absorbance was 




Western blotting was used to determine the knockdown efficiency of the siRNA transfection. To 
prepare cell lysates for Western blot analysis, cells were washed two times with ice-cold PBS and 
lysed with 1x SPB with 1:20 β-mercaptoethanol. Samples were boiled at 95°C for 5 minutes and 
stored at -20°C. Before loading, samples were denatured at 95°C for 5 minutes. 20 μl (about 30 
ug) protein solution per lane was separated by SDS-polyacrlyamide gel electrophoresis on a 7.5% 
acrylamide gel and electrophoretically transferred to a polyvinylidene fluoride membrane 
(Millipore, Billerica, MA, USA). Prior to primary antibody probe, membranes were blocked for 1 
hour at room temperature with 5% bovine serum albumin (BSA) or 5% milk in Tris-bufferd saline 
Tween 20 (TBST) buffer (100mM Tris, pH 7.4, 500mM NaCl, 0.05% Tween 20). ERK, AKT, PTEN 
and tubulin antibodies were probed in 1% BSA-TBST buffer, whereas IGF1Rβ antibodies were 
probed in 1% milk-TBST buffer. HRP-conjugated secondary antibody incubation was performed 
in 1% BSA-TBST or 1% milk-TBST buffer, corresponding to the primary antibodies used. Protein 
bands were visualized by using the ECL (Amersham) method, after which the membrane was 
scanned by using a Typhoon 9400 imager (GE Healthcare). Anti-phospho-Akt (Ser473) and anti-
phospho-Erk (Thr202, Tyr204) have been purchased from Cell signaling Technology, MA, USA). 
For a detailed description of the methods and origin of the antibodies we refer to our prior 
publications [46] [153].  
 
  





For the microarray the cells were seeded at a confluence of 60% in 6 cm plates, starved for 2 days 
in 5% CDFBS containing medium, followed by  1 hr or 6 hrs compound stimulation (10 nM) in 
serum free medium. Small and large RNA was isolated and purified using NucleoSpin® miRNA 
isolation kit (Machery Nagel, Düren, Germany) according to manufacturers’ instructions. RNA 
quality and integrity were assessed by using the Agilent 2100 Bioanalyzer System (Agilent 
Technologies, Santa Clara, CA, USA). The Affymetrix 3’ IVT Express Kit (Affymetrix, Santa Clara, 
CA, USA) was used to synthesize biotin-labeled cRNA, and this was hybridized to an Affymetrix 
HG-U133plus PM Array plate reader. Probe annotation was performed using the hgu133plus2.db 
package and probe mapping was performed with hgu133plus2cdf package installed using 
Bioconductor version 3.0. Probe-wise background correction (Robust Multi-array Average 
expression measure), between-array normalization (quantile normalization) and probe set 
summaries (median polish algorithm) were calculated with the RMA function of the Affymetrix 
package (Affy package version 1.38.1) [154]. The normalized data were statistically analysed for 
differential gene expression using a linear model with coefficients for each experimental group 
[155]. A contrast analysis was applied to compare each exposure with the corresponding vehicle 
control. For hypothesis testing the moderate t-statistical by empirial Bayes moderation was used 
followed by an implementation of the multiple testing correction of Benjamini and Hochberg 
[156] using the LIMMA package [157]. The microarray data is publically available at the Gene 
Expression Omnibus (GEO) database via accession number GSE65398. 
 
RT-Q-PCR 
For the qPCR analysis, messenger RNA from MCF7 cells (80% confluent 6-well) or mammary 
glands (30 µg tissue) was isolated/purified using NucleoSpin® miRNA isolation kit (Machery 
Nagel, Düren, Germany). cDNA was made using the universal cDNA synthesis kit (Exiqon). qPCR 
was performed in triplicate using SYBR Green PCR (Applied Biosystems) on a 7900HT Fast Real-
Time PCR system (Applied Biosystems). Primers targeting the mitogenic classifiers have been 
manually designed and are listed in Supplemental Table 1. qPCR data were collected and analysed 
using SDS2.3 software (Applied Biosystems). Relative gene expression was calculated after 
correction for β-actin expression using the 2-ΔΔQ method. Data are presented as fold change (or 
log2 fold change) compared to vehicle stimulation. 
 
Animal experiments 
40 female 12-week-old inbred FVB/NRj mice were obtained from Janvier, rodent research 
models, France. Housing and experiments were performed according to the Dutch guidelines for 
the care and use of laboratory animals (UL-DEC-14020). RM2 food SDS (technilab-BMI, Holland) 
and water were provided ad libitum. Animals received a single subcutaneous injection of 100 μl 




compound/vehicle solution. The doses were chosen so that the glucose drop was constant 
among the different compounds (Supplemental Figure 3A) (glargine and insulin 100 nmol/kg, X10 
1200 nmol/kg and IGF1 12.5 mg/kg). One or six hours after the injection the mice were sacrificed, 
blood was collected (mini collect, Greiner/Omnilabo), blood glucose levels were measured 
(Freestyle light, 70812-70, Abbott), the 3rd and 4th mammary glands were isolated and used for 
Western blot protein quantification and quantitative PCR respectively (see Ter Braak, 2014 and 
2015) [46] [153]. For each condition (treatment/time point) 4 mice were included. 
 
Statistical analysis 
For the statistical analysis of the microarray data, R (version 3.1) software was used. Rest of the 
analysis was performed with Graphpad Prism version 4.00. Student’s t-tests were used to 
determine significance between conditions. P-values lower than 0.05 were considered to be 
significant. In all graphs the error bars represent standard deviations. 
 
Results 
Mitogenic signaling is regulated via highly similar signaling cascades in the INSR and IGF1R 
signaling pathway 
To better understand the involvement of the IRA, IRB and IGF1R pathways (Figure 1A) in the 
context of mitogenic signaling of insulin analogues, we used our previously described human 
MCF7 breast cancer cell lines  that express either IRA, IRB or IGF1R [46]. Exposure of these 
individual cells to the pro-mitogenic insulin analogue X10 that activates both the INSR and the 
IGF1R, resulted in intact downstream signaling cascades in all three cell lines, indicating 
functionality of the receptors (Figure 1B). As a next step we wanted to ensure that the IRA, IRB 
and IGF1R are not entirely different regarding their key intracellular proliferative signalling 
pathways. For this purpose, we tested the proliferative potential of the cells after knockdown of 
several key signaling molecules in these pathways (Figure 1A). As a first step, we optimized the 
knockdown efficiency using IGF1R and ERK1/2 as controls. The knockdown efficiency of IGF1R 
was almost 100% and constant over five days of culturing; the knockdown efficiency of ERK1 and 
ERK2 was around 50% after day 1 till 95% at day 5 (Figure 1C), we assume that the knockdown 
efficiency is constant for other targets but obviously it was practically not feasible to test them 
all in this manuscript. To assess the proliferative and anti-apoptotic effects of these knockdowns, 
we used the SRB proliferation assay. After knockdown of ERK1/2 and IGF1R, the amount of cells 
after five days of culturing was significantly decreased with 25% (Figure 1C), indicating that the 
SRB proliferation assay is a sensitive assay to pick up any anti-proliferative effects.   
Next, we determined the effect on proliferation of ten individual signaling molecules that are key 
in the INSR/IGF1R signaling pathway (INSR, IGF1R, GRB2, RAF1, ERK2, IRS1, PI3KCA, PTEN, AKT2, 
GSK3B) in untreated IRA, IRB and IGF1R MCF7 cell lines (Figure 1D). As expected, the INSR 




knockdown only significantly affected the proliferative behaviour in the IRA and IRB cell line. 
Similarly, the siIGF1R only significantly reduced the proliferative behaviour in the MCF7 IGF1R 
cell line. Transient knockdown of downstream targets in the MAPK signaling cascade (GRB2, RAF1 
and ERK2) all had a significant inhibiting effect on proliferation. Also knockdown of targets in the 
PI3K signaling cascade (IRS1, PI3KCA and AKT2) had a significant reduced proliferative effect in 
all cell lines. It has to be noted that different members of the AKT family have redundant 
functions and can therefore take over the loss of function of the silenced member. We expect 
that a knockdown of all three members of AKT would lead to an even stronger effect on cell 
proliferation [158]. As anticipated, a knockdown of PTEN increased the proliferative potential in 
these cells, since PTEN acts as a tumor suppressor through dephosphorylation of 
phosphoinositide-3 phosphate, thereby negatively regulating PI3K signaling. Also GSK3B 
knockdown showed an increase in proliferation. The anti-apoptotic effects of GSK3B are likely to 
cause this effect which was only detected in the IGF1R overexpressing cell line. Finally, the 
proliferative potential of non-stimulated MCF7 IGF1R cells treated with different siRNAs was 
compared to insulin and IGF1 treatment conditions (Figure 1E). The effect of the stimulation itself 
was clearly detectable as the SRB absorbance increased from 1.04 (untreated, upper graph) to 
1.81 (insulin treated, middle graph) to 2.61 (IGF1 treated, lower graph) in the mock condition. 
Furthermore the effects of the different siRNA knockdowns on proliferation became more 
prominent in the stimulation conditions. Interestingly, in the insulin stimulated condition the 
siINSR significantly affected proliferation in the IGF1R cell line, suggesting that the low levels of 
INSR in this cell line (Figure 1B) are involved in proliferation once stimulated with high levels (10 
nM) of insulin. 
It could be argued that the effects described above are not (solely) due to pro-mitogenic effects, 
since the INSR/IGF1R signalling pathway can also induce anti-apoptotic effects (See figure 1A). 
These anti-apoptotic effects could also lead to more cells and thus a higher SRB assay read out. 
To investigate this we determined the apoptotic fraction with a FACS analysis upon stimulation 
with the different growth factors (insulin, glargine, X10, IGF1) at 0, 10 and 100 nM. As expected, 
we found a slightly, but dose dependent, higher fraction of apoptotic cells in the growth factor 
stimulated cells (~6%) versus the unstimulated (~4%) (data not shown). Since this is such a small 
difference we assume that the anti-apoptotic effects play a minor role compared to the pro-
mitogenic effects in the growth factor stimulation experiments. 
In conclusion, these combined data indicates that the core signaling pathways involved in cell 
proliferation are similar in the entire MCF7 INSR family cell panel, allowing us to use this panel 
to further unravel the signaling events that can differentiate between INSR versus IGF1R acting 
insulin analogues. 
 





Figure 1. Knockdown of signaling components critical in the INSR and IGF1R pathway reveals common canonical 
core in IRA, IRB and IGF1R induced proliferation signaling. A) The canonical INSR and IGF1R signaling pathway with 
the focus on proliferative and apoptotic biological outcomes. B) Western blot analysis of the cell line panel, based 
on the human breast cancer cell line MCF7 with stable retroviral overexpression (IRA, IRB and IGF1R) in combination 
with stable a short hairpin knockdown (INSR and IGF1R). Cells have been treated with 0, 10, 33 or 100 nM of insulin 




X10 for 30 min. Downstream signaling pathway activation of the receptors is intact as is indicated by the dose-
dependent activation of p-ERK/p-AKT. C) Western blot analysis of siRNA transfection efficiency in the MCF7 IGF1R 
cell line, 1 day and 5 days post transfection and the effect of the knockdown on proliferation measured with the SRB 
proliferation assay. D) The effect of transient knockdown of ten important signaling molecules (INSR, IGF1R, GRB2, 
RAF1, ERK2, IRS1, PIK3CA, PTEN, AKT2 and GSK3B) in the INSR and IGF1R signaling pathways on SRB proliferation 
measured in the different MCF7 derivatives (MCF7 IRA, MCF7 IRB and MCF7 IGF1R). E) The effect of treatment and 
knockdown of key signaling molecules in INSR and IGF1R signaling on SRB proliferation measured in MCF7 IGF1R. (* 
p<0.05, ** p<0.01, *** p<0.001) 
 
 
Figure 2.  Experimental set-up of microarray experiment. A) 2D Principle Component Analysis plot of the microarray 
gene expression data. A clear separation of the different treatments (indicated by the different colors of the dots), 
cell lines (different shapes) and time points (light; 1 hr vs dark; 6 hrs) could be observed. The triplicates or 
quadruplicates are as expected very close to each other. B) Number of significantly differentially expressed genes 
between the different cell lines at T=1 hr. The first Venn diagram shows overlap of the significant differentially 
expressed genes (DEGs) per cell line at T=1 hr. The second Venn diagram shows overlap of the significant DEGs per 
treatment at T=1. C) As in B) but then for T=6 hrs. 




Insulin analogues trigger different transcriptomes in the different cell lines.  
To detect the differences in gene expression levels between the different cell lines, we next 
performed a microarray experiment using the same cell line panel (Figure 1B). We included 5 
different stimulation conditions (vehicle, insulin, glargine, X10 and IGF1 stimulation). This 
allowed the comparison of the transcriptomes of the different treatments. We also included two 
different time points, thus enabling observation of possible time dynamics. Using a principle 
component analysis (PCA) a clear separation of the different treatments and cell lines conditions 
was observed (Figure 2A). The PCA indicated that the transcriptome after IGF1 treatment was 
most different from vehicle stimulation. Glargine and X10 treatments cluster together and insulin 
treatment is closest to the vehicle treated situation. Triplicate (or quadruplicate for the vehicle) 
samples from independent biological experiments were close to each other, indicating a strong 
robustness of the assay.  
We determined the significantly differentially expressed genes (DEGs) per condition (1 hour 
stimulation, Figure 2B; 6 hours stimulation, Figure 2C). Most DEGs were observed in the IGF1R 
cell line, which is consistent with the strongest separation of this cell line in the PCA analysis 
(Figure 2A). We combined all DEGs per cell line and determined the overlap from the different 
treatments. There was a 43 % overlap in the DEGs between the different cell lines. We also 
compared the treatment specific responses independent of the cell line (right Venn diagram 
Figure 2B/C). Again, IGF1 treatment has the biggest impact on the transcriptome, and the highest 
overlap with the X10 and glargine treatment. The total number of DEGs 6 hour after stimulation 
(Figure 2C) is considerably larger compared to the 1 hr stimulation (Figure 2B). After 6 hours of 
stimulation there was a large overlap of DEGs among the different cell lines as well as treatments 
(3531), suggesting that at this time point more general mechanisms were activated that are 
similar for the different treatment conditions. In Supplemental Figure 1 the Venn diagrams of all 
the different conditions are presented. A noteworthy finding is the very high number of DEGs in 
the X10 stimulation via the IRA at T=1 hr.  
 
Differential pathway activation by the various insulin analogues.  
To further understand the biological pathways up regulated by these different compounds we 
performed an Ingenuity Pathway Analysis (IPA), focussing on the MCF7 IGF1R cell line using both 
time points (Venn diagram Figure 3A). A mitogenic cluster was defined that included all DEGs of 
IGF1 treatment only, or IGF treatment in combination with X10 and/or glargine treatment. We 
included glargine treatment in this cluster as glargine, like X10, is highly mitogenic in the absence 
of serum [46]. In a similar way a metabolic cluster was defined, including all DEGs of insulin 
treatment only, or insulin treatment in combination with glargine and/or X10 since all these 
compounds are known to have a strong metabolic effect in vivo. Using IPA we found ‘ERK/MAPK’ 
and ‘p70S6K’ signaling pathways significantly enriched in the mitogenic cluster, while the ‘PI3K’ 




and ‘Cell cycle control’ pathways were not enriched. For the metabolic cluster the IPA results 
were the other way around. We also performed IPA analysis on the individual treatment DEG 
lists. ‘Cell cycle control of chromosomal replication’ was highly enriched after treatment with 
compounds with a high affinity for the INSR (insulin, glargine and X10). Other metabolic processes 
like glycogen degradation and D-myo-inositol-5-phosphate metabolism were also enriched in the 
DEGs of these insulin molecules. On the other hand PI3K/AKT, IGF1, p53 and ERK/MAPK signaling 
were more enriched for the insulin-like molecules that also have a strong affinity for the IGR1R. 
 
 
Figure 3.  Pathway enrichment analysis of differentially expressed gene lists. A) Separate gene clusters were 
defined based on the Venn diagram of MCF7 IGF1R. The mitogenic gene cluster consists of all DEGs in IGF1 treatment 
alone and the combinations of IGF1 with glargine and/or X10 treatment. Similar a metabolic gene cluster was defined 
including the insulin specific DEGs with combinations of the other insulin analogues. An Ingenuity Pathway Analysis 
(IPA) was performed that revealed an enrichment of the ERK/MAPK and p70S6K signaling pathways in the mitogenic 
cluster whereas the PI3K ad cell cycle control signaling pathways were enriched in the metabolic cluster. B) An IPA 
analysis was performed on the DEGs of individual treatments including all cell lines and the different time points. As 
expected the metabolic signaling (A t/m D) was up regulated after stimulation with metabolic compounds (insulin, 
glargine and X10). IGF1 stimulation led to a very significant up regulation of PI3K/AKT, ERK/MAPK, IGF1 and p53 
signaling. For insulin signaling these pathways were also enriched but less significant. 
 
A classifier gene set predictive for the pro-mitogen action of insulin analogues. 
To evaluate which genes drive the strong mitogenic responses of IGF1R signaling we performed 
a variance test with selected genes showing a strong up or down regulation after strong 
activation of the IGF1R. For this we selected IGF1 and X10 exposures and contrasted this with the 
weak mitogenic response inducer insulin. We excluded glargine for the selection. In total we 
selected the top 10 hits in both the 1 hr and 6 hrs hit lists (Figure 4A). Interestingly, many of these 
genes are known to play a role in mitogenic processes, including the early growth response (EGR) 
genes (all four EGR genes are in the top 20 gene list). Most of these genes have not directly been 
linked to the INSR or IGF1R signaling pathway so far. Next we validated these candidate genes 
using RT-Q-PCR with a separate independent set of samples. For 18 of these mitogenic classifier 
genes the RT-Q-PCR validation was successful and showed a highly similar trend for insulin, X10 
and IGF1 conditions (Figure 4B). For ZIC4 and ZMYND8 the expression was probably too low since 




no amplicon was detected even after 40 cycles. Finally, we evaluated the effect of glargine on 
the expression of these classifier genes. Importantly, the overall expression of the classifier genes 
after glargine treatment was more similar to X10 than insulin treatment. 
 
 
Figure 4. Twenty mitogenic classifier genes discriminating between insulin and X10/IGF1 signaling. A) Twenty 
genes (10 for each time point) were defined of which the gene expression was most significantly up or down-
regulated in X10/IGF1 vs insulin in the MCF7 IGF1R cell line (based on a variance test), values are presented as log 
fold 2 changes. B) Validation of 18 of these mitogenic classifier genes was successful with RT-Q-PCR. A comparison 
is given of the microarray (top panel) vs RT-Q-PCR (lower panel) gene expression of the mitogenic classifiers. 
Expression is indicated as fold changes relative to unstimulated MCF7 IGF1R. 
 
Validation of mitogenic classifiers through testing of commercially available insulin analogues. 
We hypothesized that the expression of the mitogenic classifier genes could predict the 
mitogenic outcome of other insulin analogues. We performed an exposure experiment with 




MCF7 IGF1R cells including all commercially available insulin analogues (glargine, aspart, lispro, 
glulisine, determir). Since glargine showed expression of the predictive genes (Figure 4B), and 
since glargine is rapidly metabolized into two metabolites (M1 and M2) in serum, we also 
included M1 and M2 in our study. A hierarchical clustering of the expression of all the tested 
classifier genes after stimulation with the different insulin analogues was performed (Figure 5). 
This resulted in the clustering of glargine with IGF1 and X10, while the glargine metabolites M1 
and M2 clustered with other relatively non-mitogenic insulin analogues. We calculated a ‘relative 
mitogenic potential’ which was determined as the sum of the absolute values of log 2 fold 
changes of the expression of mitogenic classifiers of one compound treatment. As expected the 
‘relative mitogenic potential’ was highest for IGF1 (69), followed by glargine (40) and X10 (31). 
The mitogenic potential of insulin (19) was very similar to that of aspart (19) and lispro (20). M1 
(10), M2 (13), glulisine (8), and determir (7) showed a lower predicted mitogenic potential 
compared to regular insulin.  
 
 
Figure 5.  The relative mitogenic potential of various insulin analogues determined by the classifier gene 
expression. A) MCF7-IGF1R cells were exposed to IGF1, X10, glargine, insulin, aspart, lispro, M1, glulisine, M2 and 
detemir and the gene expression of the mitogenic classifier genes was measured with RT-Q-PCR. A hierarchical 
clustering of the log fold 2 changes (compared to vehicle stimulation) is shown. The mitogenic potential score is the 
absolute sum of the absolute values of log 2 fold changes of the mitogenic classifiers. 
 
Validation of mitogenic classifier genes in vitro in primary human mammary gland cells and in 
vivo in mouse mammary glands. 
To further validate the insulin analogue mitogenic classifier genes we tested additional in vitro 
and in vivo models. We first determined the robustness of the insulin analogue mitogenic 
classifier genes in primary cultured cells isolated from human mammary glands. These cells were 




anticipated to be the main target for increased mitogenic signaling of insulin analogues in 
diabetic patients. Primary cells were isolated from two independent individuals and exposed to 
the different insulin-like molecules. The activation of the INSR/IGF1R pathway was validated by 
Western blotting (Supplemental Figure 2) and a clear activation of the INSR/IGF1R as well as the 
PI3K/AKT signaling pathway was observed. Next the gene expression levels of three mitogenic 
classifier genes that were up regulated (EGR4 and TNFRSF11B) or down regulated (SLC1A2) in 
MCF7 IGF1R cells were measured (Figure 6A).  
 
 
Figure 6. Validation of insulin analogue 
mitogenic classifier genes in primary human 
mammary cells and in vivo mouse mammary 
glands. A) Primary cells isolated from two 
different human mammary biopsies were 
exposed to insulin, glargine, X10 or IGF1 and the 
gene expression of EGR4, TNFRSF11B and SLC1A2 
were determined by RT-Q-PCR. Values are 
presented as fold changes relative to vehicle 
treated cells. B) Wild type FVB mice (4 per 
condition) were subcutaneously injected with the 
above mentioned compounds, RNA from the 
mammary glands was isolated and the gene 
expression of EGR4, TNFRSF11B and SLC1A2 was 
measured by Q-RT-PCR and indicated as fold 




Although the fold change expression of these three genes in these primary human mammary 
cells was not as profound compared to the MCF7 IGF1R cells, in general the same direction of 
expression was observed. In addition, we investigated these three classifier genes in vivo in the 
mammary glands of mice treated with the different insulin analogues. In this experiment 40 wild 
type FVB mice received a subcutaneous injection of vehicle, insulin, glargine, X10 or IGF1. A very 
clear and constant drop in the glucose levels was observed 1 hour after the injections of insulin, 
glargine, X10 and IGF1, indicating that these compounds did induce the expected 
pharmacological response (Supplemental Figure 3A). The glucose levels returned to their normal 
levels (5 mmol/L), 6 hours after the injection. We then investigated the activation of the INSR 
and IGF1R (Supplemental Figure 3B and 3C). 1 hour after the insulin analogue injections a clear 
up regulation of p-AKT was observed, while after 6 hours the p-p70S6K levels were significantly 
(p=0.0022) up regulated. Also the insulin analogue mitogenic classifier genes showed a very clear 




modulation after treatment (Figure 6B). Thus, EGR4 was even induced up to 18 times after IGF1 
treatment and X10 also showed a clear up regulation of this candidate gene compared to no 
stimulation. Similarly after 6 hours treatment IGF1 induced TNFRSF11B and down regulated 
SLC1A2 levels. For these latter gene changes none of the other insulin-like molecules caused a 
significant change in gene expression. Gene expression in glargine conditions showed a similar 
trend as regular insulin, suggesting that glargine is rapidly metabolized into M1 and M2 in vivo, 
which are known to be compounds with a low pro-mitogenic signaling potential [46].  
 
Discussion 
It is well established that insulin has strong metabolic effects and in addition mild pro-mitogenic 
characteristics [148]. Small changes in the structure of insulin have improved the pharmacokinetic 
parameters so that the use of the insulin analogue is more convenient for diabetic patients. Yet, 
these small structural changes might also increase the binding affinity of insulin analogues towards 
the IGF1R and, consequently, increase the mitogenic potency of these molecules compared to 
regular insulin. Current in vitro systems that are used to determine mitogenic potential of insulin 
analogues are largely based on the proliferation capacity and do not take into account the 
molecular mechanisms of receptor signaling (Bronsveld 2015 manuscript submitted). In this study 
we used a transcriptomics approach to assess the preferential activation of pro-mitogenic signaling 
pathways by insulin analogues. We identified a subset of classifier genes that can be used to define 
the primary mode of action of insulin analogues. Moreover, we demonstrated that these classifier 
genes can be translated to primary human mammary cells as well as mouse mammary glands in 
vivo. These mechanism-based novel predictive genes are likely a more reliable method to classify 
the proliferative potency of insulin analogues that act preferably on the IGF1R.  
For the safety profiling of insulin analogues this increased mitogenic potential is critical. Currently 
there is still a debate on the mechanism of such an increased mitogenic potential:  on one hand 
the high binding affinity towards the IGF1R, while on the other hand a prolonged occupancy time 
towards the IRA is suggested causative [149]. In our current study we have been in the unique 
situation to evaluate these mechanisms in our MCF7 cell line panel. We found 40% more 
differentially expressed genes in the MCF7 IGF1R cell line after X10 and glargine stimulation 
compared to the MCF7 IRA cell line. These results suggest that the IGF1R is the main receptor that 
is mediating downstream pro-mitogenic signaling after insulin analogue stimulation. This is in line 
with our previous study in which we tested the proliferative potency of nine insulin-like molecules 
using the same MCF7 cell line panel and found that X10 and glargine induce proliferation more 
profoundly in the MCF7 IGF1R cells than the MCF7 IRA cells [46]. For this reason we based the 
further mitogenic classifier analysis on the MCF7 IGF1R cell line.  
For the mitogenic classifier hit selection a training set was based on microarray gene expression of 
three compounds, in which insulin served as the reference compound with a low mitogenic 




potency. X10 and IGF1 served as two insulin-like molecules with a strong mitogenic potential. This 
resulted in a total of twenty genes either up or down regulated at 1 or 6 hrs after IGF1 and X10 
treatment that most strongly differed from the insulin effect. Many of these genes have been 
associated with mitogenic signaling but so far not directly linked to INSR/IGF1R signaling. Strikingly 
various early growth response genes were identified: EGR1 [159], EGR2 [160], EGR3 [161], EGR4 
[162] which are all well known to promote proliferation, survival and/or invasion pathways. MALL, 
FHL2 [163], PHLDA [164], NR4A3 [165] and CTGF [166]  are known oncogenic factors and its gene 
expression is negatively associated with tumor-free survival and/or. Interestingly, genes (POLQ and 
RBM6) that were down regulated after X10/IGF1 stimulation have been linked to pro-apoptotic 
and anti-proliferative effects [167] [168]. 
Glargine is the most frequently prescribed anti-diabetic insulin analogue. There are  conflicting 
conclusions regarding the intrinsic mitogenic potential of insulin glargine [127] [169]. We 
purposely excluded our glargine transcriptome analysis from the training set to identify 
candidate predictive classifier genes for pro-mitogenic signaling by insulin analogues. This 
allowed us to unravel the potency of glargine as a pro-mitogenic insulin analogue. Interestingly, 
the mitogenic potential of glargine was even higher compared to insulin X10 (Figure 5). This is in 
full agreement with the kinase activation measurement of INSR/IGF1R pathway components in 
our previous study [46]. In diabetic patients glargine is rapidly processed by enzymes in the serum 
into two metabolically active compounds, M1 and M2, in which M1 is most prominent metabolite 
[83]. Therefore we also determined the mitogenic potential of M1 and M2 based on the gene 
expression profiles of the mitogenic classifier genes and we observed that both metabolites have 
a mitogenic score that is even lower than insulin. This is in agreement with previous studies in 
which the mitogenic potential was based on IGF1R binding affinity, kinase activation or 
proliferation assays [114] [46]. 
Two other studies also performed a mitogenic assessment of a panel of insulin analogues. These 
studies included a proliferation assay (Kurtzhals, Schaffer et al. 2000) and an IGF1R affinity 
evaluation [114]. We systematically compared our mitogenic classifier gene score with these two 
independent functional read outs (Figure 7). There was a striking correlation between our classifier 
scoring (based on Figure 5) and both the proliferation and IGF1R affinity. These combined data 
sets demonstrate that IGF1, X10 and glargine have a higher mitogenic potential compared to 
insulin, which is associated with a high affinity for IGF1R. Aspart and lispro have a mitogenic 
potency similar to each other. Determir and the two metabolites of glargine (M1 and M2) have a 
lower mitogenic index compared to regular insulin, associated with a low affinity for the IGF1R.  
Some epidemiological studies suggest a correlation between insulin glargine use and breast cancer 
occurrence in the diabetic patients [76]. Since glargine might promote proliferation of mammary 
epithelial cells in vivo, we wanted to test whether expression of some of our classifier genes could 
be translated from MCF7 cells to primary human mammary cells. We could confirm a similar gene 




expression trend in primary human mammary cells after stimulation with insulin, glargine, X10 and 
IGF1 as in MCF7. Yet, the gene expression fold changes in the primary human mammary cells were 
far lower compared to the MCF7 IGF1R cells. The reason for this can be partly due to the isolation 
procedure which did not result in a pure population of mammary epithelial cells. Overall, the effect 
of glargine in the primary human mammary cells was not as profound as for IGF1 and X10.  
 
Figure 7. Correlation between 
mitogenic classifier score and the 
enhanced proliferation or IGF1R 
receptor binding. A) A correlation is 
presented of the mitogenic potential 
based on the mitogenic classifier analysis 
(x-axis) vs the mitogenic potential as 
determined by other studies with 
proliferation assays. Sommerfeld, 2010 
expressed this score as EC50 value from 
their proliferation curves (left y-axis). 
Data from Kurtzhals, 2000 are expressed 
as fold changes compared to insulin 
(right y-axis). B) A similar correlation 
graph with the mitogenic potential from 
this study plotted against the IGF1R 
binding affinity according to two other 
studies. (data adapted from Kurtzhals 
2000 and Sommerfeld 2010) [113, 114]. 
 
Previously we demonstrated that IGF1 and X10 significantly promote tumorigenesis in a 
conditional mammary gland tumor mouse model [153]. Glargine did not significantly enhance this 
tumorigenesis. Therefore we also evaluated the translation of our classifier genes to the in vivo 
situation and determined the gene expression changes in the mammary glands of mice that 
received a subcutaneous injection of the insulin-like molecules insulin, IGF1, X10 and glargine. We 
could validate the in vitro effect of IGF1 in the in vivo situation, indicating that a true IGF1R 
responses can be observed in this model. X10 showed some correlation with the effect of IGF1. 
Yet, in contrast to the in vitro data, the gene expression profiles of glargine were more similar to 
insulin than to X10/IGF1. This effect is very likely caused by the metabolism of insulin glargine by 
factors in the serum of the blood of the mice (similar to the glargine conversion in human serum). 
We therefore speculate that the observed pro-mitogenic signaling events of glargine in our in vitro 
breast cancer cell line models are presumably not occurring under in vivo conditions in the 
mammary gland. Yet, we cannot exclude that IGF1R mediated responses by glargine take place in 
other tissues in vivo.  





In the current study we propose a new robust classifier gene set that allows the quick, robust and 
quantitative analysis of the pro-mitogenic potential of newly developed insulin analogues. These 
classifiers can be used within the pharmaceutical industry as well as in a regulatory setting to 
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Supplemental Figure 1. Venn diagrams of the differentially expressed genes per cell line, time point and treatment 
showing overlap of genes between the different conditions. A) Venn diagram of the early regulators (t=1hr). the 
blue circle represents the hits in the IRA cell line, yellow the IRB cell line and green the IGF1R cell line. The first graph 
shows the number of hits after insulin treatment, the second graph glargine, the third X10 and the last graph shows 
the number of hits after IGF1 treatment. B) The Venn diagrams of the late regulators (t=6hrs).  
 
 
Supplemental Figure 2. Protein levels of primary human mammary cells stimulated with insulin like compounds. 
A) Primary human mammary gland cells were treated with different insulin-like molecules followed by Western 
blotting for various INSR and IGF1R signaling pathway components. B) Quantification of Western blot data of the p-
IGF1R/p-IR, p-Akt and p-Erk. The y-axis represents the average protein expression level compared to vehicle 
exposure. 






Supplemental Figure 3. Mammary gland protein levels of 40 FVB mice subcutaneously injected with insulin-like 
compounds. A) The blood glucose levels (mmol/L) have been measured 1 hr and 6 hrs after subcutaneous 
injections with different insulin-like molecules. B) Western blotting of the receptors and kinases in the INSR and 
IGF1R pathway measured in the mammary gland tissue; samples were from 1 hour (left graph) or 6 hours (right 
graph) after the subcutaneous injections of the presented insulin like molecules. C) the quantification of activated 
kinases (Erk, Akt, p70S6K, FOXO1/O3) relative to the Endogous Control  (EC), a sample that was loaded on every 
blot. (n=4) 
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o Chronic AspB10 and IGF1 treatment significantly decrease the mammary gland tumor latency 
time in the p53R270H/+WAPCre mouse model 
o Mice chronically exposed to AspB10 and IGF1 develop mammary gland tumors with a sustained 
activation of mitogenic pathways 
o Chronic glargine treatment did not significantly affect the tumor latency time, but mice injected 
with glargine developed more tumors with an enhanced mitogenic protein expression 
signature  
     IN THE PICTURE 
Hypodermic needle and packaged insulin 
(Nobel Museum, Stockholm). The discovery of 
insulin in 1921 opened new possibilities in the 
treatment of diabetes. Frederick Banting and 
J.J.R. MacLeod received the Nobel Prize in 
physiology or medicine in 1923 for their 
discovery. 
    IN BEELD
Injectie naald en een insuline verpakking (Nobel 
Museum, Stockholm). De ontdekking van 
insuline in 1921 opende nieuwe mogelijkheden 
voor de behandeling van diabetici. Frederick 
Banting en J.J.R. MacLeod ontvingen de 
Nobelprijs in fysiologie en geneeskunde in 1923 
voor hun ontdekking.
 





Insulin analogues are structurally modified molecules with altered pharmaco-kinetic and -
dynamic properties compared to regular human insulin used by diabetic patients. While these 
compounds are tested for undesired mitogenic effects, an epidemiological discussion is 
ongoing regarding an association between insulin analogue therapy and increased cancer 
incidence, including breast cancer. Standard in vivo rodent carcinogenesis assays do not pick 
up this possible increased carcinogenic potential.Here we studied the role of insulin analogues 
in breast cancer development. For this we used the human relevant mammary gland specific 
p53R270H/+WAPCre mouse model. Animals received life long repeated treatment with four 
different insulin (−like) molecules: normal insulin, insulin glargine, insulin X10 (AspB10) or 
insulin-like growth factor 1 (IGF1).Insulin-like molecules with strong mitogenic signalling, 
insulin X10 and IGF1, significantly decreased the time for tumor development. Yet, insulin 
glargine and normal insulin, did not significantly decrease the latency time for (mammary 
gland) tumor development. The majority of tumors had an epithelial to mesenchymal 
transition phenotype (EMT), irrespective of treatment condition. Enhanced extracellular 
signalling related kinase (Erk) or serine/threonine kinase (Akt) mitogenic signalling was in 
particular present in tumors from the insulin X10 and IGF1 treatment groups.These data 
indicate that insulin-like molecules with enhanced mitogenic signalling increase the risk of 
breast cancer development. Moreover, the use of a tissue specific cancer model, like the 
p53R270H/+WAPCre mouse model, is relevant to assess the intrinsic pro-carcinogenic potential 
of mitogenic and non-mitogenic biologicals such as insulin analogues. 
 
Keywords: IGF1, insulin glargine, carcinogenic potential, breast cancer, mouse model, 
p53R270H/+WAPCre 
Introduction 
For two decades there is an intensive debate about the human risk for increased cancer incidence 
when using insulin analogues [108]. Insulin and insulin analogues act via the insulin receptor (IR), 
of which there are two isoforms, IRA and IRB, and to a lesser extent via the insulin-like growth 
factor 1 receptor (IGF1R). An increased residence time as well as an increased binding affinity of 
synthetic insulin-like molecules towards IRA and especially IGF1R might affect carcinogenesis 
[113, 149]. Downstream signalling via these insulin receptor family members occurs via distinct 
pathways. Upon stimulation with insulin analogues with high affinity for IRB the PI3K/Akt 
pathway is activated, which is related to the metabolic role of insulin [116]. In contrast, activation 
of the IGF1 pathway via IGF1R results in an upregulation of both the MAPK/Erk signalling cascade 
and an asymmetrical activation of the Akt pathway [135], which is directly related to the limited 
mitogenic effect of insulin. Stimulation of the IRA results in a similar downstream signalling 
 




cascade to that observed after IGF1R activation [135]. Epidemiological studies indicate a strong 
association between expression levels of both IGF1 and its receptor (IGF1R) and cancer 
initiation/progression [170, 171]. This creates a situation whereby insulin analogues with 
increased affinity for IRA and/or IGF1R may increase the cancer hazard.  
Current approaches to assess the intrinsic carcinogenic potential of insulin analogues are limited. 
The binding affinity of insulin analogues to both IR and IGF1R and their subsequent activation 
and overall mitogenic capacity are currently used as part of the risk assessment in terms of 
carcinogenic potential of newly developed insulin analogues. This in vitro assessment is limited 
by the variability in the cell lines, culture conditions and proliferation assays that are used [46] 
[172]. Furthermore, kinetic parameters like administration, distribution, metabolism and 
excretion cannot always be captured in these in vitro models. Some insulin analogues that are 
currently on the market have also been tested in two-year carcinogenicity studies in rats and/or 
mice [32] [173]. So far only insulin X10 (also called AspB10) has been indicated to increase the 
tumor incidence in the chronic rodent studies and consequently it never reached the market [32, 
108, 173]. While most insulin analogues, including glargine [174, 175] [176], were negative in 
these chronic bioassays, several epidemiological studies showed an increased breast cancer risk  
[16, 76, 177] [17], which could not be observed by others [18, 19, 58, 67, 86, 143, 178, 179]. 
Altogether these data stirred concerns that growth factor-like insulin analogues are potential 
non-genotoxic carcinogens [24].  
Genetically engineered mouse (GEM) cancer models constitute powerful, alternative methods to 
assess the carcinogenetic potential of non-genotoxic compounds [180] . This in particular 
involves GEMs with constitutive or conditional tissue specific deletion of tumor suppressor genes 
[181]. We described a mammary gland specific dominant negative mutated p53 mouse model, 
p53R270H/+WAPCre [182]. The model is based on a point mutation corresponding to the p53 
mutated hotspot p53.R273H in the human Li Fraumeni cancer syndrome. Mutant p53 is only 
expressed when Cre recombinase is induced by the whey acidic protein promoter (WAP) in the 
mammary gland. This leads to spontaneous mammary gland tumor formation initiated within a 
year.  
Here we used p53R270H/+WAPCre model to evaluate the carcinogenic potential of several insulin 
(like) molecules: insulin NPH, insulin glargine, insulin X10 and IGF1. We demonstrated that 
chronic exposure to insulin X10 and IGF1 significantly promote mammary gland tumor 
development, while glargine and insulin do not. Yet, glargine-related tumors do have a different 
pro-mitogenic signalling that is distinct from control and insulin treated mice, and more 
reminiscent of insulin X10 and IGF1. 
  
 





The p53R270H/+WAPCre mouse model 
Heterozygous p53.R270H as well as the WAPCre mice were backcrossed with FVB mice over 15 
times to yield a > 99.99% FVB genetic background. >8 Week old heterozygous conditional 
p53.R270H mice were crossed to transgenic WAPCre mice of the same age to generate 
p53R270H/+WAPCre mice [182] [183]. The mammary gland specific Cre recombinase splices out the 
intronic floxed stop cassette of the p53.R270H allele that eventually would lead to spontaneous 
mammary gland tumor formation of 1 year old p53R270H/+WAPCre female mice. A high expression 
the WAP promoter was used [184], which is already active in the mammary gland of non-
pregnant, non-lactating virgin mice. Therefore we used only nulliparous mice in this experiment. 
PCR/digestion based assay was used for genotyping using the same primers as described [182] 
and subsequent restriction analysis using Hsp92II. Presence of the R270H mutation leads to 
digestion of the 486 bp p53 PCR amplicon into a 269 and 217 bp product. Presence of Cre 
recombinase was verified by a 676 bp amplicon [182]. All mice were fed ad libitum with RM1 diet 
(SDS, technilab-BMI, Holland). 
Preparation of insulin, insulin analogues and IGF1 injection solutions 
The treatments included: insulin NPH (Insuman Basal, Sanofi Aventis), insulin glargine (Lantus, 
Sanofi Aventis), insulin X10 (AspB10, Novo Nordisk) and IGF1 (Increlex, Ipsen). All compounds 
were dissolved in their original vehicle solutions: glargine (glycerol 0.2 mol/l, m-cresol 0.025 
mol/l, ZnCl2 0.0002 mol/l adjusted to pH 4.0), insulin (glycerol 0.2 mol/l, NaH2PO4 0.00135 mol/l, 
phenol 0.0063 mol/l, m-cresol 0.0138mol/l,ZnCl2 0.0001mol/l adjusted to pH 7.4), X10 (glycerol 
0.2 mol/l, phenol 0.0063 mol/l, m-cresol 0.0138mol/l, ZnCl2 0.0001mol/l adjusted to pH 7.4) and 
IGF1 (benzyl alcohol 0.083 mol/l,  sodium chloride 0.1 mol/l, polysorbate 20 0.0016 mol/l, acetic 
acid 0.0072 mol/l, sodium acetate 0.05mol/l adjusted to ph 5.4). 
Experimental set-up 
The experimental setup of the studies was examined and approved by the institute's Ethical 
Committee on Animal Experimentation, in accordance with national and European legislation.  
In a first panel of short term experiments, the maximal pharmalogical dose (MPD) was 
determined for each compound in our mouse model. In a 10 hr experiment (n=54) the glucose 
drop was measured (Freestyle light, 70812-70, Abbott) sequentially every hour after a single 
subcutaneous injection with insulin NPH, glargine, regular insulin, X10 or IGF1 (Supplemental 
Figure 1). A wide concentration range based on literature was evaluated: insulin NPH and insulin 
glargine (25 nmol/kg – 125 nmol/kg); insulin X10 (480 nmol/kg – 1800 nmol/kg); and IGF1 (5 
mg/kg – 15 mg/kg) [174]. In a subsequent experiment (n=52) the effects of frequent injections 
were determined (Supplemental Figure 2). Besides blood glucose levels, the weight and overall 
well-being were determined during one month of daily injections.  
 




Based on the above data the long-term exposure experiment was designed in which the mice 
were injected with 50% and 80% of the MPD according to Supplemental Table 1. Once the female 
p53R270H/+WAPCre mice were about 8 weeks old, they were randomly distributed in the dose 
groups using the program “randomice”. Mice were weighed every week, and a standard injection 
solution per compound/concentration was made to ensure an injection volume in the range of 
60-130 uL. To avoid adverse reactions at the injection site due to frequent injection, three 
subcutaneous injection sites were used: neck, upper back and lower back. Mice were injected 
every other day for up to 67 weeks and palpated for tumors twice a week. A typical mammary 
gland tumor could be detected once it had a volume of about 8 mm3. Dimensions were noted to 
monitor tumor growth. Once the tumor reached a volume of about 1 cm3, the mouse was 
sacrificed and dissected. Tumors from other origins were generally difficult to palpate, so other 
fitness markers (weight loss, skin condition, motility etc.) were used to decide when to sacrifice 
an animal.  
Histopathology and immunofluoresence 
When mice were destined for sacrifice based on tumor size or other markers, one day after the 
last injection mice were euthanized, blood was collected and serum was extracted (mini collect, 
Greiner/Omnilabo) according to manufactures protocol. ¼ of tumor, liver, lung, pancreas, kidney 
and spleen were fixed in a neutral aqueous phosphate buffered 4% solution of formaldehyde 
(Klinipath/VWR) for 24 hrs and stored in 70% EtOH. These tissues were embedded in paraffin 
wax, sectioned at 5 µm, and stained with hematoxylin and eosin (H&E) for histopathologic 
evaluation. Immunofluorescence (IF) was performed on twenty representive tumors (based on 
the H&E characterisation) from the different tumor types. Citrate buffer was used for antigen 
retrieval, blocking was performed in 10% normal goat serum (NGS). Antibodies were diluted (1:10 
– 1:800) in 1% NGS buffer. Antibodies used were smooth muscle actin (A2547, Sigma), 
cytokeratin 5 (PRB-160P, Covance), cytokeratin 8 (rdi-pro61038, Fitzgerald/Bioconnect), E-
cadherin (610181, BD Transduction). Fluorescently labelled secondary antibodies were from 
Jackson Laboratories. Images were made on a Nikon Eclipse TS100 microscope. The 
histopathology was based on analysis of the macroscopic tumors. The epithelial and 
mesenchymal cell distributions were estimated by a pathologist on morphological characteristics 
of these cell types. 
Western blotting 
A quarter of the tumor was snap frozen in liquid nitrogen, stored at -80˚C and used for 
subsequent protein expression profiling. A  tumor piece was grinded and lysed with 300 μL tumor 
lysis buffer (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Triton, 10% glycerol, 1:100 
protease inhibitor cocktail) for 30 minutes at 4°C. After centrifugation (10 min, 10,000 rpm) 
supernatant was collected and the protein concentration was determined (BCA TM Protein Assay 
 




Kit; Thermo Scientific, Rockford, IL, USA). The Western blotting procedures and all antibodies 
were identical to [46]. Furthermore, antibodies targeting Her2 (Cell Signalling Technology, 
Danvers, MA, USA), β-Actin, GAPDH, ER-α and EGFR, (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) have been used. The same endogenous control (EC) sample consisting of a mix of 30 random 
mammary gland tumor samples was used on each blot.  
Statistical analysis 
Statistical analyses of (mammary gland) tumor-free survival curves included calculation of 
censored Kaplan-Meijer distribution of survival of two different treatment groups and comparison 
by a two-sided log-rank test using Graphpad Prism version 4.00 software. The same software was 
used to determine p-values over de mean weight, % of epithelial cells and average number of 




Insulin analogue treatment induces a metabolic and at high concentrations a toxic response  
We first systematically determined the doses at which each insulin analogue induced a glucose 
drop (Supplemental Figure 1). Two hours after the injection the maximal (approximately 60%) 
blood glucose decrease was observed (from ~6 to ~2 mmol/L) which was followed by a  glucose 
recovery, depending on the insulin dose. Mice injected with short-acting insulin forms (X10 and 
regular insulin) required more time to recover. Next, a dose dependent positive weight effect 
was observed during one month daily treatment for most compounds; only the highest dose of 
insulin NPH and IGF1 caused a weight loss compared to control (Supplemental Figure 2). Despite 
this evident adverse effect, no mortality of mice was observed so this dose was referred to as the 
MPD.  
Insulin X10 and IGF1 treatment of p53R270H/+WAPCre female mice increases body weight  
We then performed a life long repeated dosing of 10-week old p53R270H/+WAPCre female mice 
with all four insulin analogues as well as the controls. We carefully monitored the weight up till 
35 weeks, a point in time at which the first animals developed mammary tumors (Figure 1A, top 
panel). X10 and IGF1 induced the strongest weight gain. In contrast, insulin and glargine did not 
affect the weight compared to the vehicle treated animals.  
Insulin X10 and IGF1 treatment significantly decreases the latency time for mammary gland 
tumor development  
Next we further followed mammary gland tumor formation. In total 100% of the mice that 
remained part of the experiment developed tumors, 83% of which were mammary gland tumors 
with an average latency time of 40 weeks (Figure 1B and Table 1).  
 




Subcutaneous injections of vehicle 1 and vehicle 2 did not significantly cause a difference in 
tumor latency time compared to untreated animals (p=0.7194, data not shown) and were further 
combined in one control “vehicle” group. Subcutaneous injection of the vehicle did not 
significantly affect the tumor latency time compared to untreated animals (p=0.8476, data not 
shown). Each insulin analogue was dosed at 50% and 80% of the MPD. None of the different 
compounds showed a difference between the two doses (insulin p=0.1839, glargine p=0.1447, 
X10 p=0.1619, IGF1 p=0.6064; data not shown). Therefore we also combined the two dose groups 
per compound. The tumor growth rate was next determined by calculating the tumor doubling 
time in the exponential part of the Gompertz equation curve as in [185]. All tumors showed a 
similar doubling time (1.44 -1.78 day-1), independent of treatment conditions (Table 1).   
 
Figure 1. Effect of insulin analogues on mammary gland tumor development in p53R270H/+WAPCre  female mice. A) 
Upper graphs represent the average weight of the mice in the indicated groups during the first 35 weeks of the 
experiment. Statistical analysis was determined with an unpaired T-test. B) Effect of different compounds on 
mammary gland tumor free survival shown as in Kaplan Meier curves. Statistical analysis for the survival curves was 
determined with logrank test. 
 
 




Table 1. Results overview of p53R270H/+WAPCre model subcutaneously injected with growth factors 
 Insulin Glargine X10 IGF1 Vehicle 
Number of mice analyzed 40 40 40 40 38 
Mortality 6/40 (15%) 3/40 (8%) 5/40 (13%) 4/40 (10%) 1/38 (3%) 
Mean weight of mice (grams) * 
   p-value# 
30 ± 0.5 
0.1996 
30 ± 0.5 
0.1567 
32 ± 0.6 
0.0002 
34 ± 0.7 
<0.0001 
29 ± 0.4 
NA 
Tumor-bearing mice 34/34 (100%) 37/37 (100%) 35/35 (100%) 36/36 (100%) 37/37 (100%) 
Mean tumor latency-time (wks) † 











Mammary gland tumor  
       Carcinocarcoma 
             EMT status (% epithelial) 
              p-value# 
       carcinoma 
   Adenoma 
29/34 (85%) 
24/29 (83%) 




























Mean MG tumor latency-time (wks) † 
p-value‡ 










Mean MG tumor  doubling time (days) 
p-value# 
1.75 ± 0.11 
0.1375 
1.87 ± 0.21 
0.1305 
1.83 ± 0.19 
0.1632 
1.53 ± 0.12 
0.7594 
1.470 ± 0.14 
NA 
Mice with multiple MG tumors 10/34 (29%) 16/37 (43%) 18/35 (51%) 16/36 (44%) 13/37 (35%) 
Average number of MG tumors 
p-value# 
1.50 ± 0.16 
0.5289 
2.00 ± 0.24 
0.2371 
1.82 ± 0.16 
0.4337 
2.07 ± 0.23 
0.1346 
1.64 ± 0.15 
NA 
* Mean weight depicted as average weight of mice from start of injections (mice are ± 8 wks) till mice are sacrificed.   
† Mean latency time is depicted as number of weeks after start of the subcutaneous injections.  
‡ p-values determined by comparing the Kaplan-Meijer curves of compounds with vehicle 
# p-values determined by comparing compounds with vehicle. Unpaired T-test. 
 
The overall mammary gland tumor latency time (MTLT) for control mice was 44.9 weeks. IGF1 
and insulin X10 caused a significantly decreased mean MTLT of 6,5 and 7,0 weeks respectively, 
compared to the vehicle treatment (Figure 1B; MTLT decreases from 44.9 weeks for control to 
38.4 weeks (p=0.0207) and 37.9 weeks (p=0.0044) for IGF1 and X10, respectively). Glargine 
injections led to a tumor latency time reduction of three weeks, although this was not 
significantly different (p=0.0688). No effect on MTLT was observed for treatment with human 
insulin (p=0.8329). 41% of the mice developed multiple mammary gland tumors.  
  
 




Different insulin analogues do not affect mammary gland tumor type 
All mammary proliferative lesions were next classified according to the criteria described by the 
Annapolis Pathology Panel (Figure 2A) [186]. Irrespective of treatment condition, the majority 
(123/148, 83%) of mammary gland tumors was diagnosed as EMT (Epithelial to Mesenchymal 
Transition) tumor, 16% (24/148) as carcinoma, and 1% (1/148) as adenoma (Table 1).  
EMT tumors with a clearly distinguishable histological epithelial component also showed clear E-
cadherin staining, whereas EMT tumors that predominantly consist of mesenchymal cells showed 
high levels of SMA (Figure 2B). In total 31 mice developed other tumors: 10 thymic lymphoma, 6 
lung adenocarcinomas, and a small number of lymphomas, bone, uterus or pancreas tumors 
(Figure 2C). No correlation between the prevalence of non-mammary gland tumors and 
treatment could be detected. Typically lymphomas developed significantly earlier (independent 
of treatment) compared to mammary gland EMT tumors and carcinomas (30.8 wks vs 41.4 and 
39.1 weeks respectively). 
There was no clear correlation between treatment and tumor spectrum (Figure 2D). EMT tumors 
are previously described as carcinosarcomas, and these terms can be used as synonyms[187]. 3D 
culturing of isolated cells from these primary tumors resulted in an invasive morphology, one of 
the characteristics of an EMT tumor (data not shown).  The EMT-phenotype tumor was 
considered morphologically significant in the presence of epithelial structures displaying loss and 
disruption of basement membrane and associated with epithelial-to-spindle cell morphology 
transition and gradual blending or invasion into the surrounding stroma [188]. Most mammary 
tumors showed invasion of the surrounding fat pad. Variable-sized intratumoral areas of necrosis 
were also present, often accompanied by desmoplastic reaction and severe infiltration of 
inflammatory cells composed by mostly neutrophils and reactive macrophages. 
Some mice developed more than one mammary gland tumor. There appears to be a trend in the 
incidence of increased multiple mammary gland (MG) tumors for glargine, X10 and IGF1, 
compared to vehicle treatment, but none of these treatments reached significance (Figure 2E). 
We also assessed the percentages of epithelial and mesenchymal cells. Only X10 treatment 
induced significantly (p=0.0086) more EMT tumors with a higher epithelial prevalence (Figure 
2F). To further assess the origin from either the basal or the luminal part of the mammary gland 
ducts, the expression of CK5 and CK8 was evaluated, respectively. Based on expert judgement of 
the pathologist we have screened a subset of twenty tumors, equally distributed over the 
treatment groups. From these tumors only one was stained positive for CK5 and negative for CK8, 
all other tumors showed clear CK8 staining and lack of CK5 indicating that the majority of tumors 
likely originated from the luminal part of the mammary gland. A representative 
immunofluorescent picture of a luminal tumor and the only basal tumor that we found can be 
 




found in Supplemental Figure 3. Neither a correlation was detected between the different 








Figure 2. Insulin analogues induce primarily EMT tumors in p53R270H/+WAPCre  female mice. A) H&E images of 
representative EMT tumors with predominantly epithelial cells (left panel) and an EMT tumor with predominantly 
mesenchymal cells (right panel).  B) Immunofluoresent images of CK5/8, area with normal mammary duct on the 
same slide that serves as control for CK5/CK8 staining, E-cadherin and smooth muscle actin. C) Tumor type 
distribution per treatment. D) Mammary gland tumor type distribution per treatment. E) Average number of 
mammary gland tumors. F) Percentage of epithelial cells in the EMT tumors over the different treatment groups. 
 
Molecular profiling of IR and IGF1R signaling pathways in insulin analogue induced  mammary 
gland tumors  
To further understand the underlying mechanism of the decreased tumor latency by IGF1 and 
X10, we determined the expression of proteins in the main signalling pathways associated with 
IR and IGF1R signalling as well proteins used in breast cancer classification. This included the 
quantitative analysis of IR-β, IGF1R-β, EGFR, Her2, E-cadherin, N-cadherin, Akt, p-Akt, Erk, p-Erk, 
ER-α, tubulin and β-actin protein levels in all primary mammary gland tumors. A small subset of 
the Western Blot data (n=36) is presented in Figure 3A, the quantitative analysis of Figure 3B is 
based on all Western Blots (n=148) shown in Supplemental Figure 4. Overall only IR, IGF1R, p-Erk 
or p-Akt levels were significantly affected in insulin analogue treatment-related mammary tumor 
(Figure 3B). Interestingly, the IR and IGF1R receptor levels in tumors of compound treated 
animals were all significantly upregulated compared to control. Importantly, IGF1-dependent 
tumors did not only upregulate IGF1R, but also showed a significant (p=0.0066) upregulation of 
IR; similarly insulin treated mice demonstrated IR upregulation but also showed significantly 
(p=0.0005) higher IGF1R levels. Also phosphorylated Akt was more abundant in tumors of mice 
treated with insulin-like molecules, especially insulin, X10 and IGF1 stimulation led to tumors 
with very significant higher activation of the PI3K signalling pathway. Interestingly, glargine, X10 
and IGF1 but not insulin stimulation led to an increased activation of the MAPK signalling cascade 
in the obtained tumors. This effect was only significant for glargine (p = 0.0125) and X10 (p = 
0.0018) but not for IGF1 (p = 0.0980) when compared to the tumors from the vehicle treated 
mice. We also compared the association between IR and IGF1R expression (Figure 3C). Overall 
there seemed a direct linear correlation between IR and IGF1R, suggesting interdependency. To 
evaluate the relationship between IR and IGF1R levels and tumor latency, we separated the 
entire group of tumors in five equal clusters each representing 20% of the tumors based on right-
angled distribution on the linear regression curve. For each cluster the mean latency time was 
determined irrespective of treatment condition (Figure 3D), but only involving insulin, glargine, 
X10 and IGF1 conditions. Intriguingly, a long latency time, and thus a long exposure to the insulin-
like molecules, is associated with increased insulin- and IGF1- receptor levels. While the tumors 
of all control animals showed a strong correlation between IR and IGF1R expression levels, albeit 
at lower expression level (see Supplemental Figure 4 and Figure 3B), no correlation was observed 
 




with either latency time or receptor levels. A similar correlation was observed between IR/p-Akt 
and IGF1R/p-Akt (data not shown). 
Mitogenic insulin analogue tumor formation is related to enhanced Erk and Akt activity.  
Since the insulin analogue treatment apparently affected and directed the composition and the 
activity of signalling machinery in the mammary gland tumors, we next determined whether 
specific subgroups of profiles existed and whether these would cluster with particular insulin 
analogues. We focused on those signalling components that were significantly different between 
control and insulin-like molecule treatment (i.e. IR, IGF1R, p-Erk and p-Akt) and evaluated all EMT 
tumors (n=123; the major tumor type irrespective of treatment condition), thereby eliminating 
tumor type variation. Hierarchial clustering of the quantitative signalling data separated in total 
nine clusters (Supplemental Figure 4A and 4B). Five clusters showed increased p-Erk level as a 
dominating signalling pathway: clusters 1, 5 and 7 represented high p-Erk which was dominated 
by IGF1, X10 and glargine related EMT tumors (together 78 %, n=22 tumors); clusters 2 and 8 
showed lower p-Erk with no clear enrichment (n=15 tumors). In addition, especially two clusters 
were representing Akt activation: clusters 5 and 6 preferentially showed high p-Akt activity, and 
together these clusters demonstrated enrichment for IGF1 and X10 treatment (75 %; n=16 
tumors). Importantly, there were no tumors from the control group that showed high p-Akt 
levels. Two large clusters (4 and 9) did not show any dominance or activation of either Erk or Akt; 
in these two clusters there was a slight overrepresentation of control and insulin treatment 
(61 %; n=31 tumors). These combined data suggest that pro-mitogenic insulin analogues drive 
tumor formation that are dominated by either p-Erk and/or p-Akt, although at this point we 
cannot exclude the activation of additional signalling pathways. We also determined for each 
cluster the tumor latency time (Figure 4C). Overall, clusters enriched for pro-mitogenic insulin 
analogues and associated enhanced mitogenic signalling, either Erk or Akt, did not significantly 
correlate with latency time. Yet, a tendency existed for a shorter latency time in cluster 1 which 
had the highest p-Erk level. Therefore, we also determined the correlation between either p-Erk 
or p-Akt status for any treatment condition and mammary gland tumor latency time (Figure 4D 
and 4E). A significant negative correlation was found between p-Erk status and latency time. This 
effect was strongest for IGF1 induced tumors, but glargine induced tumors also showed this 
trend. A weak non-significant positive correlation was found between p-Akt status and EMT 
tumor latency time. Interestingly, this positive effect was observed for all treatments, except for 
the control group.  
 





Figure 3. Molecular profiling of IR and IGF1R signaling in insulin analogue derived mammary gland tumors.  Tumor 
protein levels of critical mammary gland tumor related receptors (IR, IGF1R, ER, EGFR, Her2) and downstream 
signaling pathways (Erk, phospho-Erk, Akt, phospho-Akt) as well as epithelial differentiation markers (N-cadherin 
and E-cadherin) were determined by quantitative Western blotting of all primary mammary gland tumors (n=148). 
A) A small subset of the Western Blot data (n=36) is shown which are representative for the quality of the blots. B) 
The quantitative IR, IGF1R p-Akt and p-Erk levels of all primary EMT tumors are presented in dot-plots (n=148). C) 
 




The IR vs IGF1R protein levels are plotted, 5 clusters are defined. D) The mean tumor latency time has been 
determined of each cluster. Error bars represent SEM, ns = p>0.05, *= p<0.05, **= p<0.01, ***=p<0.001.  
 
 
Figure 4. Hierarchical clustering of insulin (analogue) tumors based on IR and IGF1R signalling components. 
Quantitative expression levels of IGF1R-β, IR-β, p-Akt and p-Erk in mammary gland EMT tumors of all treatment 
groups were clustered using Euclidean distance and average linkage (A). Distinct clusters appeared in which the 
treatment groups are not equally distributed. In protein clusters 1, 2, 5 and 6, the highly mitogenic treatment groups 
 




(IGF1 and X10) are overrepresented. In the graphs B and C the distribution of several parameters of the clusters are 
shown. B) Treatment group distribution, C) Latency time per cluster, in which it became apparent that the cluster 
with the highest p-Erk levels has the shortest tumor latency time. In the last two graphs the correlation between 
latency time and p-Erk (D) or latency time and p-Akt (E) is presented. Interestingly, high p-Akt levels are positively 
correlated with latency time, but only in the compound treatment groups and not in the vehicle treated animals. 
 
Discussion  
In the present study we used the p53R270H/+WAPCre mouse model to assess the carcinogenic 
potential of two insulin-like molecules, X10 (AspB10) and glargine in direct comparison to insulin 
NPH and IGF1. Our data indicate that the highly mitogenic compounds insulin X10 and IGF1, both 
stimulating the IGF1-receptor, significantly decreased the latency time for tumor development. 
This was not observed for glargine and insulin NPH. Moreover, we demonstrated that tumors 
derived after mitogenic insulin analogue treatment induce mammary gland tumors with enhanced 
intracellular signalling through either the Erk or Akt pathway, which was not observed in control 
animals. Our data indicate that the p53R270H/+WAPCre mouse model is sensitive to evaluate the 
intrinsic higher mitogenic potential of insulin-like compounds and the associated contribution to 
cancer development. Interestingly, while this mouse tumor model gives largely rise to EMT 
mammary gland tumors irrespective of insulin treatment conditions, the mitogenic insulin-like 
molecules drive the formation of tumors with enhanced key mitogenic signalling activity.    
X10 as well as IGF1 significantly decreased tumor latency time. These two compounds also induced 
a significant weight increase. However, there is no overall correlation between tumor latency time 
and mouse weight at tumor detection date (Supplemental Figure 5), indicating that chronic 
treatment of X10 and IGF1 affects  tumor latency directly by mitogenic signalling rather than 
indirectly by obesity. 
Similar to insulin NPH, chronic exposure to insulin glargine did not significantly affect tumor latency 
time compared to the vehicle treatment, although tumors developed slightly earlier in the glargine 
treated animals. These glargine data are in line with a previous report by Stammberger et al. in 
which a life long exposure of glargine did not show any difference in the incidence of mammary 
tumors reported in both mice and rats when comparing with the NaCl, vehicle-control, or the NPH 
insulin treated groups in wild type mice and rats [175]. When conducting a pathology study on the 
different tumors, we found no difference between insulin NPH versus glargine induced tumors. 
These histopathology results are in agreement with a study performed by Besic et al, in which a 
clinical and histopathological screening was performed on breast carcinomas of diabetic patients 
that were either on a glargine or other insulin (analogue) therapy [93]. We previously showed in 
in vitro models that both insulin IGF1, X10 and glargine can strongly activate both the IGF1R-
mediated signalling, but that only IGF1 and X10 have an increased mitogenic potential [46]. Insulin 
glargine did not significantly enhance cell proliferation, which was largely explained by the rapid 
 




metabolism of glargine, preventing a sustained activation of IGF1R-mediated mitogenic signalling 
[46]. These insulin-like compounds have been tested for carcinogenic side-effects in wild type mice 
and rats [32, 189] [173], but to our knowledge they have never been tested in sensitive humanized 
in vivo models. Our current in vivo findings are in agreement with these in vitro observations. Yet, 
despite the fact that insulin glargine did not significantly enhance mammary gland tumour 
development, many insulin glargine tumours also demonstrated enhanced Erk and Akt activity, 
which was hardly observed under control conditions. This suggests that insulin glargine is not inert 
and may affect the intracellular signalling in the developing tumor.     
The majority of the obtained tumors in our p53R270H/+WAPCre mouse model were classified as EMT 
tumors, these tumors are thought to be in the epithelial to mesenchymal transition state. This type 
of mammary gland tumor is not a commonly found human breast cancer subtype. Nevertheless, 
like in human breast cancer, the intracellular signalling varied considerably between the various 
tumors. In particular a strong enhancement of Erk and Akt activity was evident in the mitogenic 
insulin like molecules groups, which was hardly observed for untreated mice. This variation 
induced by our insulin treatment conditions probably provides a better representation of human 
breast cancer in general and EMT tumors in particular. Hence, a mitogenic treatment setting might 
provide enhanced information on human breast cancer development. Yet, given the biased 
formation of EMT tumors in the current study setup, further carcinogenic studies with insulin-like 
molecules are required with other humanized mouse mammary gland tumor models. This could 
involve genetically engineered mouse models (GEMMs) with a human specific mutation in e.g. the 
PI3K signalling pathway [190].  
Long-term administration of IGF1, X10, glargine and insulin, led to tumors with significantly higher 
p-Akt levels compared to vehicle treated animals. This indicates that the PI3K signalling cascade is 
up regulated upon stimulation with the insulin-like molecules. Similarly the MAPK signalling 
pathway was up regulated after IGF1, X10 and glargine treatment. Interestingly long-term 
stimulation with insulin did not affect the p-Erk1/2 levels in the obtained tumors.  
At this moment we do not know the exact mechanism by which the more mitogenic insulin like 
molecules promote the mammary gland tumor development. Since Erk and Akt activity did not per 
se coincide in the various tumors and/or relate to enhanced IGF1R levels, direct ligand-mediated 
activation of the Erk and Akt pathways seems unlikely. Possibly mutations in either Erk and/or Akt 
pathway components are underlying the enhanced activation of these signalling molecules. In such 
a scenario activation of the IGF1R and/or IR may promote the selection of the initiated cells that 
have incorporated mutations in Erk/Akt pathway components (e.g. Ras or PI3K). This could provide 
a suggestion that treatment with human insulin analogues may initiate the development of 
mammary tumors with an altered mutational and/or signalling spectrum. More in depth molecular 
 




analysis of the our mouse tumors at the genome and proteome level is needed to further 
understand the underlying mechanism for the enhanced tumor formation by IGF1 and X10 
treatment conditions and their potential role in either enhanced tumor initation and/or 
progression. While we studied the effect of insulin analogues on mammary gland tumor 
development, we cannot exclude that insulin analogues with high affinity for the IGF1R may also 
promote breast cancer progression, either locally or at distant sites, or modulate sensitivity to 
anticancer drugs. This needs further investigation and our different mouse mammary gland tumor 
banks that show different expression levels of IGF1R and IR could contribute to this.  
 
Conclusion 
The p53R270H/+WAPCre mouse model is a sensitive and human relevant model to test the 
carcinogenic properties of insulin-like molecules, as apparent with insulin X10 and IGF1. Insulin 
glargine was tested in this study and did not show a significantly decreased tumor latency time 
compared to insulin NPH, although the MAPK-signalling pathway was upregulated as found for 
X10 and IGF1. As is the case in humans, rapid conversion of glargine into metabolically active 
metabolites M1 (and to a lesser extent M2) is likely to be the reason for the low carcinogenic 
potential of subcutaneous injected glargine. All in all, based on the current tumor model, the data 
suggest that glargine users are not facing an increased carcinogenic hazard compared to insulin 
NPH users. Yet future studies in mouse models that lead to more human relevant tumors remain 
important to fully exclude a role for current clinically relevant insulin analoques in the 
development and/or progression of human breast cancer.  
 
List of Abbreviations 
IGF1, insulin-like growth factor 1; IR, insulin receptor; EMT, Epithelial to Mesenchymal Transition; 
GEM, Genetically engineered mouse; WAP, Whey Acidic Protein; MPD, Maximal Pharmalogical 
Dose; NGS, Normal Goat Serum; IF, Immunofluorescence; MG, Mammary Gland; MTLT, Mammary 
Gland Tumor Latency Time; EC, Endogenous Control 
Competing Interest  
The authors declare that they have no competing interests. 
Contribution statement 
Conceived and designed the experiments: BTB, KS, HVS, BVDW, JWVDL. Performed the 
experiments: BTB, KS, ENS, EK, DS. Analyzed the data: BTB, EK, DS. Wrote the paper: BTB. Reviewed 
and corrected paper: KS, HVS, DS, EK, ENS, BVDW, JWVDL. All authors approved the final version 
of this paper. 
Acknowledgements 
 




We thank Dr. Virginie Boulifard (Ipsen, France) for providing the Increlex, IGF1. We are grateful 
to Dr. Norbert Tennagels and Dr. Ulrich Werner (Sanofi-Aventis, Germany) for providing us with 
insulin glargine, insulin Basal and vehicle solutions for the exposure experiments. We thank Dr. 
Bo Falck Hansen (Novo Nordisk, Denmark) for providing the X10. We would like to thank Conny 
van Oostrom, Silvia Neggers and Ilma Rietbroek for excellent technical assistance during the in 
vivo experiments and Saskia van der Wal-Maas for her technical help with the pathology. Ben ter 
Braak is acknowledged for critically reviewing our manuscript. This study was funded by the 
National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands in 
the Strategic Research Program SOR 2010 (S/360003) 
 
Supplementary figures 
Supplemental Figure 3. EMT tumors can originate from both the luminal as well as myo-epithelial part of the 
mammary gland.  The first IF image is the only EMT tumor that stained positive for CK5, indicating a myo-epithelial 
origin. The second IF image is a representative example of a tumor that originated from the luminal part of the 
mammary gland as all cells express CK8 (n=19). 
 
Supplemental Figure 5. No correlation between 
tumor latencytime and weight of mice at tumor 









Supplemental Figure 1. Blood glucose levels measured in p53R270H/+WAPCre mice after injections with a 
concentration range of insulin(-like) molecules.  A) insulin NPH injections, B) glargine injection, C) IGF1 injections, 
D) regular human insulin injections and E) X10 injections. The number 1 graphs represent the blood glucose levels 
of injected mice over time. The number 2 bar plots represent the area above the curve of the first blood glucose 
drop (first 3 hours). Each data point represents the average bloodglucose levels of 2 mice. 
 





Supplemental Figure 2. Weight measured in p53R270H/+WAPCre mice after injections with a concentration range of 
insulin(-like) molecules. A) Insulin NPH injections, B) glargine injection, C) IGF1 injections, D) regular human insulin 
injections and E) X10 injections. The number 1 graphs represent the weight increase in  % of injected mice over time. 
The number 2 bar plots represent the area under the curve of the weight increase plots. 
 






Supplemental Figure 4. Protein expression profiles of all primary mammary gland tumors. Tumor protein levels of 
critical mammary gland tumor-related receptors (IR, IGF1R, ER, EGFR, Her2) and downstream signalling pathways 
(Erk, phospho-Erk, Akt, phosphor-Akt) as well as epithelial differentiation markers (N-cadherin and E-cadherin) were 
determined by quantitative Western blotting of all primary mammary gland tumors (n=148). EC is the endogenous 









Tumorigenic insulin analogues promote mammary gland 
tumor development by increasing glycolysis and 













This chapter is based on a manuscript in preparation: 
B. ter Braak, C.L.E. Siezen, J. Lee, P. Rao, C. Voorhoeve,  






    IN BEELD
Een systeem voor de geautomatiseerde injectie 
van 3D cel clusters. Ten behoeve van in vitro 
modellen worden vaak 2D cel cultures gebruikt. 
Echter, algemeen wordt aangenomen dat 3D 
modellen de in vivo situatie beter tonen/in beeld 
brengen. Met het getoonde apparaat is het 
mogelijk een cluster van ongeveer 1000 cellen in 
een 3D omgeving te injecteren. Wij hebben deze 
methode gebruikt om het invasieve karakter van 
levende cellen te bestuderen. 
     IN THE PICTURE 
Automated 3D spheroid injection system. In vitro 
models very often rely on 2D cell culture. 
However, it is thought that 3D systems 
recapitulate the in vivo situation much better. 
With the set-up presented in the picture it is 
possible to inject a cluster of about 1000 cells in 
a collagen/matrigel environment. We have used 
this method to study the invasive behaviour of 
living cells in 3D. These cells have been isolated 
from tumours discussed in chapter 3. 
o During tumorigenesis the IRB gene expression levels drop dramatically by which the mitogenic 
IRA becomes the main insulin receptor in the tumor 
o Tumors developed in mice that have been chronically treated with IGF1 show an enhanced 
mitogenic signalling and migrative gene expression signature compared to tumors from other 
treatments 
o There seems to be a correlation between the mitogenic potential of an insulin analogue and 
the Warburg effect in tumors of chronically exposed mice 
o Ezh2 and Hras mutations are enriched in X10/IGF1 tumors 
 




     Abstract  
Epidemiological studies suggest that insulin analogues might increase the (breast) cancer risk. 
In a previous experiment we found that chronic insulin X10 and IGF1 treatment decreased the 
mammary gland tumor latency time in a p53R270H/+WAPCre mouse model. Frequent insulin 
glargine treatment did not significantly decrease the tumor latency time in this mouse model. 
Here we performed next generation RNA sequencing on mammary gland tumors to unravel 
the underlying mechanisms of pro-tumorigenic insulin analogues. We found that chronic X10 
and IGF1 treatment resulted in tumors with an increased and sustained proliferative and 
invasive transcriptomic profile. Furthermore, a Warburg-like effect with increased glycolysis 
was observed in tumors of the X10/IGF1 groups and to a lesser extend also in glargine induced 
tumors. A metabolic flux analysis revealed that this enhanced glycolysis programming in 
X10/IGF1 tumors was associated with increased biomass production programs. Although none 
of the chronic insulin analogue treatments induced genetic instability or enhanced 
mutagenesis, mutations in Ezh2 and Hras were enriched in X10/IGF1 treatment tumors. Overall 
these data suggest that the decreased mammary gland tumor latency time caused by chronic 
insulin X10 and IGF1 treatment is related to modulation of tumor progression rather than 
increased tumor initiation. 
 
Keywords: Next generation sequencing, in vivo, Mammary gland tumor, insulin treatment, 
Glargine, IGF1, Hallmarks of Cancer, Warburg, mutational profiling 
Introduction 
The administration of exogenous insulin is a common therapy for types I and II diabetes. New 
insulin-like molecules have small modifications of the insulin molecular structure to improve 
pharmacokinetic parameters of the original molecule and thereby increase stability and temporal 
bioavailability. These molecular changes possibly affect the binding affinity towards receptors 
including the insulin receptor (IR) or the insulin-like growth factor 1 receptor (IGF1R). 
Consequently, insulin analogues with IGF1R affinity likely promote mitogenesis [191].   
Epidemiological studies indicate an increased risk for (breast) cancer in relation to treatment with 
specific insulin analogues [76] [144]. Yet other studies do not find this association [64] [78] [192]. 
Epidemiological studies cannot define causal relationships. Therefore many in vitro studies have 
been performed evaluating possible increased mitogenic properties of insulin analogues [46] 
[193] [118] [121]. Also here the results have been inconsistent, and further extrapolation from 
these in vitro systems to the in vivo situation remains difficult [172], (Bronsveld, submitted, 
2015). So far in vivo studies that examine the carcinogenic outcome of chronic insulin analogue 
treatment are limited [175] [46].  
 




Recently we evaluated the tumor promoting capacity of chronic insulin analogue treatment in a 
humanized breast cancer (p53R270H/+WAPCre) mouse model [194]. In this model the WAPCre 
system ensures mammary gland (MG) specific expression of the heterozygous p53 mutation, 
which corresponds to a mutational hotspot often found in patients with the Li Fraumeni cancer 
syndrome [195]. Eventually all mice develop spontaneously MG tumors within approximately 
one year. Chronic treatment with insulin like molecules, IGF1 and the insulin analogue X10, 
significantly decreased the tumor latency time. Frequent injections with insulin glargine, an 
insulin analogue currently used by more than seven million diabetic patients worldwide [196], 
showed a similar trend but the observed tumor latency time decrease was not significant 
compared to regular insulin [194]. Systematic signaling pathway mapping of all tumors revealed 
that especially the MAPK/ERK signaling cascade was strongly activated in IGF1- and X10-induced 
tumors. Although this provides some insight in the alternative signaling wiring in insulin-
analogue-related tumors, a systematic evaluation of the genetic modifications and consequently 
alterations in cellular pathways and network biological differences of insulin analogues related 
tumors is still obscure.  
To gain more insight in the modulation of tumor development and progression by insulin 
analogues in this study we performed a systematic in depth next generation sequencing (NGS) 
approach. RNAseq analysis was performed on fifty insulin analogue-induced MG tumors (control, 
insulin, IGF1, X10 and glargine treatment). Overall genetic modifications were determined on a 
tumor level. NGS transcriptome analysis did shed light on the specific tumor development and 
progression in relation to insulin analogue type. For this we specifically evaluated the alternative 
modulation of the hallmarks of cancer [197] to detect treatment specific tumor features. 
 
Materials and Methods 
Chronic in vivo insulin analogue treatment 
Previously we have reported the effect of insulin analogues on tumor development [194]. In 
short, for the chronic exposure experiment two hundred (40 mice per treatment), 8 week old 
female p53R270H/+WAPCre mice were obtained from an in house breeding project. The point 
mutation in the tumor suppressor p53 gene corresponds to the Li Fraumeni Cancer syndrome 
mutational hotspot (R273H) in humans. Every other day these mice have been injected 
(subcutaneously) with either vehicle, insulin, glargine, X10 or IGF1 till tumor development. Once 
the tumors reached a size of 1 cm3 and 24 hours after their last injection the mice were sacrificed. 
Tumors and other tissues were isolated. ¼ of the tumor was stored in RNALater (Ambion, Austin, 
Texas) at 4 degrees Celsius for RNA isolation. A miRNA isolation kit (Macherey Nagel, Germany) 
was used to isolate and purify small and large RNA molecules in one fraction.  
  
 




Single insulin analogue treatment; an animal experiment 
For the single insulin analogue exposure experiment forty (4 mice per treatment/time point) 
female 12-week-old inbred FVB/NRj mice were obtained from Janvier, rodent research models, 
France. Housing and experiments were performed according to the Dutch guidelines for the care 
and use of laboratory animals (UL-DEC-14020). Mice received a single subcutaneous injection 
with either vehicle, insulin, glargine, X10 or IGF1. One or six hours after the injection the mice 
were sacrificed, blood was collected (mini collect, Greiner/Omnilabo) and MGs were stored in 
RNALater (Ambion, USA) at 4 degrees C for RNA isolation. For this a Nucleospin RNA isolation kit 
(Macherey Nagel, Germany) was used. For further technical details we refer to our previous 
publication [194]. 
In vitro stimulation experiments 
MCF7 human breast cancer cells with an overexpression of the IGF1R and a stable knockdown of 
the INSR (MCF7 IGF1R) have been seeded at 60% confluence and starved for 2 days in 5% CDFBS 
(Hyclone, USA) containing RPMI 1640 (Gibco, USA) medium. Cells were stimulated (with 10 nM 
compound) for 1 or 6 hours after which RNA was isolated using NucleoSpin® miRNA isolation kit 
(Machery Nagel, Düren, Germany). Stimulations included: insulin NPH (Insuman Basal, Sanofi 
Aventis), insulin glargine (Lantus, Sanofi Aventis), insulin X10 (AspB10, Novo Nordisk) and IGF1 
(Increlex, Ipsen). For a more technical details we refer to our previous publication [194]. 
Next generation sequencing (NGS), gene expression analysis 
The quality and integrity of the RNA samples were analysed using the bioanalyzer with a RNA 
nanochip. The Ion Total RNA-Seq kit was used to process the samples. Samples were Poly-A 
selected prior to library preparation. This library preparation included the cDNA synthesis and 
purification steps with the Ion Total RNA-Seq kit v2 (Life Technologies, UK) according to 
manufacturer’s instructions. The Ion PI Template OT2 200 Kit v3 and Ion Sequencing 200 kit v3 
(both, Life Technologies, UK) were used according to manufactures instructions for sequencing 
libraries on the PI chip. Sequence runs were performed on the Ion Proton Sequencer (at 
ServiceXS, Leiden). PI chip analysis, base calling and quality checks were performed using the 
Torrent Server Suite. On average 40 million reads per sample were sequenced with an average 
read length of 100 base pairs. No additional trimming or filtering of reads was performed before 
processing. Reads were aligned to mouse genome build GRCm38 - Ensembl using Tophat2 
(Version 2.0.10). Reads which could not be aligned using TopHat2 were aligned in an additional 
step, using Bowtie2 (Version 2-2.10) in the local, very sensitive mode. Tophat2- and Bowtie2- 
aligned reads were merged into a single .bam file for each sample before further analysis.  
Gene expression was quantified using HTSeq-Count (Version 0.6.1), using the default options. 
Differential gene expression was analyzed for compound versus vehicle treatment and was 
performed using DESeq2 (Version1.2.10). For this analysis, genes with a read count of < 50 reads 
 




across samples (average of <1 read per sample) were filtered out before the analysis. For the 
estimation of individual exon expression analysis a RPKM table was generated with the read 
counts normalized to library size and gene length (using DEXSeq version 1.8.0). For the 
mutational profiling the reads (unfiltered and untrimmed) were aligned to mouse genome build 
GRCm38.73- DNA primary assembly using TMAP within the Torrent Suite version 4.0.2. Variant 
calling was performed using the Torrent Suite Variant Caller version 4.0-r72612 with the settings 
tuned for the detection of somatic mutations at a low stringency level. The reference genome 
used was the same as that used for read alignment - GRCm38.73. SnpEff version 3.6c was used 
to filter and annotate the mutations. The list of mutations was filtered to include only exonic 
mutations with a quality score higher than 250. Several mutations are found in the exact same 
position in all tumor samples, probably strain-specific single nucleotide polymorphisms (SNPs). 
Known SNPs in coding regions for the mouse strain FVB/NJ (the strain most closely related to the 
p53R270H+/-WAPCre) were downloaded from the Mouse Genome Informatics database and these 
mutations were discarded from the list. Mouse homologs of the list of human tumor driver genes 
[198] were used to define the most clinically relevant mutations. 
 
Phenotypic prediction based on transcriptomic data 
To predict the phenotypic characteristics of the treatments of different insulin-analogues using 
their transcriptomics, we constructed a support vector machine (SVM) classifier. The procedure 
is described by Yizhak et al, in which the genes have been identified in 52 human breast cancer 
cell lines that are important for migration and proliferation based on their respective expression 
levels and functional bio-assays [199]. We first identified the transcriptomic signatures of 
migration and proliferation based on the 52 breast cancer cell line data. We then applied them 
to the orthologs of the mouse transcriptomics data to predict the migratory and proliferative 
potential of 50 mouse mammary tumor samples using LIBSVM [200]. 
 
Metabolic flux analysis 
We estimated the metabolic fluxes that are most consistent with the transcriptomics data using 
a computational framework called iMAT [201]. iMAT integrates the transcriptomics, as ‘soft’ 
constraints, by ternary partitioning the expression to lowly (-1), mediocrely (0) and highly (1) 
expressed genes. iMAT then attempts to collect the metabolic states that best correspond to 
these cues, which constructs a mixed integer linear programming (MILP) problem. We applied 
iMAT to the human genome-scale metabolic model Recon1 [202] with a standard medium 
condition (DMEM) in a condition-specific manner for the 5 different insulin analogues 
treatments. With the predicted metabolic fluxes by iMAT, we performed a pathway enrichment 
analysis of differentially activated metabolic reactions in X10/IGF1 treated cells to the remainder 
conditions (insulin/glargine/vehicle). We selected the metabolic pathways whose reactions are 
 




significantly enriched in the up-/down- regulated group using hypergeometric test followed by 
multiple hypotheses correction with the false discovery rate (FDR) 0.05. The predicted biomass 
production rate does not involve standard deviation because we focused on the metabolic states 
where the biomass production rate is optimized (thus single-valued).  
 
Statistical analysis 
For the statistical analysis Graphpad Prism version 5.01 software was used. All standard error bars 
in the graphs represent standard deviations. Multi-experiment viewer (MeV version 4.8.1) was 
used for the hierarchical clustering analysis.  
 
Results 
Genetic profiling of insulin analogue induced mammary gland tumors might reveal cellular 
processes that have initiated the decreased tumor latency 
Previously we chronically treated p53R270H/+WAPCre mice with insulin and insulin analogues 
(Figure 1A) and found that MG tumor latency time in X10 and IGF1 treatment groups was 
significantly decreased (Figure 1B). Tumors in the glargine treated mice also developed earlier 
compared to vehicle and insulin treated animals, but this trend was not significant [194]. To 
further investigate this we evaluated receptor gene expression levels. We found that gene 
expression levels of the insulin receptor (both the A and B isoform; ira, irb respectively) and 
insulin-like growth factor 1 receptor (igf1r) are significantly up regulated in pre-neoplastic MG 
tissue of old p53R270H/+WAPCre mice compared to healthy 8 week old MGs (Figure 1C). Also ira 
and igf1r levels were slightly up regulated in MG tumors. Interestingly, we found a significant and 
seven-fold down regulation of the B-isoform of the insulin receptor in MG tumor tissue compared 
to normal MG tissue. This effect was not treatment specific (Figure 1C right). Levels of igf1r were 
only decreased after chronic treatment with IGF1.  These data are indicative for an involvement 
of INSR/IGF1R signalling in tumor development and/or progression. However, the different 
receptor distributions cannot explain the differences in tumor latency time, since there was no 
treatment-related effect.  
To gain more insight in overall differences between various insulin analogues in tumor 
development and progression, we performed RNAseq NGS of 50 tumors, 10 tumors per 
treatment group. We reasoned that transcriptome analysis would shed light on the differences 
in tumor latency time by chronic insulin analogue treatment. From the 40 tumors per treatment 
group, we selected the 10 EMT-like tumors per treatment condition as well as those tumors for 
which the tumor latency time was closest to the median latency time of that entire specific 
treatment group. In Figure 1D a correlation analysis shows the sample-to-sample distance. All 
transcriptomics data was used to define the correlation within and between the different 
treatment groups. 
 





Figure 9. Experimental overview. A) Overview of the chronic insulin analogue exposure experiment. B) The Kaplan 
Mayer MG gland tumor free mice plots with the median tumor latency per treatment group. C) the IGF1R, IRA, IRB 
gene expression levels in MG tissue of young mice, old mice and in MG tumors (first graph),  second plot shows the 
receptor gene expression distribution in the MG tumor tissue of mice chronically exposed to different insulin 
 




analogues. D) Heat map of the next generation sequencing data showing hierarchical sample clustering by sample-
to-sample distance, the lower table shows the Spearman rank correlation coefficients within the treatment groups 
(bold) and the coefficient between the different treatment groups (averaged per condition). E) The hallmarks of 
cancer with the features highlighted that we will discuss in in view of the chronic insulin analogue exposure 
experiment. (Adapted from Hanahan and Weinberg, 2011) 
 
In spite of the relatively high variation in this in vivo experiment, there was a higher correlation 
within each treatment group than between the different treatment groups. This suggests the 
existence of treatment specific response in each treatment conditions. To define these treatment 
specific responses we focussed on four particular hallmarks of cancer (Figure 1E), that might have 
been involved in the decreased tumor latency, either by tumor initiation or progression. These 
pathways were selected in close relation to the signalling pathways downstream of IR and IGF1R 
and included: i) sustained growth signalling; ii) tissue invasion and metastasis; iii) deregulated 
cellular metabolism; and iv) genetic instability and mutations. 
 
X10- and IGF1-derived tumors demonstrate ‘sustained growth signaling’.   
Proliferative signaling is normally a highly regulated process. In a tumor the replicative cell 
homeostasis is deregulated causing sustained growth signaling [197]. Since mice were chronically 
exposed to insulin analogues that activate the INSR/IGF1R, we postulated that the decreased 
tumor latency time (after X10/IGF1 stimulation) would be a direct result of an up-regulated INSR 
or IGF1R signaling pathway. We selected mouse orthologous of human genes (~60 genes) that 
are involved in INSR and IGF1R signaling according to Ingenuity Pathway Analysis (IPA) (Figure 
2A). A hierarchical clustering analysis was performed for all 50 MG tumors on the relative 
expression levels of these genes (Figure 2B). Two clusters could be defined. In cluster 1 tumors 
from low mitogenic treatments are enriched, whereas cluster 2 predominantly consists of the 
X10/IGF1 treated tumors. These two different cluster could not be linked to specific signaling 
pathways (e.g. PI3K, MAPK, JAK signaling cascade).   
To predict the proliferative potential of all the individual tumors, we next built an SVM classifier 
using transcriptomic signatures associated with proliferation (Figure 2Ci). No significant effect 
was observed; however, a clear trend for the tumors in the X10 and IGF1 treatment groups to 
have an increased proliferative potential could be seen. As a positive control for the SVM 
simulation, similarly we ran the SMV simulation on our earlier micro-array data of the MCF7-
IGF1R cells stimulated with the different insulin analogues.  We observed that 1 hour after 
glargine, X10 and IGF1 stimulation a strong and significant proliferative genetic signature could 
be detected. 
 





Figure 10. Sustained growth signaling in mammary gland tumor tissue of chronically i.a. exposed mice. A) The 
INSR/IGF1R signaling pathway with receptors, downstream targets and the biological effect. B) Hierarchical 
clustering (Euclidian distance) of the INSR/IGF1R specific gene expression per MG tumor. The pie-diagrams show the 
distribution of the different treatments in the two clusters. C) Bar graph of SVM simulation on the predicted 
proliferation potential per treatment of MG tumors of the chronically exposed mice (Ci) and human breast cancer 
cells (MCF7 IGF1R) exposed for 1h to the indicated i.a (Cii)  
 





Chronic X10 and IGF1 treatment induce tumors with a more mesenchymal phenotype and a higher 
migration potential 
Next we assessed hallmark “Tissue invasion and metastasis”. Again we selected genes that are 
directly associated with the epithelial to mesenchymal transition (EMT) or the mesenchymal to 
epithelial transition (MET) according to IPA. The gene expression of the mouse orthologues of 
these genes is presented in an unsupervised hierarchical clustering (Figure 3A). Two clear gene 
groups were observed: group A containing genes associated with epithelial phenotype (Elf5, 
Serpinb5, Cdh1, Grhl2, Elf3, Wnt4), and group B containing twelve genes associated with 
mesenchymal cells (Pdgfrb, Six1, Snai2, Tcf4, Zeb1, Klf8, Wnt5a, Snail, Vim, Twist1, Cdh2). From 
this hierarchical clustering three separate treatment clusters could be discriminated. Cluster 1 
consists of tumors that show high expression of epithelial and low expression of mesenchymal 
associated genes, three out of six tumors originate from the vehicle treated animals. Cluster 2 
shows moderate expression levels of epithelial and mesenchymal associated genes, interestingly 
the majority of these tumors were from the glargine treatment condition. Cluster 3 consists of 
tumors that have a low expression of epithelial and high expression of mesenchymal markers. 
IGF1 treatments were not present at all in cluster 1 and 2. While IGF1 and X10 treatment groups 
were overrepresented in cluster 3. This suggests that IGF1R-mediated signaling is a driver of 
tumors with an EMT phenotype. We substantiated the phenotypes for the three different 
clusters (Figure 3B). The tumors in cluster 1 predominantly expressed epithelial cells that contain 
many E-cadherin positive cells. Tumors of the cluster 2 and 3 phenotype were characterized as 
EMT tumors predominantly consisting of mesenchymal cells, lack of E-cadherin staining and clear 
smooth muscle actin (SMA) staining (data not shown) [194].  
To link the transcriptomics data further to the phenotype we performed a SVM simulation to 
derive predictions for the cell migratory potential of each tumor (Figure 3Ci). Overall no 
significant difference in the migration potential was observed for the different treatment groups. 
To evaluate whether IGF1 signaling itself is a strong activator in vitro, we also applied our SVM 
classifier to our previous MCF7-IGF1R transcriptomics data exposed to the different insulin 
analogues (Figure 3Cii). IGF1, X10 and glargine caused a significant increase in the migration 
potential. Altogether these data suggest that chronic exposure to X10, and especially IGF1 
induces tumors with a more a mesenchymal phenotype that are possibly more aggressive in 
terms of their migratory potential. 
 
Mice receiving a chronic X10 and IGF1 treatment develop tumors with a higher Warburg potential 
Through the activation of the INSR, insulin and insulin analogues directly affect cell metabolism. 
Therefore we wondered whether the chronic treatment with insulin analogues induce tumors 
with a deregulated cellular metabolism or a higher Warburg potential. 
 





Figure 11. Tissue invasion and metastasis in mammary gland tumor tissue of chronically i.a. exposed mice. A) 
Hierarchical clustering (Pearson correlation) of genes involved in EMT or MET per MG tumor. The pie-diagrams show 
the distribution of the different treatments in the three clusters. B) shows the E-cadherin/HOECHST immuno 
fluorescent  H&E pathology slides of 3 example tumors showing epithelial or mesenchymal characteristics C) Bar 
graph of SVM simulation on the predicted migration potential per treatment of MG tumors of the chronically 
exposed mice (Ci) and human breast cancer cells (MCF7 IGF1R) exposed for 1h to the indicated i.a (Cii) 
 





To test this we defined genes directly involved in glycolysis and in oxidative phosphorylation 
according to IPA. An unsupervised hierarchical clustering of the expression profiles of each tumor 
revealed two very clear gene groups (Figure 4A). Strikingly, the first gene group consists of eleven 
genes that are all directly involved in glycolysis; all the genes in the second cluster are involved 
in oxidative phosphorylation. Four clear tumor clusters could be detected: cluster 1 with high 
expression of glycolysis genes and low expression of oxidative phosphorylation genes; cluster 2 
with moderate glycolysis; cluster 3 with little glycolysis and moderate oxidative phosphorylation; 
and cluster 4 with high oxidative phosphorylation and little glycolysis. For the insulin group 
almost all tumors were related to cluster 3 (little glycolysis and moderate oxidative 
phosphorylation: 90%). For glargine-related tumors 70% relied on oxidative phosphorylation. 
IGF1 and X10 were relatively more dependent on glycolysis (60% and 50%, respectively) 
comparable to vehicle control. This suggests that chronic insulin signaling drives tumors in a more 
oxidative phosphorylation modes.  
Since IGF1 and X10 were mostly related to glycolysis we performed an independent 
bioinformatics analysis on the activity of various metabolic processes. This revealed several 
significantly down- and up regulated metabolic programs in IGF1/X10-derived tumors compared 
to the vehicle/insulin/glargine tumors (Figure 4B). Importantly, as expected oxidative 
phosphorylation was significantly down regulated in the IGF1/X10 group (p=0.000107) while 
glycolysis was significantly upregulated. Again, this analysis was also performed on the 
microarray data of MCF7-IGF1R cells exposed to the different insulin analogues. Similarly to the 
in vivo data IGF1 and X10 treatment significantly down regulated the citric acid cycle as well as 
oxidative phosphorylation (both p<0.0005) and up regulated glycolysis (p<0.00001) (Figure 4C). 
These data suggest that both IGF1 and X10 promote a Warburg effect in mammary gland tumors 
and human tumor cell lines. 
 
Biomass production rate is highly up regulated in tumors of chronic X10/IGF1 treated mice 
Tumor mice receiving a chronic X10 and IGF1 treatment showed a glycolytic activity  (figure 4) 
associated with decreased tumor latency time (Figure 5A), we evaluated whether this difference 
in metabolic capacity is related to enhanced growth. To test this hypothesis we predicted the 
rate of the accumulation of biomass in all these different tumors based on the gene expression 
profiles of biomass producing metabolic processes. In Figure 5B a bar graph of these results is 
presented. A highly increased mammary gland tumor biomass production rate was observed in 
chronic X10 and IGF1 treated tumors. This finding is in agreement with the observed increased 
proliferative potential in the X10/IGF1 tumors. These results strongly suggest that the decreased 
tumor latency time by X10 and IGF1 treatment was caused by enhancing the tumor development 
rather than interfering with the tumor initiation.  
 






Figure 12. Warburg effect in mammary gland tumor tissue of chronically insulin analogue treated mice.  A) 
Hierarchical clustering (Pearson correlation) of genes involved in glycolysis or oxidative phosphorylation per MG 
tumor. The pie-diagrams show the distribution of the different clusters per treatment group. B) Table with the 
metabolic pathways that were significantly down- or up- regulated in the X10/IGF1 treatment groups compared to 
the vehicle, insulin and glargine treatment groups. C) Table with the metabolic pathways that were significantly 
down- or up- regulated after X10/IGF1 exposure compared to vehicle, insulin and glargine treatment in the MCF7 
IGF1R model. 
 






Figure 5. Biomass production rate is increased in tumors of chronically X10/IGF1 treated mice and could possible 
explain the decreased tumor latency time in these treatments. A) Bar plot of the mean tumor latency time in weeks 
per chronic treatment. B) Bar plot of the normalized biomass production rate per treatment. 
 
Ezh2 and Hras mutations are enriched in X10/IGF1 tumors. 
Since IGF1 and X10 promote cell proliferation, this could lead to a manifestation of mutations 
and consequently modulation of tumor development and progression. To evaluate if chronic IGF1 
or X10 treatment affects the number of mutations a mutational analysis was performed on all 
tumors based on the 40 million 100 base pair reads for each tumor. The number of different 
mutations was ~3000 mutations per tumor and no significant difference between treatment 
groups could be detected. Also, there was no correlation between the number of mutations per 
tumor and the tumor latency time (best fit correlation values, slope:0.00001207, r2:0.0000099, 
p-value: 0.9827) (Figure 6A).  
Next we focused on specific clinically relevant mutations that are part of the ~140 known human 
tumors drivers according to Vogelstein and colleagues [198]. In the fifty mouse tumors that we 
sequenced, 102 of these tumor drivers were mutated. On average each tumor had about 35 of 
these tumor driver mutations and again it seems that the chronic treatment did not affect the 
overall number of tumor driver mutations per tumor (Figure 6B). Also for the tumor driver 
mutations there was no correlation between number of mutations and latency time of each 
tumor. Also no treatment specific effects could be detected for the average number of point 
mutations, the average number of frame shifts, the average number of start CODON insertions 
and the average number of stop CODON insertions (Supplemental Figure 1).  
We next determined the mutations are overrepresented (>50%) in the X10/IGF1 treatments 
(Figure 6C). All mutations are involved in cancer development and/or progression [198] [203]. 
Although no specific core pathway links these individual mutations, strikingly Ezh2 and Hras were 
strongly overrepresented in IGF1/X10 treated tumors. In a similar way we looked at specific 
mutations that have been overrepresented in insulin analogue treatment altogether and highly 
underrepresented in the vehicle condition. No general mechanism was identified that could 
explain the enrichment of these mutations in the treatment groups. However, a set of five 
 




mutations was not at all detected in vehicle control, yet specifically affected in the insulin 
treatment group. Overall these data suggest that the IGF1/X10 enhanced tumor formation is 
associated with several key candidate cancer drivers that could contribute including Ezh2 and 
Hras, which are known drivers in human breast cancer [204] [205].  
 
 
Figure 6. Genetic instability in mammary gland tumor tissue of chronically insulin analogue exposed mice.  A) The 
bar plot shows the average number of mutations per MG tumor for all chronic treatments, the dot plot indicates 
that there is no correlation between the number of mutations of a specific tumor and tumor latency time. B) Same 
as in A, but here we focus on clinically relevant human tumor driver mutations. C) Some specific tumor driver 
mutations are featured in these bar plots. The first barplot represents the mutations that are enriched in the 
 




X10/IGF1 treatment groups, the second barplot the mutations are highlighted that are underrepresented in the 
vehicle treatment group. The N shows the number of tumors in which this specific mutation was present.  
 
Discussion 
In this study we used a next generation sequencing-based transcriptome analysis to characterize 
mammary gland (MG) tumors from the p53R270H/+WAPCre mouse model that were chronically 
exposed to insulin like molecules. We found indications that tumors of mice that received chronic 
treatment of X10 or IGF1 have an increased growth potency, enhanced migratory capabilities and 
a higher Warburg potential. Moreover, the candidate cancer driver mutations in Ezh2 and Hras 
were highly enriched in X10 and IGF1 tumors.  
This is the first study in which a humanized breast cancer mouse model was used to study the 
tumorigenic effects of chronic insulin analogue treatment. Eventually, all mice from this model 
developed spontaneous MG tumors with a high human relevance. In this way it was possible to 
compare tumors induced by insulin analogue treatment with tumors induced by chronic insulin or 
vehicle treatment. This in contrast to other studies using wild type mice where only a few tumors 
with an origin less relevant to the human situation could be evaluated [174] [175].  
Tumors often have an increased IRA:IRB ratio [206] [135] that can possibly influence the in vivo 
transformational effects of insulin analogues [207]. We found that IRA gene expression levels are 
up regulated (2 fold) in pre-neoplastic MGs compared to expression levels in normal MGs, but IRA 
gene expression levels in tumors were similar to that of normal MG tissue. This indicates that the 
IRA might play a role in the transformation of normal to neoplastic MG tissue, but once the MG 
tumor is established the A isoform of the insulin receptor does not play a key role in proliferative 
signalling anymore. Surprisingly, IRB gene expression levels were strongly down regulated (over 
10 fold) in MG tumors. This suggests that the IRA:IRB ratio is indeed increased in MG tumors, but 
this effect is mainly caused by down regulation of IRB expression levels rather than an up 
regulation of IRA.  
We anticipated that chronic stimulation with insulin-like molecules would decrease the Warburg 
potency, as insulin deprivation in human fibroblast led to an induction of anaerobic glycolysis 
[208]. Indeed, we saw that 90% of the insulin induced tumors showed an increased oxidative 
phosphorylation response compared to 60% for the spontaneous vehicle induced tumors. 
Interestingly, we found that compounds that induced an equi-glycaemic response but with an 
increasing mitogenic potential at the doses used in this study (insulin, glargine, X10 and IGF1) [194] 
also showed an increasing percentage of tumors depending on anaerobic glycolysis (10%, 30%, 
50% and 60% resp.). This might suggest that proliferative signalling is indirectly or directly coupled 
to the Warburg effect.  Tumor samples were the samples have deliberately been taken 24 hours 
after the last injection, since we were interested in the long term rather than the short term in 
vivo effects. During this time the exogenous compounds are fully degraded by enzymes and 
 




therefore no short-term signalling effect of the compounds can be observed. [131] [83]. However, 
we cannot fully exclude the effect of direct insulin analogue treatment on tumor cell metabolism, 
since also treatment of MCF7-IGF1R cells to the various insulin analogues did affect the glycolytic 
metabolic program.  
Using the SVM model we could detect a sustained proliferative signalling in the chronic X10/IGF1 
treated tumors, which might suggest that chronic growth factor treatment can transform tumors 
in such a way that an autocrine growth factor signalling pathway is induced. A likely explanation 
would be differential mutational pattern in cancer driver genes that underlie such a differential 
proliferative pathway. Chronic insulin, glargine, X10 or IGF1 treatment did not result in more 
mutations and no correlation could be detected with number of mutations and tumor latency 
time. Interestingly several X10/IGF1 enriched mutations were observed, including Ezh2, Hras and 
Traf7, of which Ezh2 and Hras are prominent modulators of human breast cancer. Possibly these 
specific mutations contribute (in)-directly to the X10/IGF1 phenotypes and enhanced tumor 
development and progression.  
Altogether our data suggest that the observed decreased tumor latency time in the  
p53R270H/+WAPCre mouse model after chronic X10/IGF1 treatment is a result of an enhanced tumor 
biomass production rate. Furthermore these treatments might facilitate tissue invasion and 
metastasis and deregulate the cellular metabolism in the tumor. All these factors contribute to an 
enhanced tumor development and thus decreasing the MG tumor latency time in this model. We 
did not find evidence that chronic glargine treatment induced a more aggressive tumor phenotype 
or increased the biomass production rate, but a slight increased Warburg potential was observed 
compared to tumors induced by insulin treatment. 
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Supplemental figure 1. Chronic insulin analogue treatment does not affect the mutational profile of the tumors. 
A) The average number of point mutations per treatment group. B) The Average number of frame shifts per 
treatment. C) The average number of start CODON insertions per treatment and in D) the average number of stop 
CODON insertions are presented per treatment. 
  
 














Carcinogenicity of insulin analogues: current status 









Chapter 7  summary and discussion 
 
    IN BEELD
Cel kweek laboratorium. In vitro modellen 
berusten op het kweken van levende cellen. Om 
infecties met bacteriën, schimmels en virussen te 
voorkomen, zijn de handelingen met deze cellen 
in speciale cabines gedaan, waarin een (bijna) 
steriele omgeving is gecreëerd. In deze cabines 
worden de cellen uitgezaaid, geoogst en worden 
de blootstellingen en transfecties uitgevoerd. 
     IN THE PICTURE 
Cell culture laboratory. In vitro models depend 
on the culturing of living cells. To prevent the 
cell culture from being infected with bacteria, 
fungi or viruses, handling of these cells is 
performed in special cabinets that create a more 
or less sterile environment. In these cabinets 
cells are seeded or harvested, exposures are 
performed and transfections are executed. 
o The insulin analogue carcinogenic risk assesment guidelines of the European medicine 
administration was used as a guidance in our research strategy 
o There is no compelling evidence that any commercial available insulin analogue is inducing the 
risk of cancer 
o Glargine has an enhanced mitogenic potential compared to regular insulin and might affect some 
hallmarks of cancer 
o Future research on this topic should include chronic exposure in vivo experiments on humanized 
genetically engineered mouse models to increase the clinical relevance of these studies 
 




Biopharmaceutical drugs are medicinal products that have been manufactured or directly 
extracted from a biological source [209]. These compounds are used for therapeutic purposes, 
and should therefore be carefully assessed for potential side effects. Several regulatory national 
and international authorities, like the American FDA or European EMA, are responsible for 
legislation regarding the safety evaluation of biopharmaceuticals  [1, 2].  
Growth factors are an example of biopharmaceuticals. They show intrinsic mitogenic behavior 
and are therefore a problematic group of pharmaceuticals with regard to the carcinogenic safety 
evaluation, and their inherent proliferative action is a cause for concern [210]. Regulatory 
agencies have requested the use of specific testing strategies to ensure the safety of a sub-group 
of growth factors, i.e. insulin analogues [6]. This includes the use of well characterized and 
validated cell models, state of the art techniques to assess the mitogenic effects and the use of 
humanized in vivo models. In this thesis we have focused on carcinogenic risk assessment of a 
specific group of growth factors, the insulin analogues.  
With worldwide over 380 million cases, diabetes mellitus is the most common endocrine related 
disease [142]. Usually, patients with type 1 diabetes depend on daily insulin (analogue) 
administration to control their blood glucose levels. Small alterations to the protein structure of 
insulin affect the pharmacokinetics and dynamics of the molecule, and consequently cause 
these insulin-like molecules to either act faster (rapid-acting analogues) or slower (long-acting 
analogues) than regular insulin. Often a combination treatment of these long- and short-acting 
insulin analogues is used to mimic the endogenous insulin levels in a healthy person throughout 
the day. 
Insulin glargine (LANTUS) is the world’s most commonly used long-acting insulin analogue with 
about 7 million users in 2011 [196]. Three amino acid replacements in the molecular structure of 
glargine ensure the slow release into the patient’s blood and the prolonged action profile [173]. 
But these mutations have also altered the binding kinetics towards different receptors including 
the two isoforms of the insulin receptor (IRA and IRB) and the insulin-like growth factor 1 
receptor (IGF1R). While activation of the IRB induces the intended metabolic effects (blood 
glucose drop), it is thought that activation of IRA and IGF1R will contribute to an enhanced 
mitogenic signaling [211].  
Several epidemiological studies have suggested that the use of some of these insulin analogues 
is correlated with an increased incidence of cancer, especially breast cancer [76] [144] [212]. 
While others could not confirm these findings [19] [146] [71]. Due to the many confounding 
factors, the interpretation of this type of observational patient studies is often difficult. For 
example, diabetes mellitus is in itself thought to be a risk factor for cancer [213]. Moreover, 
insulin analogue dose, treatment duration, and age/gender/lifestyle of patients is often not 
known/taken into account while these factors are thought to have a strong effect on cancer risk 
[24]. A patient based random controlled clinical trial setup would overcome these problems, but 
 




so far this type of study on the relationship between insulin analogue treatment versus cancer 
have been rare and highly underpowered.  
It is also possible to study the direct mitogenic and anti-apoptotic effects of these insulin 
analogues using cell lines. Currently, over fifty in vitro studies are described in literature and 
sixteen of these studies have specifically focused on breast cancer, using breast (cancer) cell 
lines. The conclusions drawn from these studies are not always in agreement and sometimes 
even contradictory [118] [40] [193]. Differences in cell model and experimental procedures are 
in all likelihood the main cause for these conflicting observations. 
If in vitro data are considered insufficient and a cause for concern remains, the evaluation of the 
carcinogenic risk using an in vivo animal model provides added value. The few chronic exposure 
experiments with rats and mice that have been described have revealed an increased 
carcinogenic potential of insulin AspB10 [175], an insulin analogue that therefore never entered 
the market. All other evaluated insulin analogues, including insulin glargine, did not induce more 
tumors than regular human insulin.  
It is unlikely that growth factors at physiological levels induce tumors, however, at 
pharmacological levels these compounds might be involved in tumor progression of pre-
neoplastic lesions. The disadvantage of using the standard wild type rodent models is the rather 
low incidence of clinically relevant background tumors. Therefore, the observed carcinogenic 
effect of the growth factors is very mild in these models. The use of xenograft transplantation in 
vivo models would overcome this problem [207], but in these models only tumor progression 
features can be studied and no information can be retrieved about the earlier stages of tumor 
development.  
In this chapter we will describe our view on the testing strategy of insulin analogues in terms of 
increased mitogenic/carcinogenic potential, bearing in mind the current guidelines on this topic, 
and we will provide an integrated summary of the results obtained with the models that we used 
throughout this thesis. 
This thesis emphasizes the importance of a proper evaluation of carcinogenic side effects of 
insulin analogues used by diabetic patients. To ensure the design of a relevant experiment it is 
of course essential to evaluate the current literature about insulin analogues and cancer risk. 
Some review studies have summarized part of the available literature on this topic, but so far no 
systematic review including all in vitro, in vivo (animal) and epidemiological (human) studies is 
available. In chapter 2, we present a systematic review of current literature. We focused on 
studies that included breast (cancer) cell lines or evaluated the incidence of breast tumors in 
mice, rats or humans that have been exposed to insulin analogues. The results from the sixteen 
in vitro, eight animal and thirty epidemiological studies we included were highly diverse. Some 
studies concluded that insulin analogues, especially glargine, did have carcinogenic/mitogenic 
effects, while others found no effect or even milder carcinogenic/mitogenic effects compared to 
 




regular insulin. All in all we found no compelling evidence that any clinically available insulin 
analogue increases breast cancer risk. However, both in vitro and epidemiological studies 
suffered from methodological limitations. Besides, epidemiological studies were underpowered 
and animal data was scarce. Therefore, there is a strong need for well-designed studies that 
evaluate the carcinogenic and mitogenic potential of insulin analogues. 
A comprehensive evaluation should start with in vitro studies, performed in well characterized 
cell lines. Since the IGF1R is likely to be the main receptor regulating the mitogenic signaling of 
insulin analogues, it is crucial that the used cell line expresses this receptor, and at high levels if 
possible. Furthermore, the concentration at which the analogues are tested is very important. 
Using concentrations that are too low might lead to undetectable signaling events whereas the 
use of overtly high concentrations will overstimulate the receptor. In both cases one is unable to 
discriminate between the mitogenic effects of the different compounds. Thus, a broad 
concentration range is preferred. In addition, the use of positive and negative controls is 
essential. Without including regular insulin and IGF1 as a reference compounds, it is difficult to 
put the obtained results in perspective and provide a quantitative mitogenic score for individual 
analogues. Chapter 3 describes an in vitro study in which we tested all commercially available 
insulin analogues using a human breast cancer cell line panel that expresses either one of the 
isoforms of the insulin receptor (IRA/IRB) or the IGF1R at high levels. The activation of 
downstream signaling was evaluated upon insulin analogue treatment. We found that 
treatment with insulin glargine or AspB10 induced a significantly stronger activation of the 
MAPK and the PI3K signaling pathways, compared to regular insulin, especially via the IGF1R. 
With a functional assay we tested the direct proliferative effects of these compounds using a 
concentration range from physiological to supra-physiological levels. We found that AspB10, 
though not glargine, had a significant higher proliferative potential compared to regular insulin. 
We demonstrated that the glargine was rapidly degraded, into metabolites with a low mitogenic 
potency, by enzymes present in the plasma. This conversion could also explain the difference 
we observed between the results of the SRB proliferation assay (in which serum was present and 
thus the glargine was converted) and the WB experiments (in which no serum was added and 
most of the glargine was still present). Since this bioconversion of glargine is also relevant for 
the human in vivo situation we tested the mitogenic potential of the two main metabolites of 
glargine and found that both metabolites (M1 and M2) have a low mitogenic potential similar to 
that of regular insulin. In conclusion, glargine had a strong intrinsic mitogenic potential but due 
to the rapid degradation into metabolites with a low proliferative behavior there was no 
sustained activation of the IGF1R signaling pathway. All other tested commercially available 
insulin analogues showed a mitogenic potential that was comparable to regular insulin.  
In chapter 4, we performed a stimulation experiment using the same cell line panel as described 
in chapter 3. This time mRNA was extracted and a full transcriptomic analysis was performed 
 




using Affymetrix micro-arrays. This allowed us to study the insulin analogue induced mitogenic 
signaling cascades in more detail. In general, activation of the IRA resulted in a transcriptomic 
response similar to that of IGF1R. Only AspB10 stimulation resulted in a very distinct gene 
expression profile via the IRA, which is in line with an older study that showed a prolonged IRA 
occupancy time for AspB10, therefore it was suggested that AspB10 induces its mitogenic 
signaling especially via the IRA [149]. We identified a set of genes that was significantly 
upregulated upon IGF1 and AspB10 stimulation but to a much milder extent after regular insulin 
stimulation, suggesting that these genes could act as transcriptomic markers for mitogenic 
signaling. Examples of these markers are the early growth response (EGR) genes, all four EGR 
genes were picked up by our assay. Although these genes are well known to play a role in 
proliferation, so far they have not been linked to insulin receptor (ISNR)/IGF1R or insulin 
analogue signaling. Next we evaluated the expression of these genes after stimulation with 
other commercially available insulin analogues. The mitogenic score, or absolute expression 
value of these genes, showed a clear correlation with the mitogenic indexes as calculated from 
functional bioassays as well as receptor kinetic studies in literature [114] [113]. Furthermore, we 
were able to confirm the robustness of some of these classifiers in mammary gland tissue of an 
insulin injected mice as well as insulin analogue stimulated human primary (non-cancer) 
mammary cells. Although more research is needed to determine the clinical relevance of these 
mitogenic classifiers, we think that this straightforward RT-Q-PCR based analysis has the 
potential to become a quick alternative for a mitogenic screen of compounds that act on the 
IGF1R.  
As mentioned before, glargine itself has a strong mitogenic potential, but due to the rapid 
enzymatic conversion to low mitogenic compounds, this might not be relevant in vivo. Due to 
uncertainties about the exact rate of conversion and therefore possible exposure to parental and 
mitogenic glargine, an in vivo experiment would provide further insight into glargine induced 
carcinogenicity. In chapter 5 a chronic exposure experiment is described, in which we injected 
mice every other day with a high dose of insulin, glargine, AspB10, IGF1 or a vehicle solution. For 
this the p53R270H/+WAPCre mouse model was used. In this model, mice will develop spontaneous 
human relevant mammary gland tumors. We found that frequent AspB10 and IGF1 injections 
significantly decreased the latency time for breast tumor development, while chronic glargine 
exposure showed a slight non-significant decrease on tumor latency time. The only other 
chronic in vivo experiment that included glargine as one of the test compounds did not find any 
effect in terms of tumor latency time [175]. The time to develop a mammary gland tumor was 
not affected by regular insulin injections compared to the tumors in the vehicle treatment group. 
Insulin analogue treatment in general did not affect the tumor type in this mouse model and cell 
lines isolated from these tumors did not reveal an enhanced aggressiveness or invasiveness. This 
was in agreement with a study on diabetic breast cancer patients in which clinical and 
 




histopathological screening of the tumors revealed that glargine treatment did not affect the 
tumor stage compared to regular insulin treatment [93]. However, we found that the protein 
expression profiles of AspB10 and IGF1 treated tumors showed an enhanced/sustained 
activation of the PI3K and MAPK signaling cascades, which are thought to be the main driver for 
tumor development. These pathways were also upregulated in glargine induced tumors. A 
metabolite analysis revealed that similar to the human situation, the glargine was rapidly 
converted by enzymes in the blood. Nevertheless, in contrast to the human situation this 
enzymatic conversion seemed to be somewhat slower in mice as we were still able to detect low 
concentrations of glargine in the blood one hour after glargine injection [83] [140]. Furthermore, 
besides very high concentrations of M1 we were able to detect also some M2, which was not 
observed in the human studies. These observations suggest that glargine dynamics is slightly 
different from mice to man and highlight the need for studies that examine the differences 
between these species. 
The altered protein expression in the glargine induced tumors together with the slight decrease 
in tumor latency time suggests that frequent glargine injections might affect tumorigenesis in 
this mouse model to some degree. To further investigate this, mRNA from fifty mammary gland 
tumors was isolated and analyzed using next generation sequencing. This whole transcriptome 
analysis is described in chapter 6. This is the first study in which such an experiment was 
performed on the most clinically relevant target tissue (and not just the standard liver tissue). 
Several “Hallmarks of Cancer” appeared to be affected by chronic insulin analogue treatment 
[214] [197]. AspB10 and IGF1 treated tumors showed an increased and sustained proliferative 
and invasive potential. These tumors as well as the tumors treated with glargine also relied more 
on aerobic glycolysis than on oxidative phosphorylation for their ATP generation, which is the 
so-called Warburg effect. To our knowledge, such a link between insulin analogue signaling and 
the Warburg effect has never been described. Mutational analysis indicated that chronic insulin 
analogue stimulation did not affect the genetic instability of the tumors, since no additional 
mutations were found in the treatment groups. However enrichment of Ezh1 and Hras were 
found in tumors of mice treated with glargine, X10 or IGF1. Furthermore we found that chronic 
AspB10 and IGF1 treatment resulted in tumors with highly induced metabolic processes that are 
involved in biomass production. This confirms the hypothesis that chronic AspB10 and IGF1 
treatments decrease tumor latency time in the p53R270H/+WAPCre mouse model by inducing 
tumor progression rather than tumor initiation.  
The work described in this thesis provides novel insights into the role of insulin analogues in 
cancer and deepens the recommendations of ’’the points to consider document’’ of the EMA [6]. 
Our in vitro studies included pathway activation studies, functional proliferation studies as well 
as an in depth transcriptomic analysis. This in combination with the use of a well-characterized 
MCF7-based cell model provided new information regarding the mitogenic mode of action of 
 




the insulin analogues and contributed to the inter-species-translatory aspects of these assays. 
To further follow the EMA guidelines we were able to validate some of the transcriptomic results 
in human primary mammary cells. Future in vitro research on this topic should contain other 
functional read-outs (e.g. MTT or BrdU proliferation assays), as well as FACS-assays to 
determine a shift in cell cycle upon insulin analogue stimulation. It would be ideal to have these 
additional tests to be performed in human primary mammary cells as such a model is clinically 
more relevant and therefore the true carcinogenesis (the development of a cancerous cell) can 
be better assessed. 
In the EMA guidelines concerning carcinogenic risk assessment of insulin analogues the use of 
in vivo experiments is encouraged. It is thought that in carcinogenicity testing the rat represents 
the human situation better as a model compared to mice [4]. However, there are hardly any 
humanized breast cancer rat models available. For this reason we used the p53R270H/+WAPCre 
mouse model. All mice in this model develop spontaneous mammary tumors, so we could test 
if the insulin analogues affect tumorigenesis either by decreasing the tumor latency time, 
increasing the tumor multiplicity or affecting tumor type. The main mammary gland tumors that 
developed in our mouse model were characterized as EMT tumors. These tumors make up only 
a small fraction of the human tumors. Future chronic in vivo studies should use humanized 
breast cancer mouse models with e.g. a PI3K mutation predispositioned to develop carcinomas 
to increase the clinical relevance of their study [215] [190]. 
Although more research is needed, the available data suggests that chronic glargine treatment 
is not involved in tumor initiation but might influence several features of tumorigenesis, and 
thus it might enhance tumor progression [193]. We suggest that future epidemiological studies 
(preferably case control studies) should focus on these potentially tumor promoting effects 
rather than on the tumor initiating effects of glargine. Until this research is performed we advise 
people with a high risk of cancer (e.g. patients that have already been diagnosed with cancer, 
survivors of oncogenic diseases or people with a familial genetic predisposition to develop this 
disease) to reconsider their glargine prescription. Alternative diabetic treatments, like the use 
of long acting insulin determir or the bioglycolin metformin, are in fact sometimes correlated 
with a decreased incidence of cancer [216] [58].  
For the future it is essential that regulatory agencies react quickly, yet not overhasty to 
indications from scientific studies that a specific compound might possess an increased 
carcinogenic risk. In 2009, concerns about the carcinogenic potential of glargine were raised by 
an epidemiological study by Hemkens and colleagues [16]. Instead of directly publishing this 
article and thereby risking the possibly of setting of an unwarranted alarm, the European 
Association for the Study of Diabetes (EASD) asked several other epidemiological research 
groups to study the same topic on different patient groups. Within a couple of months three 
other epidemiological studies were performed and published together with the study of 
 




Hemkens [17-19]. The other studies found no correlation or only a correlation with breast cancer 
and the use of glargine treatment. A response from the European regulatory agencies was 
slightly delayed, but in 2011 a new FP7 “Cancer risk and insulin analogues” (CARING) program 
was initiated. This international collaboration aims to quantify the risk of cancer associated with 
the long-term use of insulin and insulin analogues, with the main focus on epidemiological 
research. The review in chapter 2 is a direct product of this program. In my opinion, also an 
additional guideline should have been proposed by these ministries directly after the 
appearance of the epidemiological studies regarding follow up in vitro and in vivo studies on this 
topic. Yet, to this day no addendum has been proposed on “The points to consider document” 
of the EMA. I expect that such a recommendation from these organizations would have led to 
more and higher quality studies in a shorter timeframe.  
In this thesis the recommendations of the ICHS6 guideline and “The points to consider 
document” of EMA were followed for the carcinogenic risk assessment of all commercial insulin 
analogues [1, 2, 6]. Although we could propose some improvements for the used models (see 
suggestions as discussed above), we think that the research described in this thesis provides the 
most accurate, complete and in-depth carcinogenic safety evaluation for insulin analogues to 
date. We hope that with this research we have contributed to the improvement of the quality 











































    IN BEELD
Donkere kamer met rood licht. Deze kamer 
werd gebruikt om licht gevoelige Western blot 
films te ontwikkelen. De blootgestelde film 
werd verwerkt door hem onder te dompelen in 
ontwikkelingsoplossing (tank met zwarte dop), 
gefixeerd met tiosulfaten (tank met rode dop) 
en schoongemaakt met water. De films zijn 
alleen gevoelig voor blauw/groen licht. Met 
behulp van het rode licht kan de onderzoeker 
zien waarmee hij bezig is zonder de film bloot 
te stellen. Tegenwoordig worden ook wel 
lichtgevoelige scanners gebruikt voor de 
detectie van lichtgevoelige films. Deze scanners 
zijn een stuk sneller. 
     IN THE PICTURE 
Dark room with red light. This room was used to 
develop the light-sensitive Western blot films (in 
front of the picture).  The exposed film was 
processed by immersing it in developing 
solution (container with black lid), fixed by 
thiosulfates (container with red lid) and cleaned 
with water. The films are only sensitive to 
blue/green light, thus red light enables the 
scientist to see what he is doing without 
exposing the film.  Nowadays there are light 
sensitive imagers that can detect 
chemiluminescent light and immediately 
convert it to a digital image. This process might 
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    IN BEELD
-150 °C vriezer. Gedurende deze PhD zijn veel 
verschillende cellijnen gebruikt, genetisch 
gemodificeerd en anderen zelfs geïsoleerd en 
gemaakt. Deze cellen kunnen voor jaren in leven 
worden gehouden door ze in de kleine buisjes 
(met gekleurde dopjes) te doen en ze heel koud 
te bewaren. DMSO zorgt ervoor dat er geen 
waterkristallen gevormd worden die de cellen 
kunnen beschadigen. De mist die uit de vriezer 
komt is waterdamp dat direct condenseert.
     IN THE PICTURE 
-150 °C freezer. In this PhD-research many 
different cell lines have been used, some 
genetically modified and others even have been 
isolated and generated. Cells can be put in small 
tubes (with coloured lids) and cryo-preserved for 
many years in these special freezers.  DMSO will 
prevent the water from forming ice crystals and 
damaging the cells. Fog coming from the freezer 
is water vapour condensing due to the drop in 
temperature. 
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    IN BEELD
DNA is een molecuul waarin alle genetische 
informatie is opgeslagen van alle organismen. 
Kleine veranderingen in dit molecuul kunnen 
grote biologische effecten teweeg brengen. Een 
onderzoeker kan specifieke mutaties maken om 
de functie van delen van dit molecuul (genoemd 
‘genen’) te achterhalen. Op de foto is een 
elektroforese apparaat te zien. Met behulp van 
dit apparaat kunnen stukjes van het DNA 
molecuul op grootte worden gescheiden. In de 
blauwe lijn op de foto zitten grote fragmenten 
van het DNA, in de gele de kleine. 
     IN THE PICTURE  
DNA is a molecule that encodes the genetic 
instructions of all living organisms. Small changes 
in this molecule may have big consequences on 
biological processes. A scientist can make 
specific mutations to unravel the function of 
specific parts (or genes) of this molecule. In the 
picture, gel electrophoreses equipment is 
presented. This machine makes use of an 
electrical current to separate fractions of the 
DNA molecule. The blue line represents large 







Wereldwijd zijn er momenteel meer dan 380 miljoen diabetes patiënten en door de westerse 
levenswijze denkt men dat dit aantal de komende jaren fors gaat toenemen. Al deze patiënten 
zullen uiteindelijk medicijnen moeten gebruiken om hun bloedglucosewaarden op pijl te houden. 
Een veel gebruikte behandeling is een dagelijks injectieregime van de zogenaamde insuline 
analogen. Dit zijn moleculen die op moleculair niveau heel veel op normale insuline lijken, maar 
kleine mutaties hebben grote gevolgen op de werkingsduur van het insuline molecuul. Zo zijn er 
kort en lang werkende insuline analogen. Insuline glargine (LANTUS) is een voorbeeld van een 
lang werkend insuline analoog en wordt wereldwijd door miljoenen mensen gebruikt.  Drie kleine 
mutaties in het glargine molecuul hebben ervoor gezorgd dat het na injectie langzaam 
opgenomen wordt door het menselijk lichaam waardoor het slechts eenmaal per dag gebruikt 
hoeft te worden door de diabetes patiënt. Deze mutaties hebben er echter ook voor gezorgd dat 
het molecuul naast een hoge affiniteit voor de insuline receptor (IR) ook een verhoogde affiniteit 
voor de insulin-like growth factor-1 receptor (IGF1R) heeft. Waar de IR voornamelijk betrokken 
is bij de metabole effecten (zoals glucose opname) heeft de IGF1R een grote rol in de mitogene 
effecten (zoals cel deling en groei). Verschillende patiëntenstudies hebben inderdaad de link 
gelegd tussen het gebruik van glargine en een hogere kans op het krijgen van kanker, met name 
borstkanker, terwijl andere studies dit effect niet hebben gevonden. De interpretatie van 
dergelijke patiëntenstudiespatiëntenstudies is vaak erg lastig omdat diabetes zelf al een 
verhoogd risico vormt voor het ontwikkelen van kanker. Daarnaast worden vaak belangrijke 
patiënten gegevens (leeftijd, geslacht, leefgewoonten, duur en dosis van insuline behandeling) 
niet meegenomen in de interpretatie van deze studies terwijl deze factoren grote effecten 
kunnen hebben op het risico op het ontwikkelen van kanker. Een studie waarbij de invloed van 
deze mogelijke factoren wordt uitgesloten, en waar slechts de insulinebehandeling verschilt, zou 
deze tekortkomingen verhelpen. Helaas zijn dergelijke studies schaars en omvatten tot nu toe 
niet genoeg patiënten. Het directe mitogene effect van deze moleculen zou ook bepaalt kunnen 
worden met in vitro experimenten waarbij het aantal celdelingen wordt gekwantificeerd door 
gebruik te maken van cellijnen. Er zijn momenteel ongeveer 50 studies in de literatuur bekend 
die dergelijke experimenten beschrijven. De resultaten van deze in vitro studies zijn daarnaast 
vaak tegenstrijdig, voornamelijk omdat ze een verschillende methodologie gebruiken. Daarnaast 
kunnen enkele parameters niet bestudeerd worden door middel van dergelijke studies. Om de 
kankerverwekkende eigenschappen van insuline analogen in een levend wezen te bepalen is het 
helaas onvermijdelijk in vivo experimenten uit te voeren. Bij dergelijke experimenten worden 
dieren, in veel gevallen muizen of ratten, geïnjecteerd met een hoge dosis van een bepaalde stof. 
Vervolgens wordt gekeken of bij deze dieren de tumor eigenschappen (incidentie, type, grote 
etc.) beïnvloed zijn. Studies die dieren chronisch hebben blootgesteld aan insuline analogen zijn 
in aantal zeer gering maar hebben er wel toe geleid dat een bepaalde insuline analoog, AspB10, 






De hoge kosten van dergelijke studies is zeer waarschijnlijk de reden van deze schaarste. De 
organisatie die verantwoordelijk is voor de toelating van nieuwe medicijnen op de Europese 
markt, EMA, heeft onlangs aangegeven hoe men beter en doelgerichter onderzoek kan doen 
naar de kankerverwekkende eigenschappen van insuline analogen. In deze thesis is beschreven 
hoe wij, gebaseerd op dit document, gedurende 4 jaar onderzoek hebben gedaan naar deze 
stoffen.  
Om iets nieuws te onderzoeken met men eerst weten wat er al is gedaan. Daarom zijn we 
begonnen met het uitvoeren van een uitgebreid en systematisch literatuuronderzoek, welke 
beschreven staat in hoofdstuk 2. In dit review hebben we resultaten van zowel patiëntenstudies, 
in vitro- als in vivo- studies opgenomen en hebben we ons gericht op de blootstelling aan insuline 
analogen in relatie tot borstkanker. Hierin kwam naar voren dat studies in veel gevallen slecht 
zijn opgezet en niet de juiste positieve en negatieve controles hanteren. Daarnaast zijn er niet 
genoeg in vivo studies uitgevoerd om uitsluitsel te kunnen geven over de mitogene potentiaal 
van deze moleculen in een levend organisme. 
In hoofdstuk 3 wordt beschreven hoe wij nieuwe cellijnen gegenereerd hebben om de mitogene 
potentiaal te kunnen bepalen van alle commerciële insuline analogen. Met dit celsysteem was 
het mogelijk om de betrokkenheid van de verschillende receptoren te kunnen bepalen. Glargine 
bleek op korte termijn mitogene signaal transducerende cascades te induceren vooral via de 
IGF1R. Maar dit leidde er niet toe dat op langere termijn veel meer cellen aanwezig waren in 
vergelijking tot de insuline blootstelling. Uiteindelijk bleek dat glargine in deze langdurige 
experimenten afgebroken werd in bepaalde moleculen met een lage mitogene potentiaal. Deze 
bevinding is ook klinisch van groot belang omdat deze omzetting ook in het menselijk lichaam 
blijkt plaats te vinden.  
Hetzelfde celsysteem wordt gebruikt in de experimenten beschreven in hoofdstuk 4. Hier 
hebben we geprobeerd om op transcriptioneel niveau te achterhalen welke genen betrokken zijn 
bij de verhoogde mitogeniteit van enkele insuline analogen. Vervolgens hebben we de expressie 
van deze twintig genen gebruikt om de mitogene potentiaal van andere insuline analogen te 
voorspellen. Het voorspellend vermogen bleek hoog en stabiel in verschillende modellen. We 
hopen dat dit systeem overgenomen kan worden door de farmaceutische industrie om vroeg in 
het ontwikkelingsproces de mitogene bijwerkingen van nieuwe medicijnen te ontdekken. 
Eerder hebben we aangegeven wat het belang is van het uitvoeren van experimenten waarbij 
een levend organisme chronisch wordt blootgesteld aan insuline analogen. In hoofdstuk 5, 
beschrijven we een dergelijk experiment. Hierbij hebben we een speciaal muismodel gebruikt 
met een genetische achtergrond waarbij ze spontaan humaan relevante borsttumoren 
ontwikkelen. Wij hebben gekeken hoe chronische blootstelling aan insuline analogen 
verschillende parameters van de tumorontwikkeling beïnvloedt. Zo hebben we kunnen 






Ook konden we meten dat de mitogene signaaltransductie in deze tumoren verhoogd was. Dit 
laatste was ook het geval bij enkele tumoren uit de glargine injectie groep.  
In het laatste experimentele hoofdstuk, hoofdstuk 6, hebben we de tumoren uit het 
bovengenoemd experiment verder onderzocht. Door gebruik te maken van een nieuwe techniek 
konden we het gehele transcriptoom van de tumoren onderzoeken. We kwamen erachter dat 
verschillende parameters die belangrijk worden geacht in de ontwikkeling van een tumor 
beïnvloed waren door de langdurige insuline analogen (AspB10) blootstelling. Zoals verwacht had 
chronische blootstelling aan insuline analogen geen direct effect op de stabiliteit van DNA in de 
tumoren.  
Kortom, het onderzoek dat in dit proefschrift beschreven staat, toont aan dat glargine zelf een 
verhoogde mitogene potentiaal heeft, maar dat er geen directe aanwijzingen zijn dat dit ook leidt 
tot een verhoogd risico op het ontwikkelen van kanker in een levend organisme. Alle andere 
commerciële insuline analogen bleken geen verhoogde celdeling te induceren in vergelijking met 
normaal humaan insuline. Meer onderzoek op dit vlak is zeker nodig en we hopen dat de kennis 
die we hier hebben opgedaan in de toekomst zal leiden tot het verbeteren van de 
mitogeniteitstesten door de farmaceutische industrie. Door het gebruik van slimme modellen en 




























    IN BEELD
In het onderzoek, en vooral bij de afdeling 
Toxicologie worden de experimenten steeds 
groter opgezet. ”Als de insuline receptor pathway 
200 moleculen bevat, waarom zou je er maar één 
testen als je ze ook allemaal zou kunnen testen?”. 
Het zou onmogelijk zijn om deze grootschalige 
experimenten allemaal met de hand te 
pipetteren. De automatische pipeteer robot op 
de foto kan 96 individuele welletjes tegelijk 
pipeteren. Qua tijdsinvestering maar ook uit 
ergonomisch oogpunt is dit gunstiger. 
     IN THE PICTURE 
In science, and especially in the laboratory of 
Toxicology, there is a strong trend to scale up the 
experiments. “If the insulin receptor 
downstream signalling pathway has 200 targets, 
why test one if you can test all of them?” It is 
impossible to perform these high throughput 
experiments with manual pipetting alone. The 
liquid handler in the picture can be programmed 
to pipette 96 individual wells all at once, which 
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